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ZUSAMMENFASSUNG 
Grundlage Autophagie ist ein grundlegender, evolutionär konservierter zellulärer Prozess, 
der in die Initiation und Progression der Tumorbildung einbezogen ist. Dabei sind sowohl 
onkogene Effekte bekannt, während in anderen Fällen diese Prozesse zur Tumorsuppression 
beitragen. GABARAP spielt bei der Autophagie eine wesentliche Rolle, indem es an der 
Reifung der Autophagosomen beteiligt ist. Die Funktion von GABARAP bei der Tumor-
genese ist jedoch bisher nicht geklärt. Während GABARAP in allen normalen Geweben 
exprimiert wird, ist das Vorkommen in Tumorgeweben sehr unterschiedlich. In einer früheren 
Studie der Arbeitsgruppe konnte gezeigt werden, dass GABARAP beim Brustkrebs als 
Tumorsuppressor fungiert. Hier sollte nun die generelle Bedeutung von GABARAP in der 
Kanzerogen-induzierten Tumorgenese näher untersucht werden. 
Methoden Die Untersuchungen erfolgten vorwiegend an GABARAP-knockout (KO)-
Mäusen, bei denen die spontane sowie die durch verschiedene Kanzerogene induzierte 
Tumorbildung analysiert wurde. Als Kontrollen dienten C57BL/6-Wildtyp-Mäuse. In den 
beiden Versuchstiergruppen wurde außerdem das Wachstum von inokulierten syngenen 
Tumorzellen (B16-Melanomzellen) verfolgt. In Milzen und im Brustdrüsengewebe wurden 
die Proliferations- (Ki-67) und Apotoseraten (TUNEL-Assay) bestimmt. Mit der Flow-
Zytometrie wurden die Milzzell-Populationen bestimmt und in Überständen von kultivierten 
Peritoneal-Makrophagen und Milz-Lymphozyten wurde mittels ELISA die Zytokinsekretion 
gemessen. In Totalpräparaten von Brustdrüsen von Mäusen, die mit dem Kanzerogen DMBA 
behandelt worden waren, wurde die Proliferation von Epithelzellen und das Auswachsen und 
Verzweigen der Ausführungsgänge untersucht. Mittels Analysen des Gesamt-Genoms 
(Agilent Whole Mouse Genome Array) und quantitativer RT-PCR wurden Veränderungen der 
Genexpression analysiert und mögliche molekulare Mechanismen identifiziert, die durch die 
GABARAP-Defizienz und die Kanzerogenbehandlung induziert werden. Durch Behandlung 
von isolierten embryonalen Mausfibroblasten (MEFs) mit den genotoxischen Agenzien 
DMBA und Camptothecin (CPT) wurde mittels Western-Blotting die Bedeutung von 
GABARAP im Autophagieprozess und bei der Reparatur von DNA-Schäden untersucht. In 
DMBA-induzierten Tumoren wurden schließlich noch H-ras-Mutationen analysiert. 
Ergebnisse Im Vergleich zu WT-Kontrollen war in GABARAP-KO-Mäusen die spontane 
und die DMBA-induzierte Tumorentwicklung signifikant geringer ausgeprägt. Nach der 
Kanzerogenbehandlung wurden verschiedene phänotypische Veränderungen beobachtet, so 
z.B. ein reduziertes Überleben der Tiere und eine hohe Toxizität von DMBA für Milzzellen 
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(deutlich verringertes Volumen der Milz und der Zellzahl). FACS-Analysen zeigten, dass 
diese Verringerung alle Zellpopulationen betraf, d.h. kein selektiver Einfluss auf bestimmte 
Populationen stattfand. Die Verringerung der Zahl der Milzzellen nach DMBA-Behandlung 
war dabei in GABARAP-KO-Mäusen deutlich stärker ausgeprägt als in den WT-Kontrollen. 
Makrophagen aus GABARAP-KO-Mäusen produzierten nach DMBA-Behandlung 
signifikant höhere Mengen der proinflammatorischen Zytokine IL-1ß und IL-6 als Zellen von 
WT-Kontrollen, bei den Milz-Lymphozyten war in ähnlicher Weise nach Stimulation mit 
Anti-CD3 die Sekretion von IL-2 und IFN-γ erhöht. In Brustdrüsenpräparaten aus 
GABARAP-KO-Mäusen war nach DMBA-Behandlung die Proliferation der epithelialen 
Zellen und das Auswachsen und Verzweigen der Ausführungsgänge signifikant geringer als 
in WT-Kontrollen. Im Brustdrüsengewebe und in der Milz waren darüber hinaus die zelluläre 
Proliferation (Ki-67) verringert und die Apoptose (Zahl TUNEL-positiver Zellen) erhöht. 
Genexpressions-Analysen und qRT-PCR belegten im Brustdrüsengewebe von GABARAP-
KO-Mäusen sowie in Milz, Leber, Lunge und Niere eine hohe und differentielle Expression 
des Tumorsuppressor- und Apoptoseinducer-Gens Xaf1. Darüber hinaus waren verschiedene 
Zelltod-Gene (Bid, Apaf1, Bax, Tnfrs10b, Ripk1 und Siva1) und die Zellzyklus-Inhibitoren 
Cdkn1a (p21) und Cdkn2c (p18) hochreguliert. In GABARAP-defizienten MEFs war nach 
Behandlung mit DMBA und CPT die Reparatur von DNA-Schäden beeinträchtigt, wie die 
Akkumulation von phosphoryliertem γH2AX und des Autophagiemarkers p62 sowie die 
Verringerung der Cyclin D1-Proteine belegen. In GABARAP-KO-Mäusen war auch das 
Tumorwachstum nach Inokulation von B16-Melanomzellen reduziert. Mutationsanalysen 
haben gezeigt, dass bei GABARAP-KO-Mäusen in den DMBA-induzierten Tumoren keine 
H-ras-Mutationen nachweisbar sind, im Gegensatz zu 5 Mutationen, die in den 14 Tumoren 
bei den WT-Kontrollen auftraten. 
Schlussfolgerung Unsere Ergebnisse zeigen, dass GABARAP auf unterschiedliche Weise in 
die Hemmung der Tumorgenese einbezogen sein könnte. Die in GABARAP-KO-Mäusen 
nach DMBA-Behandlung beobachtete Modulation der Immunreaktivität lässt vermuten, dass 
GABARAP bei der Steigerung der Anti-Tumor-Immunität eine Rolle spielt, wie die erhöhte 
Sekretion von IL-1ß, IL-2, IL-6 und IFN-γ zeigen. Die hohe Expression von Xaf1 in 
GABARAP-KO-Mäusen könnte nach genotoxische Einflüssen die zelluläre Todesrate 
erhöhen und auf diese Weise die Tumorbildung verhindern sowie das Wachstum/Verzweigen 
des Brustdrüsengewebes hemmen. Die Beeinträchtigung der Reparatur von DNA-Schäden in 
GABARAP-defizienten MEFs wiederum lässt vermuten, dass GABARAP auch in diesem 
Prozess eine wichtige Rolle spielt. Bei GABARAP-Mangel könnte so der Zellzyklusarrest 
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gefördert werden, der nach Behandlung mit genotoxischen Agenzien auftritt. Die Hemmung 
des Wachstums von inokulierten Melanomzellen und das Fehlen von H-ras-Mutationen in den 
DMBA-induzierten Tumoren bei GABARAP-KO-Mäusen unterstreichen die besondere 
Bedeutung von GABARAP für die Tumorprogression. 
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SUMMARY 
Background: Autophagy is a basic, evolutionary conserved cellular process has been linked 
with tumor initiation and progression. In some instances, it may serve as oncogene, whereas 
in others, it contributes to tumor suppression. GABARAP has an essential role in the 
autophagic process through its involvement in the maturation of the autophagosome. The role 
of GABARAP in tumorigenesis is not yet clarified. It is ubiquitously expressed in all tested 
normal tissues, while its expression in tumors is divers. A previous study of our group 
revealed that GABARAP may function as a tumor suppressor in breast cancer. Here the 
general impact of GABARAP should now be examined in the carcinogen-induced tumor 
formation. 
Methods: GABARAP knockout (KO) mice were used as the main experimental substrate. 
They were investigated for spontaneous and induced tumorigenesis by applying different 
carcinogens to the GABARAP KO and C57BL/6 control mice. Furthermore, the growth of 
inoculated syngeneic tumor cells (B16 melanoma) was monitored. Murine spleen and 
mammary gland tissue was investigated for proliferation and apoptosis by using Ki-67 
immunostaining and the TUNEL assay. Peritoneal macrophages and splenic lymphocytes 
were isolated and cultured. Flow cytometry and ELISA were implemented to detect the 
populations of splenocytes and measure their cytokine secretion. Mammary gland whole 
mount analysis was carried out to investigate the proliferation of epithelial cells and ductal 
branching after treatment with the carcinogen DMBA. Agilent Whole Mouse Genome 
expression analysis and quantitative reverse transcriptase PCR (qRT-PCR) were performed to 
analyse the alteration of gene expression and to identify candidate molecular mechanisms 
being affected by GABARAP knockout and carcinogen treatment. Mouse embryonic 
fibroblasts (MEFs) were cultured and treated with the genotoxic agents DMBA and 
camptothecin (CPT) to reveal the role of GABARAP in autophagy and DNA damage repair 
by using western blotting. H-ras mutation analysis was performed in the DMBA-induced 
tumors. 
Results: GABARAP KO mice exhibited significantly less tumor formation after DMBA 
treatment and less spontaneous tumor growth. Several phenotypic changes were observed in 
GABARAP KO mice upon carcinogen treatment: reduction in animal survival and high 
toxicity of DMBA to splenocytes represented by decrease of the spleen volume and the total 
cell number. FACS analysis revealed that the decreased number of splenocyte populations 
was in agreement with the reduction in total cell number and there was no discrimination for 
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the effect of DMBA on particular cell types. However, the reduction of splenocytes was more 
profound in GABARAP KO mice. GABARAP-deficient macrophages of DMBA-treated 
mice produced higher levels of proinflammatory cytokines (IL-1β and IL-6) compared to 
wild-type counterparts. Moreover, GABARAP-deficient lymphocytes of DMBA-treated mice 
enhanced the immune response through increasing the production of IL-2 and IFN-γ upon 
CD3 stimulation. Mammary glands of GABARAP KO mice showed a significant reduction in 
epithelial cell proliferation and ductal branching after DMBA treatment. Mammary gland and 
spleen sections revealed a decrease of proliferation cells and an increase of positive cells in 
the TUNEL assay. Gene expression profiling and qRT-PCR manifested a high and  
a differential expression of tumor suppressor and apoptosis inducer gene Xaf1 in mammary 
glands of GABARAP KO mice as well as in the spleen, liver, lung and kidney. Moreover, 
several cell death genes (Bid, Apaf1, Bax, Tnfrsf10b, Ripk1 and Siva1) and cell cycle 
inhibitors (Cdkn1a (p21) and Cdkn2c (p18)) were upregulated. GABARAP-deficient MEFs 
treated with DMBA and CPT showed impairment in DNA damage repair through 
accumulation of phosphorylated γH2AX which was accompanied by accumulation of the 
autophagy marker p62 and downregulation of the Cyclin D1 protein. Reduced tumor growth 
in GABARAP KO mice was also evident after B16 melanoma cell inoculation. Furthermore, 
mutation analysis of DMBA-induced tumors revealed no H-ras mutation in the tumors of 
GABARAP KO mice compared to 5 mutations in 14 tumors of the wild-type mice. 
Conclusion: Our results indicated different aspects for the role of GABARAP in the 
inhibition of tumorigenesis. The immunomodulation by GABARAP deficiency upon DMBA 
treatment suggests the involvement of GABARAP in the enhancement of anti-tumor immune 
response by increasing IL-1β, IL-6, IL-2 and IFN-γ. High Xaf1 expression in GABARAP KO 
mice may mediate increased cellular death upon genotoxic insult thereby preventing tumor 
formation and favoring inhibition of growth/branching of the mammary glandular tissue. 
Impairment of DNA damage repair in GABARAP-deficient MEFs suggests that GABARAP 
plays an important role in this process and that its deficiency promotes cell cycle arrest after 
treatment with genotoxic agents. Inhibition of inoculated B16 melanoma cell growth and 
absence of H-ras mutation in DMBA-induced tumors of GABARAP KO mice further 
underscores the importance of GABARAP in tumor progression. 
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1.       Introduction 
1.1     GABARAP 
Gamma (γ)-aminobutyric acid type A (GABAA) receptor-associated protein (GABARAP) is 
an evolutionarily highly conserved gene family from yeast to mammals and ubiquitously 
expressed in a wide range of organisms and tissues. The amino acid level for mammalian 
forms of GABARAP showed 100% identity suggesting that the function of this gene is 
essential or beneficial in mammals (Mohrlüder et al., 2009). GABARAP, a cytoplasmic 
protein of 14 kDa, belongs to a gene family including GEC1 (glandular epithelial cell protein 
1) or GABARAPL1; GATE-16 (Golgi associated ATPase enhancer of 16 kDa) or 
GABARAPL2 or GEF-2 (Ganglioside expression factor 2); GABARAPL3; LC3 
(Microtubule-associated protein light chain 3); yeast Apg8 or Aut7p; and Caenorhabditis 
elegans (C. elegans) LGGs (LC3, GABARAP and GATE-16) protein (Chen and Olsen, 
2007). GABARAP was previously described acting as a trafficking molecule for different 
receptors like the GABAA receptor, a major inhibitory neurotransmitter in cortical neurons, or 
the transferrin receptor, a type II integral membrane protein responsible for delivery of iron-
laden transferrin to the endosomal compartment (Wang et al., 1999; Chen et al., 2000; Green 
et al., 2002). It is involved in the transport of proteins or vesicles from intracellular pools to 
the cell surface through its interaction with microtubules, tubulin, and N-ethylmaleimide-
sensitive factor (NSF), an ATPase and chaperone that activates soluble NSF attachment 
protein receptor (SNARE) proteins in membrane fusion events (Wang and Olsen, 2000; Coyle 
et al., 2002; Kittler et al., 2001). The N-terminus of GABARAP is highly positively charged 
and features a putative tubulin-binding motif. GABARAP was identified in a yeast two-
hybrid search for proteins that bind to the loop of the GABAA receptor and has been 
implicated in the clustering of these receptors (Wang et al., 1999; Chen et al., 2000), thus 
GABARAP mediated inhibitory neurotransmission in mammalian through its interaction with 
the γ2 subunit of GABAA receptors in the central nervous system. In subsequent studies, 
GABARAP was shown to increase the cell-surface expression of GABAA receptors, implying 
that GABARAP might be an important factor regulating the intracellular trafficking of 
GABAA receptors (Leil et al., 2004; Boileau et al., 2005; Chen et al., 2005). Furthermore, it 
has been reported that GABARAP binds to the C-terminal region and thereby inhibits Ost-III, 
a splice variant of the guanine nucleotide exchange factor Ost, suppressing Rac-1-dependent 
negative regulation of transferrin receptor endocytosis (Ieguchi et al., 2007). Sequence 
analysis showed similarity between GABARAP and light chain-3 of microtubule-associated 
proteins 1A and 1B at the NH2-terminus, whereas the COOH-terminal part of the GABARAP 
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protein is thought to interact with the target protein (Wang et al., 1999). Figure 1 represents 
schematic protein structure of GABARAP indicating the alpha helix and beta sheet domains 
(Bavro et al., 2002).  
 
 
 
 
 
 
 
 
 
 
Figure 1. Ribbon presentation of the GABARAP structure. The N-terminal region (N) is shown in grey, the 
core structure displaying a conserved ubiquitin-like fold is shown in red and Carboxyl  terminal ends is 
indicated as C (Source: Bavro et al., 2002). 
 
By using yeast two-hybrid analyses and/or coimmunoprecipitation assays, GABARAP has 
been found to interact directly with several proteins. For instance, GABARAP interacts with: 
P130 ⁄ phospholipase C-related inactive protein (PRIP); one of the essential factors in the 
dynamic regulation of GABAA receptor expression at inhibitory synapses (Kanematsu et al., 
2002), transferrin receptor (TfR); a carrier protein needed for the import of iron into the cell 
through receptor-mediated endocytosis (Green et al., 2002), glutamate receptor-interacting 
protein 1 (GRIP1); a synaptic protein that plays an important role in trafficking, synaptic 
targeting and recycling of glutamate receptors (Kittler et al., 2004), DEAD box polypeptide 
47 (DDX47); an RNA helicase implicated in pre-mRNA splicing or ribosome biogenesis (Lee 
et al., 2005), Ras-related protein 24 (RAB24); one of the small GTP-binding proteins that are 
involved in vesicular transport and fusion events (Wu et al., 2006), and calreticulin (CRT); a 
multifunctional protein known as a luminal Ca2+ dependent chaperone located in the 
endoplasmic reticulum (ER) (Mohrlüder et al., 2007). Finally, Schwarten et al. (2009)  
have been identified BNIP3L ⁄ Nip-like protein x (Nix) as a direct interaction partner  
of GABARAP. BNIP3L (Bcl-2 and adenovirus E1B 19 kDa interacting protein-like),  
is commonly known to be implicated in apoptosis and known to localize to mitochondria, 
ER and the nuclear envelope (Imazu et al., 1999; Ohi et al., 1999; Yussman et al., 2002). 
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1.2     Autophagy 
The cellular homeostasis requires for a constant turnover of continuous synthesis of cellular 
components and clearance of damaged or superfluous proteins and organelles. Eukaryotic 
cells have developed two degradation pathways to achieve this homeostasis and controlling 
the balance between anabolism and catabolism in order to have a normal cell growth and 
development. These degradation pathways are the ubiquitin-proteasome system (UPS) and the 
lysosomal pathway. Proteasomal degradation has high selectivity; generally the proteasome 
recognizes only ubiquitinated substrates, which are primarily short-lived proteins, that’s mean 
the proteasome only has the ability to degrade proteins; it is unable to degrade damaged 
organelles (Ciechanover, 2005; Cuervo et al., 2005). The lysosomal degradation does not 
follow such a simple pattern as the proteasomal pathway; it is mainly supported by autophagy 
(Mizushima and Komatsu, 2011). The term autophagy derived from the Greek words “auto” 
and “phagy” which means “self” and “eating”, this term was coined by de Duve in 1963 when 
he described the presence of single- or double-membrane vesicles that contain parts of the 
cytoplasm and organelles (De Duve and Wattiaux, 1966). 
Autophagy is an intracellular pathway for bulk degradation of proteins and organelles within 
the lysosome/vacuole. It is used for recycling cytoplasm to generate macromolecular building 
blocks and energy under stress conditions (Feng et al., 2014). There are three primary types of 
autophagy (Fig. 2) (Wirawan et al., 2012): macroautophagy (hereafter referred as autophagy), 
microautophagy and chaperone-mediated autophagy (CMA). Both macroautophagy and 
microautophagy can be selective or nonselective. Nonselective autophagy is used for the 
turnover of bulk cytoplasm under starvation conditions, whereas selective autophagy 
specifically targets damaged or dispensable organelles, including mitochondria and 
peroxisomes, as well as invasive microbes. The CMA degrades only soluble targeted proteins 
in a selective manner (Feng et al., 2014). Autophagy is initiated by the formation of a cup 
shaped membrane (termed “phagophore”), suggested to originate from the ER (Hayashi-
Nishino et al., 2009; Yla-Anttila et al., 2009). The phagophore enwraps parts of the 
cytoplasm to form a double-membrane vesicle, called autophagosome, which eventually fuses 
with the lysosomes/vacuole (Fig. 2). Autophagy was initially revealed in mammalian systems, 
but the molecular identification of it has been expanded and differentiated through genetic 
screening of autophagy-defective mutants in Saccharomyces cerevisiae (Tsukada and 
Ohsumi, 1993; Thumm et al., 1994). 
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Figure 2. Schematic representation of the types of autophagy.  Microautophagy: the cargos are sequestered 
by direct invagination of the lysosome membrane. Chaperone-mediated autophagy: the protein transported by 
chaperone hsc70 complex to the lysosome membrane. Macroautophagy: the most distinguishing feature is the 
initiation of isolated membrane (phagophore) that encloses and isolates the cytoplasmic components by 
formation the autophagosome which eventually fuses with the lysosomes/vacuole (Wirawan et al., 2012). 
 
In 1997, the first autophagy-specific gene, APG1 (now Atg1 (Klionsky et al., 2003)), was 
identified, and the corresponding gene product, Apg1/Atg1, was characterized as a Ser/Thr 
protein kinase (Matsuura et al., 1997). Subsequently, multiple laboratories discovered more 
than thirty autophagy-related (Atg) genes in the autophagy machinery. The morphology of the 
autophagy process is essentially the same in yeast, plants and animals. The mammalian 
autophagy pathway can be divided into six discrete steps: initiation, nucleation, elongation, 
closure, autophagosome maturation and degradation by fusion with the lysosome  
(Kang et al., 2011). A critical regulator of autophagy is the serine/threonine kinase mTOR 
(mammalian target of rapamycin). The mTOR pathway involves two functional complexes: 
mTORC1 and mTORC2 (Fig. 3). The rapamycin-sensitive mTOR complex 1 (mTORC1) is 
composed of mTOR catalytic subunit, raptor (regulatory associated protein of mTOR, a 
protein that acts as a scaffold for the mTOR-mediated phosphorylation of mTOR substrates), 
GβL, PRAS40 (proline-rich Akt substrate of 40 kDa), and Deptor (DEP domain-containing 
mTOR-interacting protein) (Fig. 3). This complex functions as a nutrient/energy/redox sensor 
and controls protein synthesis (Kim et al., 2002; Hay and Sonenberg, 2004; Laplante and 
Sabatini, 2009). The other mTOR complex, mTORC2, which is less sensitive to rapamycin, 
includes mTOR, rictor (rapamycin-insensitive companion of mTOR), GβL, Sin1 (SAPK-
interacting protein 1), PRR5/Protor-1 (protein observed with rictor), and Deptor (Fig. 3). The 
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mTORC2 promotes cellular survival by phosphorylating the Ser473 of Akt/PKB and also 
functions as an important regulator of cytoskeletal organization and metabolism (Sarbassov et 
al., 2006; Laplante and Sabatini, 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic representation of mTOR signaling network 
(Source: http://www.iimcb.gov.pl/Jaworski-Laboratory-research-focus.html) 
 
ULK1 (homolog of yeast Atg1), Atg13, and FIP200 (FAK family-interacting protein of 200 
kDa) form a stable complex that signals to the autophagic machinery downstream of 
mTORC1. In nutrient-rich states, mTORC1 forms a complex with ULK1/2 kinase, mAtg13, 
FIP200 and Atg101. mTOR phosphorylates ULK1 and Atg13 and thereby keeps the kinase 
activity of ULK1 in check. Under starvation conditions or if the AMP-to-ATP ratio increases 
or upon treatment with rapamycin (mTOR inhibitor), mTORC1 dissociates from the ULK 
complex resulting in the activation of ULK1 (the inhibitory phosphorylation of ULK1 is lost). 
ULK1 then autophosphorylates and activates Atg13 and FIP200 to initiate autophagy.  
The activated ULK complex localizes to the developing phagophore (Jung et al., 2009;  
Mehrpour et al. 2010). 
Another important nutrient-sensitive entry route to autophagy signaling is the class III 
phosphatidylinositol 3-kinase complex (PI3K-III) consisting of hVps34, Beclin-1 (yeast Atg6) 
and p150/hVps35. Phosphatidylinositol-3-phosphate is bound to its core partner Beclin-1 and 
p150/hVps35. The complex is found on the phagophore and might facilitate recruitment of 
other Atgs to the developing vesicle (Funderburk et al., 2010; Rosenfeldt and Ryan, 2011). 
Moreover, the autophagy pathway can be stimulated by multiple forms of cellular stress apart 
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from nutrient or growth factor deprivation, for instance hypoxia, reactive oxygen species, 
DNA damage, protein aggregates, damaged organelles or intracellular pathogens (Kroemer et 
al., 2010).  
GABARAP belongs to a family of mammalian orthologues of the yeast autophagy-related 
ubiquitin-like protein Atg8 (autophagy-related 8 proteins) (Ohsumi, 2001), it has an essential 
role in the autophagic process possibly in the elongation of the phagophore membrane by 
mediating hemi-fusion events (Nakatogawa et al., 2007; Xie et al., 2008; Weidberg et al., 
2010). In mammalian cells, three Atg8 homologs have been identified: MAP1LC3 or LC3 (in 
human: LC3A, LC3B, LC3C), GABARAP and GATE-16 (GABARAPL2). LC3 and 
GABARAP proteins are the most studied protein in the autophagy machinery and appear to 
be modified by lipids in the same manner as described in yeasts, and have been shown to 
localize to the autophagosome (Kabeya et al., 2004). The GABARAP family is not only 
structurally similar to ubiquitin, but also undergoes a similar posttranslational cascade 
modification process as occurs in ubiquitinylation (Hochstrasser, 2000). GABARAP contains 
117 amino acids and consists of an ubiquitin-like fold with two additional amino terminal 
helices. In vivo, the C-terminal Leu-117 of GABARAP is cleaved off leaving Gly-116 as a 
C-terminal residue that can be conjugated covalently to proteins and lipids via an E1 (Atg7), 
E2 (Atg3) and E3 (Atg12/Atg5/Atg16 complex) enzymes cascade (Tanida et al., 1999; 
Kirisako et al., 2000; Hanada et al., 2007). Although LC3 proteins and GABARAP are 
known to be conjugated to phosphatidylethanolamine (PE) and incorporated into 
autophagosomes, the biological relevance of the expansion of Atg8 proteins in higher 
mammals is largely unknown (Behrends et al., 2010; Wild et al., 2014). This autophagic 
factor is known to decorate autophagosomes and recruit factors such as p62/SQSTM1 and 
NBR1 (Bjorkoy et al., 2005; Kirkin et al., 2009; Shvets et al., 2011). However, the exact role 
of this gene in autophagy is not yet fully understood. Weidberg et al. (2010) indicated that 
LC3 is involved in elongation of the phagophore membrane whereas GABARAP is essential 
for a later stage of autophagosome maturation, this study have been done by using RNA 
silencing to target GABARAP and other Atg8 family members in HeLa cells. 
The autophagosomes origin is still a matter of debate. Several hypotheses have been 
generated about the origin of autophagosome, but the most well accepted theories are those 
which hypothesized ER or mitochondrial origin.  In yeast, the cytoplasm of cell contained 
vesicles forming the phagophore assembly site (PAS). At this site, autophagy machinery 
proteins have been identified to be coupled to the PAS (Suzuki et al., 2001), which matures 
from a phagophore to an autophagosome (Kim et al., 2002). In mammals, no PAS has been 
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identified but the growing and expansion of isolated membranes is induced under the action 
of ULK1, coupled to the PI3K complex (hVps34, Beclin-1 and p150/hVps35) and to mAtg9, 
homolog of yeast Atg9 (Young et al., 2006). The further expansion, closure and maturation of 
the autophagosomes rely on the mammalian homologs of the Atg12/Atg5/Atg16 complex and 
on Atg8 (Tanida et al., 2004). Figure 4 shows a schematic model of autophagy signaling 
pathway. 
E1-like protein (Atg7) is the first enzyme that activates Atg8 (Tanida et al., 1999), then Atg8 
is transmitted to an E2-like protein (Atg3) (Kirisako et al., 2000). Thereafter, Atg8 is 
conjugated to PE by an amine bond through the free C-terminus of the Atg8 glycine residue. 
Under the cleavage action of Atg4, PE can be released later from Atg8 to facilitate 
autophagosome-lysosome fusion (Ichimura et al., 2000). Since the Atg12/Atg5/Atg16 
complex stimulates Atg8-PE formation, this complex acts potentially as an E3-like enzyme in 
the Atg8 conjugation system (Hanada et al., 2007). When Atg8 is conjugated to PE, it joins to 
the membrane of the autophagosome; therefore Atg8 is used as an autophagosomal marker 
(Kirisako et al., 1999). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Signaling pathway of autophagy (Source: http://www.cellsignal.com/). 
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1.2.1    Role of autophagy in cellular homeostasis and survival 
Autophagy occurs at low basal levels in most normal cells to perform homeostatic functions 
such as protein and organelle turnover or when the cells need to ‘self-cannibalize’ and to 
proceed to cell survival under stress in order to maintain cellular integrity (Mizushima et al.; 
2008). Observations and genetic analyses in patients, as well as studies in transgenic animal 
models, clearly implicate autophagy in diseases, including neurodegenerative diseases (such 
as Parkinson’s disease), skeletal muscle diseases (myopathy), cardiac failure, hepatic 
disorders, infectious diseases, inflammatory disorders (such as Crohn’s disease), aging, 
diabetes, obesity and cancer (Levine and Kroemer, 2008; Mizushima et al., 2008; Mizushima 
and Komatsu, 2011). Investigations of the role of autophagy in cellular homeostasis 
have been performed in liver and brain tissue pathophysiology. Mice with brain-specific Atg5 
or Atg7 deletion revealed neuronal degeneration accompanied with protein aggregates and 
damaged mitochondria accumulation, which are hallmarks of Huntington’s and Parkinson’s 
diseases (Hara et al., 2006; Komatsu et al., 2006); whereas, mice with liver-specific Atg7 
deletion exhibited p62-containing protein aggregations in the liver which prompted liver 
injury and accelerated the death of hepatocytes (Komatsu et al., 2007). Furthermore, a mouse 
model with a targeted deletion of Atg7 in adipose tissue displayed unique anti-obesity and 
insulin sensitization effects with impaired adipogenesis (Singh et al., 2009; Zhang et al., 
2009). Survival mechanism of autophagy has been shown in autophagy-deficient mice  
that die within 1 day of birth due to lack of nutrients (Kuma et al., 2004). In addition, mice 
with homozygous mutant of Beclin-1 die in early embryonic development (E7.5 or earlier) 
(Yue et al., 2003); in contrast to mice with other homozygous autophagy gene deficiencies 
which showed normal embryonic phenotype, for example GABARAP, Atg4 and FIP200 
(O’Sullivan et al., 2005; Marino et al., 2007; Wei et al., 2011). 
Autophagy proteolysis has been shown to extensively decrease with age (Cuervo et al., 2005; 
Martinez-Vicente et al., 2005). Diminishing and alteration in the regulation of autophagy 
leads to the accumulation of altered organelles and membranes, and may start a vicious  
pro-aging circle (Bergamini et al., 2004). Furthermore, blockage of autophagy genes in  
long-lived C. elegans mutants prevents life-span extension (Melendez et al., 2003). 
Moreover, autophagy related gene Atg16L1 is expressed in the intestine and particularly 
strongly in Crohn’s disease, and the functional knockdown of this gene abrogates autophagy 
of the intracellular pathogen Salmonella typhimurium (Rioux et al., 2007). 
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1.2.2    Role of autophagy and GABARAP in tumorigenesis 
The role of autophagy in cancer is complex and likely tissue and genetic context-dependent. 
There is evidence that autophagy may be oncogenic in some instances, whereas in others, it 
clearly contributes to tumor suppression (Levine, 2007; Mathew et al., 2007; Wilkinson and 
Ryan, 2010; Rosenfeldt and Ryan, 2011). Indeed, the connections between autophagy and 
cancer occur at two aspects, first at the level of tumor initiation and progression, and the 
second during cancer treatment. Autophagy is regulated by many sensors involved in tumor 
suppression (PTEN, TSC1-TSC2, p53, DAPk) or oncogenesis (Akt, Ras), and the signaling 
pathways of these sensors form part of a cell program that is constantly modified in cancer 
cells, such as growth, proliferation, survival, death and processes that play important roles in 
tumor progression, such as tumor immunity and angiogenesis. Botti et al. (2006) represented 
these potential interconnections between autophagy and cell functions that are often disrupted 
in cancer cells as an integrative model designed by cogwheels moving in a concerted manner 
to influence autophagy and other cell properties in an alternative manner (Fig. 5). 
 
 
Figure 5. Potential interconnection of autophagy and cellular functions that are constantly disrupted in 
malignant cells. Autophagy signaling (outer cogwheel on the left), autophagy machinery (inner cogwheel on 
the left) and cell functions (cogwheel on the right) are symbolized by cogwheels connected by chains. The 
movement of one cogwheel drives the other two. Bold black arrows and bold black bars indicate the 
stimulation and inhibition of autophagy, respectively (Source: Botti et al., 2006). 
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One example of a tumor suppressor sensor of autophagy is p53 that has been demonstrated to 
play a dual role in autophagy regulation depending on its subcellular location. In the nucleus, 
p53 executes a pro-autophagic role in a transcription-dependent or independent manner (Feng 
et al., 2007), whereas the cytoplasmic p53 has been characterized as a master repressor of 
autophagy (Tasdemir et al., 2008). Ras oncogene is an example of an oncogenic sensor of 
autophagy; it is a member of the small GTPase family which plays a fundamental role in 
regulation of cell growth and survival that is frequently activated in cancer (Schubbert et al., 
2007). It has been reported that active oncogenic Ras induces autophagy, but depending on 
the cellular context, autophagy induction can either promotes autophagic cell death (Elgendy 
et al., 2011) or promotes and facilitates oncogenic transformation by maintaining and 
improving cell metabolism (Guo et al., 2011; Kim et al., 2011; Lock et al., 2011). 
In 2003, Qu et al. and Yue et al. provided the first genetic link between autophagy and 
tumorigenesis. They conferred evidence that mice with heterozygous loss of Beclin-1; an 
autophagy and apoptosis regulating gene (Kang et al., 2011), promoted spontaneous 
malignancies including lung and liver cancers and lymphomas in aged mice. Many human 
and murine tissues express Beclin-1, and it localizes primarily within cytoplasmic structures, 
including the ER, mitochondria and the perinuclear membrane. A monoallelic deletion of 
Beclin-1 has been frequently observed in sporadic human breast cancers and ovarian cancers 
(Aita et al., 1999; Kondo and Kondo 2006). In addition, inhibition of autophagy by 
heterozygous loss of Beclin-1 or homozygous deletion of Atg5 in apoptosis-defective tumor 
cells induced reactive oxygen species (ROS), mitochondrial damage, and p62 accumulation 
which led to increased DNA damage and ultimately facilitated cancer progression  
(Karantza-Wadsworth et al., 2007; Mathew et al., 2009). Paradoxically, Atg5, Atg7, or 
FIP200 knockout in various tissues did not lead to malignant tumor development in vivo  
(Wei et al., 2011), but the mice with systemic mosaic deletion of Atg5 and liver-specific  
Atg7 deletion developed benign liver adenomas originating from autophagy-deficient 
hepatocytes (Takamura et al., 2011). Moreover, Atg4C-deficient mice showed increased 
susceptibility to fibrosarcoma induction by the chemical carcinogen methylcholanthrene 
(MCA) (Marino et al., 2007). 
It is unlikely that the increased rate of tumorigenesis in mice with heterozygous loss of 
Beclin-1 is due to autophagy deficiency. First of all, Beclin-1 has been shown to interact with 
Bcl-2 (B-cell lymphoma 2); an important anti-apoptotic protein. Substantially decreased 
levels of Beclin-1 in the cells with heterozygous loss of Beclin-1 may promote the activity 
of Bcl-2 to boost cell survival which in turn promotes tumorigenesis (Pattingre et al., 2005). 
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Surprisingly, Beclin-1 deficiency has been associated with deficiency in the tumor 
suppressor p53, suggesting that p53 deficiency, rather than autophagy deficiency, 
provide a mechanism to promote genomic instability which in turn leads to tumorigenesis 
in Beclin-1 deficient mice (Liu et al., 2011). Moreover, Liu et al. (2011) showed that 
increased ubiquitination of both Beclin-1 (in the class III PI3K complex) and p53 have 
been achieved by the inhibition of the deubiquitinating activities of USP10 (ubiquitin specific 
peptidase 10) and USP13 (ubiquitin carboxyl-terminal hydrolase 13), and subsequently 
promotes their proteasome-mediated degradation. Beclin-1 by interacting with USP13 
regulates the deubiquitinating activities of both USP13 and USP10. Thus, Beclin-1 appears to 
sit at the center of the mechanisms directing the levels of p53 (Lorina et al., 2013). On the 
other hand, there is a similarity in the tumor spectra of heterozygous deletions of Beclin-1 and 
p53 mice. The frequencies of tumors in mice with heterozygous deletions of Beclin-1 and p53 
are lung carcinoma, lymphoma and hepatoma (Jacks et al., 1994; Qu et al., 2003), and the 
Beclin-1 gene is frequently monoallelically deleted in human sporadic ovarian, prostate and 
breast cancers similar to that of p53 mutations (Liu et al., 2011). 
In an elegant study of Wei et al. (2011), autophagy inhibition by FIP200 knockout suppressed 
mammary tumor initiation and progression in a mouse model of breast cancer driven by 
the PyMT oncogene in association with decreased Cyclin D1 expression, induction of 
interferon (IFN)-responsive genes, effector T-cell tumor infiltration and increased production 
of cytokines, such as CXCL10. Furthermore, the consequences of FIP200 deletion resulted 
in defects in the autophagy machinery including deficient LC3I to LC3II conversion, 
accumulation of ubiquitinated protein aggregates and p62/SQSTM1, and increased  
number of abnormal mitochondrial morphology in tumor cells. Mammary tumor cells or 
Ras-transformed mouse embryonic fibroblasts (MEFs) harbouring FIP200 deletion 
exhibited decreased cell proliferation in both cell systems with no changes in apoptosis 
(Wei et al., 2011). 
GABARAP is ubiquitously expressed in all tested normal tissues, however, its expression in 
human tumors has shown diversity; for instance neuroblastoma (Roberts et al., 2004), breast 
tumors (Klebig et al., 2005), thyroid tumors (Roberts et al., 2009) and colorectal tumors 
(Miao et al., 2010) were investigated. Roberts et al. (2004) studied a cohort of primary 
neuroblastoma tumor samples and predicted that a low mRNA expression level of 
GABARAP were associated with decreased survival among patients with neuroblastoma. 
Moreover, GABARAP transfection into the CAL51 breast cancer cell line influenced the 
growth rate of cancer cells in vitro and the ability of colony formation in soft agar and, 
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furthermore, suppressed the tumorigenicity of the cells in nude mice (Klebig et al., 2005). 
They suggested that GABARAP functions as a putative tumor suppressor gene in breast 
cancer, however, the precise role and mechanism that GABARAP played to inhibit cell 
growth was not elucidated. In an effort to explore the involvement of neurotransmitter and 
neurotrophic factors in thyroid carcinogenesis, Roberts et al. (2009) showed that the 
expression level of GABARAP was increased in adenomas and thyroid cancer suggesting its 
role in early stages of thyroid tumorigenesis. Moreover, Miao et al. (2010) found that 
GABARAP expression was significantly higher in colorectal cancers than that in adjacent 
matched non-tumor tissues, and the high expression of GABARAP was significantly 
correlated with a low grade of differentiation and shortened survival. 
The second aspect of connection between cancer and autophagy occurs during cancer 
treatment. Indeed, autophagy induction have been found to spatially localize to hypoxic tumor 
regions (Mathew et al., 2007), poorly vascularized tumor regions (Degenhardt et al., 2006) or 
following cytotoxic treatments (Ertmer et al., 2007; Apel et al., 2008; Amaravadi et al., 
2011), and thus promotes cancer cell survival under stressful conditions. In general, 
autophagy induction after both radiation and chemotherapy (Yang et al., 2011), essentially 
acts as a treatment resistance mechanism, stress-relieving and pro-survival function that is 
crucial for viability of cancer cell (Lozy and Karantzaa, 2012). In such cases, genetic or 
pharmacologic autophagy inhibition preferentially sensitizes cancer cells to treatment 
(Vazquez-Martin et al., 2009; Wang et al., 2011). It has been shown that chloroquine,  
a non-specific autophagy inhibitor, could enhance the γ-irradiation-induced cell death 
in glioma cells and enhanced cyclophosphamide-induced tumor cell death in a murine 
Myc-driven lymphoma model (Firat et al., 2012; Amaravadi et al., 2007). Combination 
treatment of cisplatin or paclitaxel with chloroquine in non-small cell lung cancer (NSCLC) 
cell line A549 enhanced the cisplatin- and paclitaxel-induced apoptosis (Liu et al., 2012a). 
Furthermore, 3-methyladenine, another non-specific autophagy inhibitor, augments 
5-fluorouracil chemotherapy by increasing cancer cell apoptosis accompanied by tumor 
regression in colon cancer xenografts (Li et al., 2010). Pancreatic ductal adenocarcinoma 
(PDAC) has been shown to require elevated autophagy for growing, and it is highly 
resistant to chemotherapy. Inhibition of autophagy sensitized PDAC cell lines and xenograft 
mouse model to gemcitabine; the current standard treatment for PDAC (Donohue et al., 
2013). These findings might be a promising approach for augmenting the efficacy of 
standard anticancer regimens. 
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1.2.3    Role of autophagy in cancer cell metabolism 
Autophagy is a cellular process of self-cannibalization, by which the cells seize their own 
cytoplasm and organelles and consume them in lysosomes for reusing the resulting 
metabolites as a source to generate energy and to provide building blocks for the synthesis of 
new macromolecules. Thus, autophagy is considered being a major cell survival mechanism 
and deeply integrated into metabolism, stress response and cell death pathways (Rabinowitz 
and White, 2010; Arroyo et al., 2014). Metabolism function of autophagy is a highly 
advantageous to cancer cells, which have demonstrated high metabolic demands and a 
requirement for metabolic reprogramming, as evidenced by the Warburg and reverse Warburg 
effects (Lozy and Karantzaa, 2012). 
Warburg effect is the observation that cancer cells predominantly produce energy by 
glycolysis followed by lactic acid fermentation in the cytosol, rather than by an oxidation of 
pyruvate in mitochondria as in most normal cells. Rapidly growing tumor cells have higher 
glycolytic rates than those of their normal tissues of origin; this occurs even if oxygen is 
plentiful (aerobic glycolysis) (Warburg, 1956; Kim and Dang, 2006; Vander Heiden et al., 
2009). For example, leukemia cells are highly glycolytic despite residing in the bloodstream. 
Reverse Warburg effect has been elucidated in human epithelial breast cancers. According to 
this model, aerobic glycolysis (Warburg effect) actually takes place in tumor associated 
fibroblasts, not in cancer cells. Aerobic glycolysis in cancer associated fibroblasts results in 
the production of high-energy metabolites (such as lactate and pyruvate), which can then be 
transferred to adjacent epithelial cancer cells, which are undergoing oxidative mitochondrial 
metabolism, resulting in increased adenosine triphosphate (ATP) production in cancer cells, 
driving tumor growth and metastasis (Pavlides et al., 2009; Martinez-Outschoorn et al., 2010; 
Pavlides et al., 2010). Increased reactive oxygen species (ROS) production and oxidative 
stress in tumors are caused by the high rates of aerobic glycolysis and glutaminolysis  
(Lozy and Karantzaa, 2012). ROS act as signal transducers in various intracellular pathways 
and play critical roles in cell survival, death, and immune defenses.  It has been found that 
ROS production in tumor cells commonly upregulates autophagy for survival (Scherz-
Shouval and Elazar, 2007; Huang et al. 2011). Furthermore, autophagy in stromal cells 
stimulates by cancer cell-induced oxidative stress and result in release of metabolites by 
tumor-associated fibroblasts and their subsequent utilization by neighboring cancer cells 
(Lozy and Karantzaa, 2012). 
The protumorigenic function of autophagy has been demonstrated in recent years through  
its ability to increase the glucose metabolism in tumor cells in response to diverse stresses. 
 
 13    
1. Introduction 
 
Lock et al. (2011) showed that H-Ras transformation in autophagy-competent MEFs 
displayed enhancement in glucose uptake compared with their autophagy-deficient 
counterparts. Increased glycolysis in autophagy-competent cells facilitates Ras-mediated 
adhesion-independent transformation, indicating a unique mechanism for autophagy to 
promote Ras-driven tumor growth in specific metabolic microenvironments. In contrast, 
autophagy-deficiency in Ras-transformed cells and in cancer cells possessing activating Ras 
mutations has decreased the rate of glycolysis accompanied with decreased the sensitivity to 
dropped glucose concentrations in comparison with autophagy-competent counterparts, both 
in terms of proliferation and adhesion-independent transformation (Lock et al., 2011). 
Implication of autophagy in prevention and progression of cancer has been elucidated in 
human normal breast epithelial cells (MCF10A). MCF10A cells infected with retroviral 
MFG-K-RasV12 undergo cellular transformation with increased levels of autophagy-related 
genes. In contrast, pharmacological inhibition of autophagy or targeted suppression of Atg5 
and Atg7 expression by short hairpin (sh) RNA completely blocked K-RasV12-induced 
anchorage-independent cell growth on soft agar and inhibited tumor formation in nude mice 
(Kim et al., 2011). Moreover, Kim et al. (2011) provided evidence for the cross-talk between 
ROS and MAPK (mitogen-activated protein kinases) signaling that is required for both 
autophagy-related gene expression and autophagy induction in cells overexpressing 
oncogenic K-Ras. Increased ROS production in K-Ras transformed cells resulted in 
autophagy induction via activation of JNK (c-Jun N-terminal kinase) that lead to MAPK 
signaling activation. 
Because Ras mutations are frequently observed in pancreatic, lung and colon cancers, the role 
of autophagy has been studied extensively in these cancer models (Guo et al., 2011; Yang et 
al., 2011). Although Ras mutation is not routinely observed in breast tumors, there is evidence 
that the Ras pathway is activated in breast cancer cell lines (Eckert et al., 2004), as Ras 
hyperactivation may occur downstream of ErbB2 signaling, which is often amplified in breast 
cancers (Birnbaum et al., 2009; Arias-Romero and Chernoff, 2010). High levels of basal 
autophagy in human cancer cell lines bearing activating Ras mutations have been commonly 
observed, and down-regulating the expression of essential autophagy genes impaired cell 
growth through accumulation of abnormal mitochondria and reduced oxygen consumption. In 
addition, suppression of autophagy in cells transduced with Ras reduced the tumor growth in 
nude mice, and the tumors displayed abnormal histology, active caspase-3, and p62 and 
ubiquitin accumulation (Guo et al., 2011). 
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1.3     Autophagy and apoptosis 
Autophagy and apoptosis are both well-controlled biological processes and play fundamental 
roles in development, maintenance of tissue homeostasis and diseases, and subsequently 
determining cellular fate. Although autophagy is primarily considered to have a 
cytoprotective function, it can also promote cell death during normal development and 
disease, which is called type II programmed cell death (Mizushima et al., 2008; Mizushima 
and Levine, 2010). There are many crucial factors governing the cross-talk between 
autophagy and apoptosis. Several autophagic proteins have potential roles in apoptosis, and 
vice versa, i.e. several proteins known to regulate apoptosis have also been identified as 
inducers of autophagy (Table 1) (Mukhopadhyay et al., 2014). For example, the functional 
and structural interaction between Beclin-1 and anti-apoptotic proteins Bcl-2 and Bcl-xL is 
well documented (Fig. 6) (Pattingre et al., 2005; Takacs-Vellai et al., 2005; Maiuri et al., 
2007a; Nikoletopoulou et al., 2013). Inactivation of Beclin-1 triggers apoptotic cell death as 
evidenced by the increased number of apoptotic cell corpses in somatic tissues and in the 
germline of animals (Takacs-Vellai et al., 2005). Proteins of Bcl-2 family classified into three 
groups based on their apoptotic properties. One group inhibits apoptosis (Bcl-2, Bcl-xL, Bcl-
w, Bcl-B, Mcl-1, and A1), and two groups of pro-apoptotic proteins: the multi-domain 
proteins (Bax, Bak, and Bok) contain three Bcl-2 homology (BH) domains, and the BH3-only 
proteins (Bad, Bid, Bim, Bmf, Bik, Hrk, Noxa, and PUMA), which interact with the anti-
apoptotic Bcl-2 protein family to promote apoptosis (Oltvai et al., 1993; Wong and 
Puthalakath, 2008; Hou et al., 2010). Beclin-1 has a BH3 region, which can bind to BH3 
receptors and inhibit anti-apoptotic Bcl-2 proteins, such as Bcl-2 and Bcl-xL, or can stimulate 
the pro-apoptotic Bcl-2 family members, such as Bax and Bak (Galonek and Hardwick, 
2006). Moreover, Bcl-2 inhibits autophagy when it localized to the mitochondria and ER by 
binding to nutrient-deprivation autophagy factor-1 (NAF-1), which stabilizes the interaction 
between Bcl-2 and Beclin-1 at the ER surface. Cellular stress conditions cause displacement 
of Bcl-2 from Beclin-1 and Bax thereby inducing autophagy and apoptosis, respectively. Pro-
apoptotic BH3-only protein Bad disrupts the interaction of Bcl-2/Bcl-xL and Beclin-1 to 
induce autophagy by binding to the BH3-binding domain of Bcl-2 or Bcl-xL (Levine et al., 
2008; Marquez and Xu, 2012). In addition, anti-apoptotic Bcl-2 proteins regulate apoptosis at 
the mitochondrial membrane, where they sequester Bax (pro-apoptotic protein), thus 
preventing mitochondrial membrane permeability and cytochrome c release to cytosol to 
execute apoptosis (Wong and Puthalakath, 2008). Recently, specific cellular inhibitors called 
inhibitor of apoptotic proteins (IAPs), for example Xiap (X-linked inhibitor of apoptosis 
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protein), have been shown to regulate autophagy via interaction of Xiap with Mdm2 (p53 E3 
ubiquitin protein ligase), a negative regulator of p53, and subsequently suppresses autophagy 
(Huang et al., 2013). 
 
Table 1.  Proteins with dual role in autophagy and apoptosis (Source: Mukhopadhyay et al., 2014) 
 
Protein              Role in autophagy           Role in apoptosis 
Autophagic proteins   
mTOR Inactive form involves in initiation mTOR regulates apoptosis 
Beclin-1 Autophagosome nucleation Cleaved C-fragment induces mitochondrial apoptosis 
UVRAG Upregulates Vps34–Beclin1 interaction 
Antiapoptotic, inhibits Bax 
translocation from cytosol to 
mitochondria 
AMBRA Upregulates Vps34–Beclin1 interaction Regulate mitochondrial apoptosis; cleaved by caspases and calpains 
Atg3 Conjugates with Atg12 Regulates mitochondrial cell death 
Atg5 Conjugates with Atg12, autophagosome elongation 
Interacts with FADD to inhibit 
apoptosis, cleaved N-fragment induces 
mitochondrial apoptosis 
Atg12 Autophagosome elongation Stimulates mitochondrial apoptosis by inactivating Bcl-2 and Mcl-1 
Atg4D LC3 processing Cleaved Atg4D localize to mitochondria and induces apoptosis 
p62 Binds with LC3, promotes degradation of polyubiquitinated protein aggregates Caspase-8 processing and activation 
Apoptotic proteins   
Bcl-2, Bcl-xL Interacts with Beclin-1 and inhibit autophagy Antiapoptotic 
Bad, Bak, BNIP3, 
Nix 
Proautophagic, disrupting Beclin-1/Bcl-2 
interaction Proapoptotic 
Bax, PUMA Proautophagic, noncanonical type Proapoptotic 
p53 - Inhibits by cytoplasmic p53 - Induces by nuclear p53 through DRAM 
Proapoptotic 
Proapoptotic 
Noxa Induces autophagy by disrupting Mcl-1/Beclin-1 interaction Proapoptotic 
Bim Sequesters Beclin-1, inhibits autophagy Proapoptotic 
XIAP Inhibits by Mdm2-p53 signaling Inhibits caspase 3,7 
cFLIP Prevent interaction between Atg3 and LC3 Inhibits caspase 8 
 
 
Furthermore, autophagic proteins have been involved in intrinsic and extrinsic apoptosis 
pathways (Table 1 and Fig. 6) (Mukhopadhyay et al., 2014; Nikoletopoulou et al., 2013). The 
extrinsic apoptosis pathway gets stimulation by soluble molecules that bind to plasma-
membrane receptors (cell surface death receptors), such as Fas (CD95/APO1), TNFα (tumor 
necrosis factor-α) and TRAIL (TNF related apoptosis inducing ligand) receptors (Mathew et 
al., 2009), whereas the intrinsic pathway is triggered by various intracellular (mitochondrial) 
stimuli resulting from hypoxia, DNA damage, oxidative stress, and growth factor deprivation, 
which induce outer mitochondrial membrane permeabilization (Galluzzi et al., 2012). In both 
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circumstances, activation of caspases results in mitochondrial membrane permeabilization, 
chromatin condensation and DNA fragmentation, thereby leading to the destruction of the cell 
(Fig. 6) (Green, 2005). Caspases are controlled by IAPs, which bind to and inhibit caspases. 
Despite this, caspases can escape IAP’s inhibitory control through antagonist of IAPs either 
with Smac/DIABLO and HtrA2/Omi, which are released from the mitochondria (Galluzzi et 
al., 2012), or Xaf1 (Xiap-associated factor 1) (Liston et al., 2001). 
 
Figure 6. The complex interplay between autophagy and apoptosis (Source: Nikoletopoulou et al., 2013) 
 
The autophagic pathway works as an adaptive response to cellular stress, however, in the case 
of extreme or prolonged stress, cells are forced to undergo autophagic cell death (Ouyang et 
al., 2012; Bhutia et al., 2013). It has been shown that autophagy and apoptotic cell death are 
induced in response of ER stress; for instance perturbation of either ER calcium homeostasis 
or ER function (Nikoletopoulou et al., 2013). ER-induced autophagy in colon and prostate 
cancer cells has an essential role in eliminating unwanted polyubiquitinated protein 
aggregates, thereby safeguarding the cell from death. However, in normal human colon cells 
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and in non-transformed murine embryonic fibroblasts, autophagy does not mitigate ER stress 
but rather is engaged in ER-induced apoptosis (Ding et al., 2007). 
Searching for a particular binding protein of GABARAP, Lee et al. (2005) identified DEAD 
(Asp-Glu-Ala-Asp/His) box polypeptide 47 (DDX 47), a putative RNA helicase, as a binding 
partner of GABARAP. Co-transfection of GABARAP and DDX47 cDNA into ovarian cancer 
cells was shown to induce apoptosis. Moreover, direct interaction of GABARAP  
and proapoptotic protein Nix/ BNIP3L has been elucidated in mammalian cells (Schwarten et 
al., 2009). Nix belongs to the BH3-only protein group of Bcl-2 protein family, and is known 
to localize to mitochondria and to a lesser extend to the ER and nuclear envelope (Imazu et 
al., 1999; Ohi et al., 1999). Nix induces and contributes to cell death upon transient 
expression in non-neuronal cells (Imazu et al., 1999, Chen et al., 1999, Yussman et al., 2002). 
Nix knockout was shown to enhance tumorigenicity, whereas its transient overexpression in a 
number of cancer cell lines was shown to inhibit colony formation mediated by p53-
dependent apoptosis (Fei et al., 2004). Moreover, autophagy has been induced in tumor cells 
transfected with the Nix homologous gene BNIP3 (Daido et al., 2004). Atg5 overexpression 
increased autophagy in cells overexpressing BNIP3 compared to BNIP3 alone, and this 
autophagy enhancement correlated with reduction in BNIP3-mediated cell death (Hamacher-
Brady et al., 2007). Atg4, a crucial regulatory component of the autophagosome biogenesis 
pathway (Scherz-Shouval et al., 2007), has four assumed Atg4 paralogues (autophagins 
Atg4A-Atg4D) (Marino et al., 2003). Betin and Lane (2009) have shown that caspase-cleaved 
Atg4D acquires increased priming and delipidation activities against GABARAPL1. The 
siRNA silencing of Atg4D expression has suppressed the autophagy by abrogating 
GABARAPL1 autophagosome formation and sensitizes cells to starvation and staurosporine-
induced cell death. These findings favor the hypothesis that caspases stimulate Atg4D-
mediated autophagy to promote the cellular survival under stress (Betin and Lane, 2009). 
Autophagy deficiency or inhibition occurred during knockdown of autophagy related genes or 
during pharmacological block by chloroquine and 3-methyladenine, resulting in accumulation 
of ubiquitinated protein aggregates, reactive oxygen species (ROS), p62 accumulation, 
mitochondrial damage and increased abnormal mitochondrial morphology (Karantza-
Wadsworth et al., 2007; Komatsu et al., 2007; Kim et al., 2008; Mathew et al., 2009; Wei et 
al., 2011). Under cellular stress and anti-cancer therapy, the autophagosome engulfs damaged 
mitochondria and apoptotic proteins to promote cellular survival, whereas under serum 
starvation condition, autophagy protects cells by sequestering ROS-producing mitochondria 
through autophagosome formation (Liu et al., 2012b). Moreover, p62/sequestosome 1 is a 
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multi-functional and multi-adaptor protein and has been implicated in several cellular 
signaling pathways, for example the signaling axis that shuttles ubiquitinated proteins to the 
lysosome during autophagy and the activation of the transcription factor NF-κB (Moscat and 
Diaz-Meco, 2009; Huang et al., 2013). Mathew et al. (2009) showed that the modulation of 
p62 by autophagy is a key factor in tumorigenesis, whereas recently, Huang et al. (2013) 
linked p62 activity to the extrinsic apoptosis pathway. In the setting of autophagy inhibition, 
upregulation of p62 can mediate apoptosis via caspase-8 activation that was Bax-dependent 
and a consequence of mitochondrial amplification (Huang et al., 2013). Moreover, p62 
upregulation and increased level of active caspases-8, in the context of autophagy inhibition, 
can trigger apoptosis in the presence of H2O2 in U87MG cells (Zhang et al., 2013). 
In addition to the relationship between autophagy and apoptosis, autophagy also prevents  
cell death that occurs due to cell detachment from the extracellular matrix (ECM); which is 
called anoikis, in both nontumorigenic epithelial cell lines and in primary epithelial cells 
(Fung et al., 2008). 
 
1.4     Autophagy and immune response 
Autophagy has been implicated in both innate and adaptive immunity. Published studies 
suggested that the autophagy machinery is an innate immunity effector against intracellular 
bacteria and viruses (Nakagawa et al., 2004; Paludan et al., 2005; Yoshimori and Amano, 
2009), whereas other studies showed that autophagy has roles in adaptive immunity functions 
through its impact on MHC (major histocompatibility complex) class II presentation (Dengjel 
et al., 2005; Gannage and Münz, 2010). The importance of the role of autophagy in immunity 
(innate and adaptive) is highlighted in part by the association of defects in autophagy with 
several disease states including metabolic syndrome, inflammatory disorders (Crohn's 
disease), neurodegeneration, aging and cancer (Levine and Kroemer, 2008).  
Autophagy of tumor cell may recruit the immune cells through facilitating of adenosine 5′-
triphosphate (ATP) releases from tumor cells in response to chemotherapy. In turn, ATP 
recruits dendritic cells and a T cell response, thereby stimulating antitumor immune responses 
(Michaud et al., 2011). Furthermore, Michaud et al. (2011) found that inhibiting Atg5 or Atg7 
expression in highly immunogenic allograft mouse tumors blunted the ATP release by the 
tumor cells in response to chemotherapy. The role of autophagy in efficient antigen cross-
presentation in tumor cells has been shown in few studies (Li et al., 2008; 2011). Li et al. 
(2008) found that siRNA-mediated knockdown of Beclin-1 or Atg12 in antigen donor tumor 
cells resulted in less cross-presentation. They postulated a mechanism by which the 
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autophagosome acted as a carrier of protein antigens from tumor cells (Li et al., 2011). In 
contrast, autophagy can also limit immune-mediated cytotoxicity (Amaravadi, 2011). Noman 
et al. (2011) found that autophagy prevent T cell-mediated cytotoxicity in the context of 
hypoxia in lung cancer cells. Moreover, in the B16-F10 melanoma allograft mouse model, 
inhibition of Beclin-1 resulted in a reduction of tumor growth and increased tumor apoptosis, 
and combination of autophagy inhibition with melanoma peptide vaccination heightened 
tumor regression compared to either treatment alone (Noman et al., 2011). Consistent with 
these results, preclinical data indicated that blocking of autophagy with chloroquine enhanced 
the efficacy of chemotherapy, targeted therapy, and immunotherapy (Amaravadi et al., 2011). 
Furthermore, attenuation of autophagy by Atg5 knockdown in human melanoma cells 
enhanced basal surface exposure of the phagocytosis signal calreticulin, dendritic cell 
maturation, interleukin-6 (IL-6) production and proliferation of antitumorigenic CD8+IFN-γ+ 
and CD4+ IFN-γ + T cells (Garg et al., 2013). 
The tumor stroma consists of tumor cells and tumor-associated cell types including 
fibroblasts, endothelial cells and immune cells. The accepted current view is that the dynamic 
interaction and coevolution between tumor cells and stromal cells dictates tumor progression 
and the response to cancer therapy (Pietras and Ostman, 2010; Maes et al., 2013). 
Accumulating observations suggest that autophagy may play an important 
immunomodulatory role by regulating the tumor stroma and surface proteome (Maes et al., 
2013). Various stress factors are present in the tumor microenvironment due to intratumoral 
hypoxia resulting from insufficient vasculature (blood supply) and lack of growth factors as 
well as tumor acidosis. All of these stress factors stimulate autophagy in the tumor 
compartment. Increased autophagy in tumor cells can support the energy metabolism, but it 
can also act as transporter for dangerous signals, proinflammatory cytokines and chemokines, 
and different intracellular proteins to the extracellular space (Garg et al., 2010; Dupont et al., 
2011; Michaud et al., 2011). 
It has been shown that innate immunity plays an essential role in controlling the maintenance 
of tissue homeostasis and reacts to tissue disruption, for example disruption which occurs 
during breast branching morphogenesis at puberty and pregnancy, and in post-weaning 
involution (Demaria et al., 2011). These processes are regulated mainly by macrophages, and 
are associated with inflammation that resolves once tissue homeostasis is restored (Gyorki 
and Lindeman, 2008). In contrast, carcinogenesis is a chronic process, predominantly 
characterized by disordered proliferation and death of the neoplastic cells, and the releasing of 
damage-associated molecular patterns (DAMP) molecules from dying cancer cells can  foster 
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a state of chronic inflammation (Zeh and Lotze, 2005; Mantovani et al., 2008). Moreover, 
death of epithelial cells during transformation releases tumor-associated antigens  
which activate tumor specific T and B cell responses, and subsequently prevent tumor 
outgrowth. On the other hand, genetically unstable cancer cells can become resistant to the 
recognition and killing by immune effector cells by a process called immunoediting 
(Schreiber et al., 2011). 
There are a wide variety of close interactions between autophagy and the pattern recognition 
receptors (PRRs) of the innate immune response, for example Toll-like receptors (TLRs) and 
Nod-like receptors (NLRs) (Araya et al., 2013). During innate immune signaling, TLRs can 
induce autophagy (Shi and Kehrl, 2010). Disruption of the association between Beclin-1 and 
Bcl-2 is a proposed mechanism of the induction of autophagy mediated by the TLR adaptors, 
MyD88 and TIR-domain-containing adapter-inducing interferon-β (TRIF) (Levine et al., 
2011). NLRs are components of inflammasomes, an integral part of the innate immune 
system’s response to infections and cellular stress. The activation of inflammasome leads to 
recruit the apoptosis-associated speck-like protein that contains a caspase recruitment domain 
and pro–caspase-1, which results in caspase-1 activation. The activation of caspase-1 is 
required to mature interleukin 1β (IL-1β) and IL-18, which are then secreted out of the cells. 
Autophagy has been shown to negatively regulate inflammasome activation by eliminating 
dysfunctional mitochondria (Nakahira et al., 2011; Shi et al., 2012). The disruption of 
autophagy-related genes, including Beclin-1, Atg5, Atg16L1, LC3 and GABARAP, in 
macrophages have been shown to increase ROS production and translocation of 
mitochondrial DNA (mtDNA) into the cytosol upon treatment with lipopolysaccharides 
(LPS), an effective inducer of the inflammatory response, and ATP, an NLRP3 (NLR family, 
pyrin-domain containing 3) inflammasome inducer (Tal et al., 2009; Nakahira et al., 2011; 
Zhang et al., 2013). Thereby, secretions of proinflammatory cytokines such as IL-1β and  
IL-18 are have augmented, which, in the context of sepsis that is associated with massive 
infections, can mediate tissue injury and lethal shock (Hotchkiss and Karl, 2003).  
Several studies using mouse models demonstrated that developing tumors are indeed 
recognized and destroyed by the intact immune systems through anti-tumor immune 
surveillance mechanisms (Shankaran et al., 2001; Bui and Schreiber 2007; Wei et al., 2011). 
It has been shown that interferon gamma (IFN-γ) inhibited cell growth in various cells (Gooch 
et al., 2000; Platanias, 2005), as well as could inhibit growth of mammary tumor cells driven 
by PyMT (Wei et al., 2011). The protumorigenesis function of autophagy has been evaluated 
directly by using loss-of-function approaches directed against the FIP200 gene, a regulator of 
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mammalian autophagy, in a PyMT oncogene driven mouse model of breast cancer in vivo. 
FIP200 knockout halted tumorigenesis by not only affecting cellular energy metabolism and 
proliferation but also by increasing host antitumor immunosurveillance (Wei et al., 2011). 
Moreover, FIP200 deletion in mice enhanced infiltration of antitumorigenic CD8+IFN-γ+ and 
CD4+IFN-γ+ T cells in the tumor microenvironment, triggered by increased production of 
chemokines, such as CXCL9 and CXCL10, from FIP200-null tumor cells (Wei et al., 2011). 
Interestingly, inhibition of cytotoxic T lymphocyte in this model retrieved accelerated 
mammary tumor initiation (Wei et al., 2011). All together, these observations proposed that 
cancer cell-associated autophagy plays a key role in subverting antitumor immunity, thereby 
supporting tumor progression (Maes et al., 2013). 
Interestingly, “no inactivating somatic mutations in any autophagy genes have been reported, 
thus autophagy probably play an essential role in tumorigenesis, and autophagy-deficient 
tumors may be rare” (Amaravadi, 2011). 
 
1.5     Chemical carcinogens 
Carcinogens are a number of agents that can cause tumors in humans and animals. They can 
be divided into three major groups: chemical carcinogens, physical carcinogens, and 
oncogenic viruses. Most of them, single or in combination result in tumor initiation by 
interfering with DNA in cells and thereby impact on cellular function. Chemical carcinogens 
are environmental factors that act through genotoxic and non-genotoxic mechanisms and they 
may require metabolic activation to elicit detrimental effects (Fig. 7). The activation of 
carcinogens is often linked to the activity of ‘xenobiotic metabolizing enzymes’ such as 
cytochrome P450-dependent monooxygenases, glutathione S-transferases, sulphotransferases 
and others (Fig. 7) (Luch, 2005). 
The most used types of chemical carcinogens are polycyclic aromatic hydrocarbons (PAHs), 
nitrosoureas and urethane that have been applied in experimental animals to induce tumors 
(Medina, 1974 and 2007; Uno et al., 2004). Among PAHs, 7,12-dimethylbenz(a)anthracene 
(DMBA) is a reliable, potent and widely used carcinogen. In addition, it is immunotoxic in 
various species, tissues, and cell types (Medina, 2007). N-ethyl-N-nitrosourea (ENU) and  
N-methyl-N-nitrosourea (MNU) are alkylating agents and potent mutagens of the nitrosourea 
carcinogen family (Medina, 2007). The environmental exposure to DMBA comes from 
burning of organic matters, including coal, charred foods, cigarette smoke and car exhaust 
fumes (Gelboin, 1980). DMBA acts at multiple sites and can induce various type of cancer in 
animal models, for instance mammary, skin, lung neoplasms, lymphoma and oral cavity 
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tumors (de Oliveira et al., 2013). The response of mice to DMBA is strain-dependent with 
DBA2f and Sencar mice being the most sensitive and C57BL/6 being the least sensitive 
(Medina, 2010). Most studies have used DMBA to induce mammary tumors following 
administration by oral gavage in mouse models (Medina, 1974, Currier et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Overview of genotoxic and non-genotoxic effects of carcinogens (Source: Luch, 2005) 
 
In general, chemical carcinogens induce molecular changes in target organ, and the most 
frequently involved genes are Ras and Tp53 (Hoenerhoff et al., 2009). Many previous studies 
reported the DNA damaging effect of environmental carcinogens, for example the induction 
of point mutations in genes such as c-H-ras by DMBA (Dandekar et al., 1986; Cardiff et al., 
1988; Qing et al., 1997). Upon DMBA oral gavage treatment, the cellular cytosolic receptor 
for DMBA, the aryl hydrocarbon receptor (AhR) is upregulation and through its translocation 
to the nucleus associates with the cofactor ARNT, the AhR nuclear translocation protein 
(Swanson et al., 1995; Trombino et al., 2000; Denison and Nagy, 2003). Subsequently, the 
AhR/ARNT complex binds to specific DNA recognition sites and induces gene transcription 
(Denison and Nagy, 2003). In addition, cytochrome P450 (CYP1A1 and CYP1B1) is 
upregulated in an AhR-dependent response. Cytochrome P450 has been reported to be 
involved in the metabolism of DMBA. It converts it into a mutagenic epoxide intermediate 
that readily forms DNA adduct (Shimada and Fujii-Kuriyama, 2004). These adducts are 
correlating with DNA mutations and the malignant transformation of PAH-mediated 
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carcinogenesis (Nebert et al., 1990; Rundle et al., 2000). Moreover, Currier et al. (2005) have 
elucidated the oncogenic signaling of DMBA in mouse mammary tumors. DMBA-induced 
mammary tumors demonstrated high expression of AhR, c-myc, Cyclin D1, and 
hyperphosphorylated retinoblastoma (Rb) protein. Moreover, elements of the Wnt signaling 
pathway, the NF-κB pathway, and prolyl isomerase Pin-1 have been up-regulated in the 
tumors when compared to normal mammary glands. They proposed that “environmental 
carcinogens can produce long-lasting alterations in growth and anti-apoptotic pathways, 
leading to mammary tumorigenesis” (Currier et al., 2005).  
 
1.5.1    Immunosuppression and immunotoxicity of carcinogen (DMBA) 
Suppression of immune response by chemical carcinogens has been reported several decades 
ago (Malmgren et al., 1952). Chemical carcinogens, especially DMBA, can suppress both 
cell-mediate immunity and humoral immunity for prolonged periods of time (Prehn, 1963; 
Ward et al., 1986; Burchiel et al., 1990; Gao et al., 2007, 2008). DMBA suppresses immune 
response through inhibition of lymphocyte activation, mainly by depressing the ability to 
generate cytotoxic T-lymphocytes (CTL) and natural killer (NK) cells (Ward et al., 1986; 
Burchiel et al., 1990). It has been proposed that immunosuppression induced by DMBA, 
including CTL and NK cell tumoricidal functions, may act as an important mechanism in 
association with the genotoxic effect, contributing to tumor outgrowth and metastasis (Ward 
et al., 1986). Microsomal epoxide hydrolase (mEH, EPHX1) has been found as a crucial 
enzyme for metabolic activation of DMBA in vivo leading to immunosuppression of spleen 
cells (Gao et al., 2007). Furthermore, Gao et al. (2008) have shown that genotoxicity of 
DMBA is responsible for DMBA-induced immunosuppression in vivo via activation of p53 
and ataxia telangiectasia mutated (ATM) signaling. 
Interleukin-2 (IL-2) is a T cell growth factor that has been discovered in the supernatants of 
activated T cells (Morgan et al., 1976). IL-2 stimulates the growth, differentiation and 
survival of antigen-specific CD4+ T cells and CD8+ T cells (Stern and Smith, 1986; Liao et 
al., 2011). It can modulate effector cell differentiation (T helper type 1 (Th1) cells, Th2, 
Th17, and regulatory T cells (Tregs)) as well as IL-7 via regulation of cytokine receptor 
expression (Liao et al., 2011). Several studies demonstrated that DMBA highly suppressed 
the production of IL-2 from splenocytes in response to mitogenic or allogeneic stimulation  
in vivo and in vitro (House et al., 1987; Saas et al., 1996). Recently, IL-2 has been used for 
the treatment of patients with advanced renal cancer and subsequently of patients with 
melanoma (Clement and McDermott, 2009; Halama et al., 2010), but it was accompanied 
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with toxicity. In an effort to reduce the IL-2 toxicity in cancer patients, Liang et al., (2012) 
provided evidence that inhibition of autophagy by using chloroquine during IL-2 
immunotherapy in mouse model lead to regression of tumor growth significantly and 
prolonged survival. 
The immunotoxicity of DMBA is accompanied by a decrease of the spleen weight as well as 
changes in spleen cellularity (total number of spleen cells reduced) and bone marrow 
cellularity (Miyata et al., 2001; Page et al., 2003). These decreases were associated with cell 
death of splenocytes after DMBA treatment (Miyata et al., 2001; Gao et al., 2007). Moreover, 
it has been reported that DMBA induced pre-B-cell apoptosis (Heidel et al., 1999; Near et al., 
1999). For instance, Page et al. (2003) have shown that bone marrow toxicity in mice is 
dependent on p53 activation in vivo after DMBA exposure. Further, Teague et al. (2010) 
showed that DMBA activates apoptosis in pro/pre-B cells in a bone marrow stromal cell-
dependent manner, via activation of caspase-3. 
 
1.5.2    Carcinogen, autophagy and DNA damage 
Modifications in DNA structure (DNA damage) can happen by exogenous environmental 
agents such as ionizing radiation (IR), ultraviolet (UV) and genotoxic chemicals (for instance, 
carcinogens) or by endogenous byproducts of regular cellular metabolism including ROS 
(Rodriguez-Rocha et al., 2011). In response to genotoxic stimuli or cytotoxic lesions (such as 
double strand breaks (DSB)), cells trigger several processes in order to retain genomic 
stability; these processes include DNA damage response (DDR) to repair or remove the 
lesions and keep DNA integrity, cell cycle checkpoint activation to arrest the progression of 
the cell cycle and to allow DNA repair and thereby prevent the transmission of the  
DNA damage, transcriptional response activation to change the transcription profile, and  
activation of apoptosis pathways in order to remove the damaged or deregulated cells  
(Roos and Kaina, 2006; Rodriguez-Rocha et al., 2011). A key player in DNA damage is p53 
(Caspari, 2000; Hickman et al., 2002), however, the response to genotoxic stress is a complex 
process and requires the activation of several proteins involved in sensing aberrant DNA 
structures and the initiation of subsequent events (Rodriguez-Rocha et al., 2011). 
DNA damage occurs in several tissues of rat following exposure to DMBA (Muqbil et al., 
2006). In general, PAH-DNA adducts may trigger nucleotide excision repair (NER), 
including p53-dependent apoptosis in certain cell types, depending on the degree of the DNA 
lesion and cell cycle progression (Henkler et al., 2012). Ganesan et al. (2013) found that 
DMBA induces DSB with the subsequent activation of DNA repair as potential mechanism  
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to prevent the follicle loss in rat ovaries. Moreover, DNA damage activates ATM and/or ATR 
(ATM and Rad3 related) which in turn phosphorylate a variety of signaling proteins  
such as checkpoint kinases 1 and 2 (CHK1, CHK2), and p53. Phosphorylated p53  
induces transcriptional activation of pro-apoptotic factors such as Fas, Bax and PUMA  
(Roos and Kaina, 2006). Therefore, DNA-repair deficiency sensitizes cells to apoptosis 
induced by DNA lesions, such as bulky DNA adducts (Rodriguez-Rocha et al., 2011). 
Several studies showed that autophagy was induced in response to DNA damage (Klionsky 
and Emr, 2000; Polager et al., 2008; Kang et al., 2009), however, the role of autophagy in 
DDR is still unclear. It has been demonstrated that cells initiate cell cycle arrest and 
autophagy upon treatment with DNA-damaging agents, for example camptothecin (CPT) 
(Abedin et al., 2007; Bae and Guan, 2011), etoposide and tomozolomide (Katayama et al., 
2007), p-anilioaniline (Elliott and Reiners, 2008) and IR (Bae and Guan, 2011). Autophagy 
delayed apoptotic cell death in breast cancer cells treated with CPT (Abedin et al., 2007). The 
interaction of anti-apoptotic proteins Bcl-2/Bcl-xl with Beclin-1 in ER inhibits autophagy 
(Maiuri et al., 2007b). The pro-apoptotic and anti-apoptotic Bcl-2 proteins regulate apoptosis 
induced by DNA damage; this suggests a regulatory role of Bcl-2 family proteins in 
mediating the crosstalk between autophagy and apoptosis signaling (Zinkel et al., 2006). 
Furthermore, doxorubicin induced DNA damage in association with autophagy induction 
which was observed to depend on PARP-1 (poly [ADP-ribose] polymerase 1). Inhibition of 
autophagy enhanced doxorubicin-mediated cell death suggesting that autophagy acts as a 
protective mechanism against DNA damage-induced apoptosis (Munoz-Gamez et al., 2009; 
Huang and Shen, 2009). On the other hand, mitochondrial damage produces ROS which is in 
turn may stimulate mitophagy to remove the damaged organelles, therefore autophagy 
malfunction lead to increased ROS causing DDR (Mathew et al., 2007). DDR insufficiency 
could stimulate genomic instability resulting in tumorigenesis; however, extremely increased 
DNA damage may also result in cell death (Bae and Guan, 2011). Bae and Guan (2011) 
demonstrated that inhibition of autophagy by FIP200 knockout resulted in deficient repair of 
DNA damage produced by ionizing radiation and anticancer agents. In this work, persistent 
DNA damage after CPT treatment was associated with increased apoptosis and reduced 
survival of FIP200 knockout cells. They suggested that accumulation of p62 protein due to 
autophagy insufficiency is responsible for impaired DDR and CPT-induced cell death (Bae 
and Guan, 2011). 
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1.6     Aims of the study 
We previously reported that GABARAP may function as a tumor suppressor in breast cancer 
cells and that the expression of the gene was associated with larger vesicle formation. 
However, the precise role and mechanism that GABARAP plays in tumorigenesis could not 
elucidated so far. Instead, GABARAP was identified in the meantime as one of the 
autophagy-related genes that play a role in the maturation of the autophagosome. In the last 
decade, increasing studies have implicated autophagy in the tumor initiation and progression. 
Recently, autophagy has been involved in cancer therapy by using autophagy inhibitors, for 
instance chloroquine. GABARAP is ubiquitously expressed in all tested normal tissues. Its 
expression has been studied in some cancer types, for example neuroblastoma, breast tumors, 
thyroid tumors and colorectal tumors. Furthermore, autophagic proteins have been involved in 
the regulation of both innate and adaptive immunity. Autophagic gene deletions demonstrated 
an increase in the lethality of sepsis in mouse models and enhanced infiltration of 
antitumorigenic T cells in the tumor microenvironment. 
The primary aim of the study was to explore the role of GABARAP in tumorigenesis by using 
a knockout mouse model. Specifically the following questions were addressed: 
- Does treatment of GABARAP knockout mice with carcinogens or the inoculation of the 
mice with syngeneic tumor cells affect tumorigenesis differently compared to wild-type mice? 
- And if this is the case what are the cellular mechanisms being affected by GABARAP 
deficiency that govern the differences in the tumor phenotype? 
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2.       Materials and Methods 
2.1     Materials 
2.1.1    Chemicals 
Chemical Company 
7,12-Dimethylbenz(a)anthracene (DMBA) Sigma-Aldrich, St. Louis, MO, USA  
Agarose  Serva, Heidelberg, Germany  
Albumin Fraction V (BSA)  Roth, Karlsruhe Germany  
Alum potassium sulfate Merck KGaA, Darmstadt, Germany 
Aqua ad injectabilia  Braun, Melsungen, Germany  
Ammonium chloride ( NH4Cl) Sigma-Aldrich, St. Louis, MO, USA 
Ammonium persulfate (APS)  Sigma-Aldrich, St. Louis, MO, USA  
Camptothecin (CPT) Bio Vision, Milpitas, California, USA 
Carmine Fluka, Bassersdorf, Switzerland 
Citric acid monohydrate Sigma-Aldrich, St. Louis, MO, USA 
Chloroquine (CQ) diphosphate salt Sigma-Aldrich, St. Louis, MO, USA 
Deoxycholate AppliChem, Darmstadt, Germany  
Developer Kodak, Rochester, USA 
Diethylether Otto Fischar, Saarbrücken, Germany 
Diethylpyrocarbonate (DEPC) Sigma-Aldrich, St. Louis, MO, USA 
Dimethylsulfoxid (DMSO)  Sigma-Aldrich, St. Louis, MO, USA  
Ethylenediaminetetraacetic acid (EDTA)  Sigma-Aldrich, St. Louis, MO, USA  
Ethanol  Merck KGaA, Darmstadt, Germany  
Fixer Kodak, Rochester, NY, USA 
Formaldehyde J.T. Baker, Deventer, Netherlands 
GelRED  Biotium, Hayward, USA  
Glacial acetic acid J.T. Baker, Deventer, Netherlands 
Glycin  Roth, Karlsruhe, Germany  
Heparin Roche, Grenzach-Wyhlen, Germany 
Hydrochloric acid (HCl)  J.T. Baker, Deventer, Netherlands  
Hydrogen peroxide solution (H2O2) Roth, Karlsruhe, Germany 
Isopropanol Roth, Karlsruhe, Germany 
Medroxyprogesteron acetate (MPA) Pfizer, Madrid, Spain 
Methanol Merck KGaA, Darmstadt, Germany  
N-methyl-N-nitrosourea (MNU) Santa Cruz, CA, USA 
N-ethyl-N-nitrosourea (ENU) Sigma-Aldrich, St. Louis, MO, USA  
Non-fat dry milk  BD, Sparks, France  
Nonidet P-40 substitute  AppliChem, Darmstadt, Germany  
Ortho-phenylenediamine (OPD) Sigma-Aldrich, St. Louis, MO, USA 
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Permount Fischer Scientific, New Jersey, USA 
Potassium chloride (KCl) Serva, Heidelberg, Germany 
Potassium phosphate monobasic (KH2PO4) Merck KGaA, Darmstadt, Germany 
Rotiphorese Gel40 (Acrylamide) Roth, Karlsruhe, Germany  
Sesame oil Local market 
Sodium azide (NaN3) Sigma-Aldrich, St. Louis, MO, USA 
Sodium bicarbonate (NaHCO3) Merck KGaA, Darmstadt, Germany 
Sodium citrate Merck KGaA, Darmstadt, Germany 
Sodium hydroxide (NaOH) J.T. Baker, Deventer, Netherlands 
Sodium lauryl sulfate (SDS)  Roth, Karlsruhe, Germay  
Sodium phosphate dibasic (Na2HPO4)  Merck KGaA, Darmstadt, Germany  
Sodium phosphate dibasic dehydrate  
(Na2HPO4 x 2 H2O) 
Merck KGaA, Darmstadt, Germany 
Sodium phosphate monobasic monohydrate 
(Na2HPO4 x H2O) 
Merck KGaA, Darmstadt, Germany 
Sulfuric acid ( H2SO4) J.T. Baker, Deventer, Netherlands 
Target Retrival Solution, citrate pH 6  DAKO, Glostrup, Denmark  
Tetramethylethylenediamine (TEMED)  Sigma-Aldrich, St. Louis, MO, USA  
Tris-Base  EMD Chemicals, San Diego, CA, USA  
Tween20  Roth, Karlsruhe, Germany  
Xylol  Sigma-Aldrich, St. Louis, MO, USA  
 
2.1.2    PCR and cell culture reagents 
Reagent Company 
10 x buffer S peQlab, Erlangen, Germany 
2.0 mM dNTP mix Thermo Scientific, Rockford, IL, USA 
2.5% Trypsin (10 x) Gibco, Paisley, UK 
2-mercapto-ethanol Sigma-Aldrich, St. Louis, MO, USA 
Adenosine triphosphate (ATP) InvivoGen,  Toulouse, France 
Dulbecco’s MEM (DMEM) Biochrom, Berlin, Germany 
Earle’s balanced salt solution (EBSS) Sigma-Aldrich, St. Louis, MO, USA 
FastStart Universal SYBR Green Master 
(Rox) Roche, Mannheim, Germany 
Fetal calf serum (FCS) Biochrom, Berlin, Germany 
HEPES Invitrogen, Karlsruhe, Germany 
L-glutamine Invitrogen, Karlsruhe, Germany 
Lipopolysaccharide (LPS) Sigma-Aldrich, St. Louis, MO, USA 
Penicillin Invitrogen, Karlsruhe, Germany 
Protease inhibitor cocktail tablets Roche, Mannheim, Germany 
RPMI 1640 Biochrom, Berlin, Germany 
Sodium pyruvate Invitrogen, Karlsruhe, Germany 
 
 29    
2. Materials and Methods 
 
 
2.1.3    Kits and assays 
 
2.1.4    Laboratory equipment and consumables 
Streptomycin Invitrogen, Karlsruhe, Germany 
Taq-polymerase (HotStarTaq) peQlab, Erlangen, Germany 
Trypsin-EDTA Biochrom, Berlin, Germany 
Kit Company 
BCA protein assay kit Thermo Scientific, Rockford, IL, USA 
DAKO REAL™ Detection System Alkaline 
Phosphatase/RED  Rabbit/Mouse DAKO, Glostrup, Denmark 
DNA Clean & Concentrator™-5 Kit Zymo Research, Irvine, CA, USA 
Horseradish peroxidase-labeled streptavidin Dianova, Hamburg, Germany 
Luminol Reagent (Western Blotting 
Detection Kit) Santa Cruz, CA, USA 
Maxwell® 16 FFPE Plus LEV DNA 
Purification Kit Promega, Madison, WI, USA 
QuantiTect® Reverse Transcription Kit QIAGEN GmbH, Hilden, Germany 
REDExtract-N-Amp™ Tissue PCR Kit Sigma-Aldrich,  Seelze, Germany 
Trizol reagent (peqGOLD TriFast) peQlab, Erlangen, Germany 
Material Company 
0.2 ml flexi-PCR-tubes Kisker Biotech, Steinfurt, Germany 
0.5/1.5/2.0 ml microtubes Sarstedt, Nümbrecht, Germany 
10/100/200/1000 µl pipette tips Sarstedt, Nümbrecht, Germany 
5/10/25 ml glass pipette sterile / cell culture Greiner bio-one, Kremsmünster, Germany 
200 μl gel loading pipette tips round Nerbeplus, Winsen/ Luhe, Germany 
6/12/24/96 well cell culture plates sterile Greiner bio-one, Kremsmünster, Germany 
Accu-jet pipette Integra Bioscience, Fernwald, Germany 
Amersham HyperfilmTM ECL GE Healthcare, Buckingshamshire, GB 
Autoclave SHP Steriltechnik, Schloss Detzel, Germany 
Axio Lab.A1 microscope (Zeiss) Zeiss, Oberkochen, Germany 
Camera Power shot A650 IS Canon, Tokyo, Japan 
Cell culture dishes Greiner bio-one, Kremsmünster, Germany 
Centrifuge 5415 R Eppendorf, Hamburg, Germany 
Centrifuge Universal 320R Hettich, Tuttlingen, Germany 
Cleanbench HERA safe Thermo Scientific, Waltham, MA, USA 
CO2 Incubator MCO-17AI Sanyo, Moriguchi, Japan 
Countess automated cell counter Invitrogen, Carlsbad, CA, USA 
Easy-Cast Electrophoresis system Model B2 Owl Scientific, San Francisco, CA, USA 
Electrophoresis Power Supply EV231 peQlab, Erlangen, Germany 
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2.1.5    Immunohistochemistry and Western blot primary antibodies 
Hotplate/Stirrer VWR, Darmstadt, Germany 
Hybaid hybridization oven MWG-Biotech, Ebersberg, Germany 
Imager Fluorchem® FC2 Alpha Innotec,  Minneapolis, MN, USA 
Kodak X-ray Film NEN Life Science Products, MA, USA 
Maxwell 16 instrument Promega, Madison, WI, USA 
Microplate absorbance reader Tecan, Crailsheim, Germany 
Microtome Leica, Nussloch, Germany 
Microtome blades Feather, Seki, Japan 
Mini PROTEAN Tetra System for SDS-
PAGE BIO-RAD, Hercules, CA, USA 
Mini-Vac eco vacuum pump peQlab, Erlangen, Germany 
NanoDrop Spectrophotometer ND-1000 peQlab, Erlangen, Germany 
peQSTAR 96 Universal Gradient cycler peQlab, Erlangen, Germany 
PerfectBlue™ 'Semi-Dry'-Electro Blotter peQlab, Erlangen, Germany 
PerfectSpin 24 centrifuge peQlab, Erlangen, Germany 
pH-Electrode SenTix 81 inoLab, Weilheim, Germany 
Pipettes peQlab, Erlangen, Germany 
Plastic 15 ml and 50 ml falcon tubes greiner bio-one, Frickenhausen, Germany 
Polypropylene cell strainer BD Biosciences, Sparks, MD, USA 
Rotor-Gene Q real-time PCR Machine QIAGEN,  Hilden, Germany 
Scout Pro SPU402 scale Ohaus, Parsipanny, IN, USA 
TELAVAL 31 inverse microscope Zeiss, Oberkochen, Germany 
Thriller thermoshaker peQlab, Erlangen, Germany 
Tissue culture flask Greiner bio-one, Kremsmünster, Germany 
Ultra-Turrax T8 (homogeniser) IKA Labortechnik, Staufen, Germany 
Vasco nitril white Braun, Melsungen, Germany 
Vortex-Genie 2 Scientific Industries, Bohemia, NY, USA 
Water bath typ 1003 GFL, Burgwedel, Germany 
Whatman™ PVDF Membrane Protran BA83 GE Healthcare, Buckingshamshire, UK 
Primary Antibody Species Company Clonality Dilution 
Anti-Cyclin D1 Rabbit Santa Cruz polyclonal 1:200 in 5% TBST-Milk 
Anti-GABARAP Rabbit Abcam monoclonal 1:2500 in 5% TBST-Milk 
Anti-Ki-67 Biotin Rat eBioscience monoclonal 5 µg/ml 
Anti-LC3A/B Rabbit Cell Signaling polyclonal 1:1000 in 5% TBST-BSA 
Anti-p- γH2AX Rabbit Cell Signaling monoclonal 1:1000 in 5% TBST-BSA 
Anti-SQSTM1 (p62) Rabbit Novus Biologicals polyclonal 1:4000 in 5% TBST-Milk 
Anti-β-Actin Mouse Millipore monoclonal 1:1000 in 5% TBST-Milk 
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2.1.6    Secondary antibodies 
 
2.1.7    ELISA antibodies 
 
2.1.8    Cytokine standards 
 
2.1.9    Genotype primer sequences 
 
 
Secondary antibody Species Company Dilution 
HRP-conjugated anti-mouse IgG Rabbit DAKO 1:1000 
HRP-conjugated anti-rabbit IgG Goat Santa Cruz 1:1000 
Cytokine Catalog nr. Concentration Marker Buffer Company 
IFN-γ 551216 554410 
1 µg/ml 
0,5 µg/ml 
none 
Biotin 
Na-Phos., pH 9,0 
- 
BD Biosciences 
BD Biosciences 
IL-17 MAB721 BAF421 
2 µg/ml 
0,1 µg/ml 
none 
Biotin 
PBS 
- 
R&D Sytstems 
R&D Sytstems 
IL-1β 51-26661E 13-7112 
4 µg/ml 
0,5 µg/ml 
none 
Biotin 
NaHCO3, pH 9,5 
- 
BD Biosciences 
eBioscience 
IL-2 554424 554426 
1 µg/ml 
0,5 µg/ml 
none 
Biotin 
Na-Phos., pH 9,0 
- 
BD Biosciences 
BD Biosciences 
IL-6 554400 554402 
2 µg/ml 
0,25 µg/ml 
none 
Biotin 
NaHCO3, pH 9,5 
- 
BD Biosciences 
BD Biosciences 
TNF-α 551225 554415 
3 µg/ml 
0,5 µg/ml 
none 
Biotin 
Na-Phos., pH 6,5 
- 
BD Biosciences 
BD Biosciences 
Cytokine Catalog nr. Max. concentration Company 
IFN-γ 485-MI/CF 30000 pg/ml R&D Sytstems 
IL-17 421-ML 10000 pg/ml R&D Sytstems 
IL-1β 51-26666E 2000 pg/ml BD Biosciences 
IL-2 212-12 2000 pg/ml Tebu-bio 
IL-6 216-16 5000 pg/ml Tebu-bio 
TNF-α 554589 1000 pg/ml BD  Biosciences 
Primer pairs Direction Oligonucleotide sequence Size (bp) 
Annealing  
temperature 
GRAP23FW1 Forward 5’-GCCACCTTCAGCGTAGAAAC-3’ 
300 62°C 
GRAP23BW1 Reverse 5’-GCCTGCTAACATACGCCACT-3’ 
GRAP23FW Forward 5’-ACTGGATGGAGTCCCTGATG-3’ 
640 62°C 
VICTR23C Reverse 5’-GAGTGATTGACTACCCGTCAGCG-3’ 
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2.1.10    Quantitative reverse transcriptase PCR (qRT-PCR) primer sequences 
* Ta, Annealing temperature (°C) 
 
2.1.11    Primer sequences for mutation analysis 
* F, Forward primer; R, Reverse primer 
* Annealing temperature was 68°C for the first eight cycles, then 60°C for the next 32 cycles 
of exon 1 primers and 62°C for the next 32 cycles of exon 2 primers. 
 
2.1.12    Solutions and buffers 
Western blot & electrophoresis Composition  
10 x electrophoresis buffer (1 l) 250 mM Tris-Base  
1.92 M Glycin  
1% SDS  
→ pH 8.3  
 
Gene Direction Oligonucleotide sequence Accession number 
Ta 
(°C) 
Size 
(bp) 
Bax 
Forward 5’-TTGGAGATGAACTGGACAGC-3’ 
NM_007527.3 60 124 
Reverse 5’-CAGTTGAAGTTGCCATCAGC-3’ 
Bid 
Forward 5’-AGACGAGCTGCAGACAGATG-3’ 
NM_007544.3 60 137 
Reverse 5’-GGTCCATCTCATCGCCTATT-3’ 
GAPDH 
Forward 5’-CACACCGACCTTCACCATTTT-3’ 
NM_008084.2 60 67 
Reverse 5’-GAGACAGCCGCATCTTCTTGT-3’ 
p21 
Forward 5’-AGGCCCAGTACTTCCTCTGC-3’ 
NM_007669.4 60 183 
Reverse 5’-CAATCTGCGCTTGGAGTGATA-3’ 
Xaf1 
Forward 5’-TCCAAGTGTGCAGGAACTG-3’ 
NM_001037713 60 144 
Reverse 5’-CAACTTCCATGTGCTCTTTCATC-3’ 
Gene Exon Oligonucleotide sequence Accession number 
Size 
(bp) 
H-ras1 1 
5’-CCTTGGCTAAGTGTGCTTCTCATTGG-3’ (F) 
NM_008284.2 214 
5’-ACAGCCCACCTCTGGCAGGTAGG-3’      (R) 
H-ras1 2 
5’-TGTGGATTCTCTGGTCTGAGGAGAG-3’  (F) 
NM_008284.2 269 
5’-CATAGGTGGCTCACCTGTACTGATG-3’  (R) 
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10 x PBS (1 l) 2 g KCl  
2 g KH2PO4  
14.4 g Na2HPO4  
80 g NaCl  
→ pH 7.4  
10 x TBST (1 l) 24.2 g Tris-Base 
80 g NaCl 
14 ml HCl 
→ pH 7.6 
10 ml Tween20 
10 x Western blot transfer buffer (1 l) 30.03 g Tris-Base 
112.6 g Glycine 
→ pH 8.3 
→ for preparing 1 x buffer add 100 ml methanol 
50 x TAE buffer (1 l) 242 g Tris-Base 
57.1 ml Glacial acetic acid 
100 ml 0.5 M EDTA (pH 8) 
Blocking buffer 2.5 g Non-fat dry milk or BSA 
50 ml 1 x TBST 
RIPA buffer (100 ml) 1 ml NP-40 
200 μl 0.5 M EDTA 
10 ml 0.5 M Tris pH 7.4 
15 ml 1 M NaCl 
0.25 g Desoxycholat 
 
RNA isolation Composition 
DEPC-treated H2O 1 l H2O 
1 ml Diethylpyrocarbonate (DEPC) 
 
→ The solution was stirred on a magnetic stirrer 
overnight and autoclaved the next day. 
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Carcinogens dissolvent Composition 
0.2 M dibasic sodium phosphate 
(Na2HPO4) 
3.56 g Na2HPO4 
100 ml H2O 
Citrate-buffered saline 1 g KCl 
0.44 g Sodium citrate 
100 ml H2O 
→ pH 4.5 
Citric acid monohydrate 2.1 g Citric acid monohydrate 
100 ml H2O 
Citric acid-phosphate buffer 36.85 ml Citric acid monohydrate 
63.15 ml 0.2 M Na2HPO4 
→ pH 6.0 
 
ELISA buffers Composition 
Ammoniumchlorid/TRIS, pH 7.2 a) 0.83% NH4Cl (7.47 g at 900 ml H2O) 
b) TRIS (2.059 g at 100 ml H2O), pH 7.65 
mix a) and b) 9:1 
Citrate buffer, pH 4.8 2.1 g Citric acid 
16.2 ml 1 N NaOH 
84 ml Aqua dest 
Na2HPO4-coating buffer, pH 6.5 1.48 g Na2HPO4 x 2 H2O 
1.85 g NaH2PO4 x H2O 
100 ml Aqua dest 
NaH2PO4-coating buffer, pH 9.0 1.38 g NaH2PO4 x H2O 
100 ml Aqua dest 
NaHCO3-coating buffer, pH 9.5 0.84 g NaHCO3 
100 ml Aqua dest 
OPD-solution 2 mg/ml OPD in citrate buffer 
20 μl/ml 3% H2O2 
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2.2     Methods 
2.2.1    Animals 
Female wild-type (Wt) C57BL/6 mice were purchased from Charles River (Sulzfeld, 
Germany). GABARAP knockout (GABARAP KO) mice were obtained from the Max Planck 
Institute for Brain Research in Frankfurt, Germany (O’Sullivan et al., 2005). GABARAP KO 
mice were generated from the Omnibank of embryonic stem cell library by insertion of 
targeting vector 345 bp upstream of exon 1 of the GABARAP locus (Zambrowicz et al., 
1998) (Fig. 8). The heterozygous animals were crossed to produce + ⁄ + (wild-type), + ⁄ – 
(heterozygous) and – ⁄ – (homozygous) mice. Mice were housed in standard cages (10 animals 
per cage) under controlled temperature (22 ± 2ºC) and lighting conditions (monitored 12 h 
light/12 h dark cycles), and supplied with water and food (Altromin, Lage, Germany)  
ad libitum. All animal experiments were approved by the Thuringian commission for animal 
protection (No. 02-018/08 and 02-007/13). 
 
Figure 8. Location of gene-trap vector insertion into the GABARAP gene and primers designed for 
genotyping (O’Sullivan et al., 2005). The PCR fragment sizes for the different GABARAP genotypes are 
indicated in the inset. 
 
2.2.2    Genotyping of GABARAP knockout mice 
Genomic DNA was extracted from the tails of mice by using REDExtract-N-Amp™ Tissue 
PCR Kit (Sigma-Aldrich, Germany) according to the manufacturer's protocol, as follows: 
 
2.2.2.1    Genomic DNA extraction 
First of all, 100 µl of extraction solution was added into 1.5 ml microcentrifuge tube, and then 
25 µl of tissue preparation solution was appended to the tube with pipetting up and down to 
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mix. Fresh mouse tail tips (end down) of about 0.5 cm were cut by using sterile scissors and 
forceps. The piece of mouse tail tip was transfer into the extraction solution and mixed 
thoroughly by vortexing. The sample was incubated at room temperature for 10 minutes, and 
then incubated at 95ºC for 3 minutes. After that, 100 µl of neutralization solution B was added 
to sample and mixed by vortexing. The neutralized tissue extract was used immediately for 
polymerase chain reaction (PCR); if not, the samples were stored at 4°C. 
 
2.2.2.2    PCR amplification 
The following reagents were prepared in duplicate, one reaction for the GRAP23FW1/ 
GRAP23BW1 primer pairs, and the second reaction for the GRAP23FW/VICTR23C primer 
pairs. The PCR fragment sizes for each primer pairs are indicated in the inset of Figure 8. 
 
 
 
 
 
 
 
 
Then, the following PCR program was used for each primer pairs: 
 
 
 
 
 
 
After the program was completed the PCR products were stored at 4°C or loaded directly onto 
an agarose gel. 
 
2.2.2.3    Agarose gel electrophoresis 
PCR products were separated in a 1.5% (w/v) agarose gel. To pour a gel, agarose powder was 
mixed with 1 x TAE buffer to the desired concentration and heated in a microwave oven until 
the agarose was completely molten. After cooling down to about 60°C the solution was 
poured into a casting tray containing a sample comb and allowed to solidify at room 
temperature. The solid gel was inserted horizontally into the electrophoresis chamber, the 
Reagent Volume/reaction 
REDExtract-N-Amp PCR Reaction Mix 10.0 µl 
Forward Primer (100 pmol/μl = 100 μM) 0.08 µl 
Reverse Primer (100 pmol/μl = 100 μM) 0.08 µl 
H2O 5.84 µl 
Tissue Extract 4.00 µl 
Total volume 20 µl 
Step Temperature Duration Cycle 
1 Initial denaturation 94°C 1 minute 1 
2 Denaturation 94°C 30 seconds  
 
35 3 Annealing 62°C 1 minute 
4 Extension 72°C 1 minute 
5 Final elongation 72°C 10 minutes 1 
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comb removed and the gel covered with 1 x TAE buffer. PCR products were mixed with 
loading buffer and pipetted into the sample wells. The gel was run with 100 voltages for  
40 minutes. Thereafter, the gel was incubated with GelRED for 15 - 30 minutes and a 
photograph was taken after placing the gel under the imager FluorChem® FC2. Figure 9 
showed an example of the genotyping results for a group of mice. 
  
 
Figure 9. Genotyping results for the different GABARAP genotype mice, wild-type (+/+), heterozygous (+/-) or 
homozygous (-/-). A) Electrophoresis image for the primer pairs GRAP23FW1/GRAP23BW1 with a band of 
300 bp and GRAP23FW/VICTR23C with a band of 640 bp. B) Table to illustrate the results shown in A. 
 
2.2.3    Carcinogen treatment 
The genetic background of GABARAP KO mice is C57BL/6 mice. Female C57BL/6 wild-
type and GABARAP KO mice at 6 – 8 weeks of age were used in all our experiments for 
carcinogen treatment. Wild-type and GABARAP KO mice were divided each into 2 groups, 
control (vehicle-treated) group and carcinogen-treated group. The treatment regimens used in 
our experiments was according to the literature with some modifications. 
 
2.2.3.1    DMBA treatment 
7,12-Dimethylbenz(a)anthracene (DMBA) was dissolved in sesame oil (5 mg/ml) by 
vortexing for 2 h at room temperature. Several experiments had shown that complete 
dissolution was obtained using this protocol for DMBA dissolving. All steps in the 
preparation were carried out under minimum illumination. DMBA-treated groups of wild-
type and GABARAP KO mice received 6 weekly doses of 1 mg DMBA/mouse in  
200 µl of dissolvent by oral gavage. Control groups received 6 weekly dosed of 200 µl 
sesame oil. The mice were monitored weekly for palpable tumor formation. The tumor-
A B 
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bearing mice were anesthetized and killed by cervical dislocation. The tumor specimens were 
fixed in 5% neutral buffered formalin. 
 
2.2.3.2    ENU treatment 
N-Ethyl-N-nitrosourea (ENU) was obtained from Sigma in Isopac bottles containing 
approximately 1 g of ENU. The desired concentration of ENU was obtained by dissolving it 
in citric acid-phosphate buffer at pH 6.0, because it is highly decomposition in aqueous media 
at pH values above 7.0 (Goth and Rajewsky, 1974). In addition, care was taken to prevent 
decomposition from light during preparation of ENU solution. ENU-treated groups of wild-
type and GABARAP KO mice were administered a single intraperitoneal (i.p.) injection of 
150 mg ENU/kg of body weight. The mice were monitored weekly for palpable tumor 
formation. The tumor-bearing mice were anesthetized and killed by cervical dislocation. The 
tumor specimens were fixed in 5% neutral buffered formalin. 
 
2.2.3.3    Hormone stimulation and MNU treatment 
Medroxyprogesterone acetate (MPA) was used together with N-methyl-N-nitrosourea (MNU) 
in order to increase the incidence of mammary tumors in mice (Pazos et al., 1998). MPA was 
dissolved in sterile injectable water and MNU was dissolved in citrate-buffered saline pH 4.5. 
Female mice were administered at 6 weeks of age the first dose of 40 mg MPA/mouse by 
intramuscular injection. In the next week, i.e. at 7 weeks of age, the mice received a single 
intraperitoneal (i.p.) injection of 1 mg MNU/mouse in 200 µl of dissolvent. Four weeks  
after the first MPA dose, a booster dose of 20 mg MPA/mouse was administered 
intramuscularly. The mice were monitored every other day for lethality and weekly for 
palpable tumor formation. 
 
2.2.3.4    MNU and DMBA treatment 
In attempt to increase the tumor incidence in our mice model, we used the synergistic 
treatment of MNU and DMBA in mice (Shirai et al., 1997), which are already promoted with 
MPA. Female mice at 6 weeks of age were injected with 20 mg MPA/mouse intramuscularly. 
One week later, the mice were administered i.p. injection of 1 mg MNU/mouse. At 8 weeks of 
age, the mice received the booster dose of 20 mg MPA/mouse. After that, the mice were 
given a single oral dose of 1 mg DMBA/mouse at 10 weeks of age. DMBA and MNU were 
dissolved as mentioned in (2.2.3.1) and (2.2.3.3), respectively. The mice were monitored 
every other day for lethality and weekly for palpable tumor formation. 
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2.2.4    Tumor and tissue specimens 
2.2.4.1    Haematoxylin and eosin (H & E) staining 
Tumor specimens of DMBA-treated mice were fixed and embedded in paraffin. Four-µm 
sections were cut from blocks, mounted on glass slides, dewaxed with xylene and gradually 
hydrated. Subsequently, the sections were stained with haematoxylin and eosin, dehydrated 
and cleared with xylene. Then the sections were mounted with aqueous mounting medium. 
The slides were analysed under light microscope and evaluated by Prof. Dr. Iver Petersen. 
 
2.2.4.2    Immunohistochemistry (IHC) 
Immunohistochemistry staining of tissue sections from spleen and mammary glands of 
vehicle-treated (control) and DMBA-treated mice was performed. After 6 weekly oral doses 
of 1 mg DMBA, spleen specimens and mammary glands were fixed in 5% neutral buffered 
formalin. Subsequently, paraffin-embedded tissue blocks were constructed, 3 µm sections 
were obtained by cutting with a rotation-microtome. The sections were mounted on glass 
slides (Superfrost Plus, Menzel GmbH), carefully transported to a 50°C water bath to 
straighten the tissue and dried overnight at 37°C in a heater (Medax). The sections were 
dewaxed with xylene and gradually hydrated before staining. Antigen retrieval was performed 
by pressure cooking the slides in citrate buffer (DAKO Target Retrieval Solution, Citrate pH 
6) for 5 minutes to break up the proteins cross-links due to fixation. The primary anti-
mouse/rat Ki-67 biotin conjugated antibody was incubated at room temperature for  
30 minutes in a humidity chamber. Detection was carried out according to the manufacturer’s 
instructions (DAKO REAL™ Detection System Alkaline Phosphatase / RED). Afterwards the 
slides were briefly counterstained with haematoxylin and aquaeously mounted. 
 
2.2.4.3    TUNEL assay 
The TUNEL reaction was performed on paraffinized sections. Sections were deparaffinized, 
transferred to antigen retrieval buffer (10 mM sodium citrate pH 6.0), heated in a microwave 
until boiling and kept at sub-boiling temperature for 10 minutes and then allowed to cool 
down at room temperature for 30 minutes. The sections were washed three times 5 minutes 
each with PBS and reacted with terminal deoxynucleotidyl transferase mixture (Fermentas, 
St. Leon-Rot, Germany) according to the manufacturer’s instructions for 1 h in a humidified 
chamber. After removal of the reaction mixture, sections were washed for three times  
5 minutes each with PBS and incubated with Streptavidin-Cy3 (Sigma-Aldrich) at a dilution 
of 1:500 in PBS containing 1% BSA for 2 h at room temperature. Thereafter, the sections 
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were washed with PBS three times (5 minutes each) and then mounted with coverslips and a 
DAPI-containing mounting medium (ProLong Gold, Invitrogen). Tissue section images were 
taken using a virtual microscope (BX61VS, Olympus, Japan). 
 
2.2.5    Immunology experiments 
2.2.5.1    Cytokine analysis from lymphocyte cell cultures 
Female wild-type and GABARAP KO mice at 6 - 8 weeks of age were treated with 6 weekly 
oral doses of 200 µl sesame oil (vehicle-treated, control group) or 1 mg DMBA/mouse. For 
analysis of cytokines released from lymphocytes, mice were anesthetized and killed by 
cervical dislocation after one week of the last DMBA dose. Subsequently the spleen was 
removed under sterile conditions, and single cell suspensions were made. Thereafter cells 
were washed with warm cell culture media and erythrocytes were lysed with ammonium 
chloride/TRIS. The lymphocytes were washed again twice and the cell suspension was 
adjusted to 2 x 105 cells/ml. Then, the cells were cultured at 1 ml at 37°C with 5% CO2 in 
Roswell Park Memorial Institute (RPMI) 1640 medium containing 10% FCS, 2 mM sodium 
pyruvate, 10 mM HEPES, 15 µg/ml L-glutamine, 5 µg/ml streptomycin, 5 U/ml penicillin, 
and 5 x 10-5 M 2-mercapto-ethanol in 12-well-cell culture plates with or without 1 µg/ml 
plate-bound anti-CD3 antibodies (from 1452C11 hybridoma cell supernatant) for T cell 
receptor stimulation. Supernatants were harvested after 48 h of incubation and frozen  
at -80°C. To analyse the levels of secreted cytokines a standard sandwich enzyme-linked 
immunosorbent assay (ELISA) was used. Therefore 96-well-plates were coated with the 
primary antibodies (IL-2, IFN-γ or IL-17) in the specific coating buffer over night at 4°C  
(50 µl/well). Then the plates were washed using a wash buffer containing 0.05% Tween 20 in 
PBS and unspecific binding sites were blocked by incubation with a solution of 2% BSA in 
H2O (300 µl/well) for 2 h. In the following, the plates were washed again. The probes  
and standards (recombinant cytokines) were plotted into the wells (100 µl/well) and incubated 
over night at 4°C. The next day the plates were washed again and the biotin-labeled  
secondary antibodies in a solution of 1% BSA were plotted to the wells (100 µl/well). After  
2 h of incubation at room temperature, plates were washed and standard horseradish  
peroxidase-labeled streptavidin (2 µl in 10 ml 1% BSA) was pipetted into the wells  
(100 µl/well). After 30 minutes incubation at room temperature, plates were washed and 100 
µl/well ortho-phenylenediamine (OPD)-solution was plotted into the wells in the dark. The 
enzymatic reaction was stopped by adding 50 µl/well 2N H2SO4 and the extinction was 
measured at 492 nm with a microplate absorbance reader. 
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2.2.5.2    Cytokine analysis from macrophage cell cultures 
The same mice and treatment regimens, which are mentioned above for lymphocytes culture, 
were used for macrophages culture. For analysis of cytokines released from macrophages, 
mice were anesthetized and killed by cervical dislocation after one week of the last DMBA 
dose. Subsequently the peritoneum was exposed under sterile conditions and the abdominal 
cavity was flushed out with a cold solution containing heparin (20 µl/100 ml PBS). The cells 
were collected in centrifuge tubes and washed twice with cold PBS. Then, the cells were 
adjusted to 2 x 105 cells/ml in RPMI cell culture medium. To separate the macrophages from 
other cells, the whole pool of cells was incubated for 2 h at 37°C with 5% CO2 in 24-well-cell 
culture plates (1 ml/well). Then the non-adhering cells were removed by washing the wells 
with warm RPMI medium. The adhering cells are suspected to be > 95% macrophages due to 
former investigations (Yui et al., 1993). In the following the macrophages were stimulated 
with LPS (1 µg/ml RPMI medium) and incubated for 4 h at 37°C with 5% CO2, and then 
either treated or not with ATP (5 mM) for 1 h. At the end of the incubation the supernatants 
were harvested and stored at -80°C. To analyse the levels of secreted cytokines (IL-1β, IL-6 
and TNF-α) a standard sandwich enzyme-linked immunosorbent assay (ELISA) was done as 
previously described in cytokine secretion from lymphocytes (2.2.5.1). 
 
2.2.5.3    Cell surface marker analysis for splenocytes by FACS 
For analyses of splenocytes surface marker, mice were anesthetized and killed by cervical 
dislocation after one week of the last DMBA dose. Subsequently the spleen was removed 
from vehicle-treated (control) and DMBA-treated groups under sterile conditions, and single 
cell suspensions were made. The cells were dispersed by gentle pipetting and filtered through 
a cell strainer to eliminate clumps and debris. Cell suspension was collected in a conical tube, 
centrifuged 5 minutes at 300 x g at 4°C, and the supernatant was discarded. The cell pellet 
was washed once again with PBS. Then the cells were resuspended in PBS and cell count and 
viability analysis was performed. The experiment of cell surface markers was performed in 
the Institute of Immunology, Jena by kindly support of Martin Böttcher. The cells were 
decanted into labeled fluorescence-activated cell sorting (FACS) tubes containing 2 ml PBS, 
centrifuged for 6 minutes at 300 x g (4°C), and the supernatant was discarded. The cell pellet 
was washed once again with PBS. The cells were permeabelized by washing with 1 ml  
PBA-S (0.5% saponin in PBA). PBA is a PBS containing 0.25% bovine serum albumin 
(BSA) and 0.02% sodium azide (NaN3). Thereafter 25 µl of antibody master-mix was added 
and incubated for 20 minutes in the dark on ice. The master-mix was prepared as following: 
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Cell type Antibody Clone Source Dilution factor Fluorochrome  (diluted in 100 µl PBA) 
B cell B220+ RA3-6B2 
Institute of 
Immunology, 
Jena 
1:200 in PBS Pacific Blue 
CD4 T cell CD4+ GK1.5 
Institute of 
Immunology, 
Jena 
1:200 in PBS Dye647 
CD8 T cell CD8+ 53-6.7 eBioscience 1:300 in PBS PE/Cy7 
Macrophages CD11b+ M1/70 eBioscience 1:800 in PBS Alexa Fluor 700 
Neutrophils 
CD11b+ M1/70 eBioscience 1:800 in PBS Alexa Fluor 700 
Ly6G+ RB6-8C5 eBioscience 1:200 in PBS APC 
 
Thereafter the cells were washed with 1 ml PBA, and resuspended in 200 µl PBA. The 
samples were measured with flow cytometer (BD LSR II). 
An alternative protocol was used for FoxP3 staining according to the manufacturer's 
instruction (eBioscience). The splenocytes were prepared as mentioned above. After the last 
wash with PBS, the supernatant was discarded and the cell pellet was dissociated by pulse 
vortexing. The surface staining for CD4+ and CD25+ was performed as described above. 
 
 
 
 
Then, 1 ml of freshly prepared FoxP3 Fixation/Permeabilization working solution 
(eBioscience) was added to each tube and mixed by pulse vortexing. The samples were 
incubated at 4°C for 60 minutes in the dark. Thereafter 2 ml of PBA was added to each tube, 
centrifuged at 300 x g at room temperature for 5 minutes, and the supernatant was discarded. 
Subsequently, 25 µl of antibody was added and incubated for 30 minutes in the dark on ice. 
Blocking reagent Clone Source Dilution factor 
αCD16/CD32 2.4G2 Institute of Immunology, Jena 1:100 in PBS 
Rat IgG - Jackson Immuno Research 1:200 in PBS 
Blocking reagent Source Dilution factor 
Rat IgG Jackson Immuno Research 1:200 in PBS 
Antibody Clone Source Dilution factor Fluorochrome (diluted in 100 µl PBA) 
CD4+ - eBioscience 1:200 in PBS APC/Cy7 
CD25+ PC61.5 Institute of Immunology, Jena 1:200 in PBS Dye647 
Antibody Clone Source Dilution factor Fluorochrome (diluted in 100 µl PBA) 
FoxP3 - eBioscience 1:50 in PBS FITC 
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Thereafter, the cells were washed with 1 ml PBA, and resuspended in 200 µl PBA. The 
samples were measured with flow cytometer (BD LSR II). 
 
2.2.6    Whole mount analysis of mammary glands 
Whole mount of mammary gland is a desirable method to visualize the morphology of  
the ductal tree; epithelial cell proliferation and ductal branching. Female wild-type and 
GABARAP KO mice were treated with 6 weekly oral doses of 200 µl sesame oil as  
vehicle (control) or 1 mg DMBA/mouse. Mice were anesthetized and killed by  
cervical dislocation after one week of the last DMBA dose. Whole mount analyses was 
carried out according to the procedure of Banerjee et al. (1976) with small modifications.  
A longitudinal ventral incision along the midline was made in the skin that extended from  
the genital to the thoracic region. Then, an inverted V-shaped cut was made on either side of 
the genitalia and the skin peeled back. The 4th abdominal mammary gland was dissected from 
the pelt by using surgical scissors and forceps. The 4th abdominal mammary gland was 
selected for whole mounting because of the presence of the lymph node for orientation. The 
mammary gland was spread on a glass slide and kept short time (2 - 3 minutes) at room 
temperature then submerged into a mixture of 1 part glacial acetic acid and three parts 100% 
ethanol for 3 h. In the following the glands were washed with 70% ethanol for 15 minutes and 
subsequently rinsed with distilled water for 5 minutes. Subsequently, the glands were stained 
with alum carmine overnight or until the fat pad was a uniform pink colour (at room  
temperature with minimum illumination). Then they were rinsed with 70, 90 and 100% 
ethanol each for 30 minutes. After dehydration, the glands were transferred to xylene for 
clearing and mounted with aqueous mounting medium (permount). The mammary glands 
were analysed and evaluated under stereo microscope. 
 
Alum carmine stain:  
1 g carmine + 2.5 g alum potassium sulfate in 500 ml distilled water.  
Then the mixture were boiled for 20 minutes, the volume adjusted to 500 ml with water, 
filtered with Whatman filter paper and kept at 4°C with minimum illumination. The alum 
carmine stain has stored for not more than one week at refrigerator. 
 
2.2.7    Microarray gene expression profiling analysis of mammary glands 
Female wild-type and GABARAP KO mice were treated with 6 weekly oral doses of 200 µl 
sesame oil as vehicle (control) or 1 mg DMBA/mouse. Mice were anesthetized and killed by 
cervical dislocation after one week of the last DMBA dose. Abdominal mammary glands 
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were isolated and directly fixed in 5% neutral buffered formalin, and subsequently paraffin 
blocks were constructed.  Almost all the procedures of tissue preparation, fixation and storage 
were performed as recommended for successful gene expression profiling analysis of 
formalin-fixed paraffin-embedded (FFPE) samples, as mentioned by von Ahlfen et al. (2007). 
Microarray analysis was carried out by the Miltenyi Biotec GmbH, Bergisch Gladbach, 
Germany, using the Agilent Whole Mouse Genome oligo microarrays 8x60K chips according 
to standard protocols of FFPE samples. The workflow for gene expression analysis of FFPE 
samples is illustrated in Figure 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Workflow for Agilent gene expression profile of FFPE samples. Flowchart indicates the various 
kits and steps involved in the analysis of FFPE samples with the Agilent gene expression microarray 
workflow (Source: Agilent Technologies). 
 
2.2.7.1    Quality control of total RNA 
Eighteen FFPE tissue samples (3 wild-type control (CWt), 3 GABARAP KO control (CKO), 
6 wild-type DMBA-treated (DWt), 6 GABARAP KO DMBA-treated (DKO)), each 
consisting of approximately twenty 10 μm slices, were sent to Miltenyi Biotec. The RNA 
isolation was performed using the Absolutely RNA FFPE Kit (Stratagene). The quality of 
total RNA was checked via the Agilent 2100 Bioanalyzer platform (Agilent Technologies). 
The results of the Bioanalyzer run are visualized in a gel image and an electropherogram 
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using the Agilent 2100 Bioanalyzer expert software. In addition, RNA Integrity Number 
(RIN) was generated by the same software to check the integrity and overall quality of total 
RNA samples. The RIN value is calculated by a proprietary algorithm that takes several 
quality control parameters into account, for example, 28S RNA/18S RNA peak area ratios 
and unexpected peaks in the 5S RNA region. A RIN number of 10 indicates high RNA 
quality, and a RIN number of 1 indicates low RNA quality (Fleige and Pfaffl, 2006). Our 
RNA samples revealed RIN values ranging from 1.4 to 5.9.  
 
2.2.7.2    Library preparation and WTA amplification of RNA 
For the library preparation and Whole Transcriptome Amplification (WTA) step, 200 ng 
RNA were used. To produce cDNA, the RNA samples were amplified using the Complete 
TransPlex® Whole Transcriptome Amplification Kit (WTA2, Sigma) following the 
manufacturer’s protocol. Yields of cDNA were measured with the ND-1000 
Spectrophotometer (NanoDrop). 
 
2.2.7.3    ULS-Labeling 
For the ULS-Labeling step, 500 ng of each cDNA sample was used. To produce Cy3-labeled 
DNA, the DNA samples were labeled using the Genomic DNA ULS Labeling Kit (Agilent 
Technologies) following the manufacturer’s instruction (Gene Expression FFPE Workflow 
protocol, Agilent). Yields of Cy3-labeled cDNA and the dye-incorporation rate were 
measured with the ND-1000 Spectrophotometer (NanoDrop). According to the 
manufacturer’s instruction the optimal degree of labeling is between 1.5% and 3%. All our 
Cy3-labeled cDNA samples revealed an adequate degree of labelling (2.4 - 2.9%). 
 
2.2.7.4    Hybridization of Agilent Whole Genome Oligo Microarrays 
The hybridization procedure was performed according to the Agilent Gene Expression FFPE 
Workflow protocol using the Agilent Gene Expression Hybridization Kit and Agilent 
CGHblock. Cy3-labeled DNA in hybridization buffer and CGHblock were hybridized 
overnight (17 h, 65°C) to Agilent Whole Mouse Genome Oligo Microarrays 8x60K using 
Agilent’s recommended hybridization chamber and oven. Finally, the microarrays were 
washed once with Gene Expression Wash Buffer 1 (Agilent Technologies) for 1 minute  
at room temperature followed by a second wash with Gene Expression Wash Buffer 2 
(Agilent Technologies) 37°C for 1 minute. The last washing step was performed with 
acetonitrile for 5 seconds. 
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2.2.7.5    Scanning results 
Fluorescence signals of the hybridized Agilent Microarrays were detected using Agilent’s 
Microarray Scanner System (Agilent Technologies).  
 
2.2.7.6    Image and data analysis 
The analysis of whole genome expression for 18 samples (belonging to four conditions) was 
kindly performed by the Network Modelling group of Prof. Dr. Rainer König at the Hans-
Knöll-Institute (HKI), Jena, Germany. Limma, R package was used to read out and process 
the microarray image files derived using Agilent's platform (Smyth, 2005). Background 
correction was performed and arrays were normalized using loess method. 23544 probes were 
selected having expression intensities above background at least in 3 samples. Expression was 
averaged for genes having more than one probe set. A total of 15815 genes were finally 
analyzed further. Differential expression was assessed using Limma for four pairs namely 
CWT-CKO, CWT-DWT, CKO-DKO and DWT-DKO. Limma calculates a fold change and 
standard error for each gene by fitting a linear model. Then it calculates empirical Bayes 
moderated t-test statistics for each gene. P-values derived from moderate t-tests were 
corrected using the Benjamin and Hochberg approach (Benjamini and Hochberg, 1995). The 
genes with p-values ≤ 0.05 considered as differentially expressed. 
 
2.2.8    Reverse transcription polymerase chain reaction (RT-PCR) 
2.2.8.1    RNA isolation 
Total RNA was isolated from several organs of wild-type and GABARAP KO mice by using 
Trizol reagent (peqGOLD TriFast, peQlab) according to the manufacturer's instruction. For 
homogenization, the tissue samples (about 100 mg) were lysed directly by addition of  
1 ml TriFast. Subsequently the samples were kept on ice during the process of crushing by 
pestle and power homogeniser (Ultra-Turrax T8). The cell lysate was passed through  
a pipette several times, transferred to a 1.5 ml tube and kept for 5 minutes at room 
temperature for dissociation of the nucleoprotein complexes. After addition of 200 µl 
chloroform, samples were shaken for 15 seconds and kept at room temperature for another  
10 minutes. During centrifugation at 12,000 x g the mixture separated into the lower red 
phenol-chloroform phase, the interphase and the colourless upper aqueous phase. The upper 
aqueous RNA containing phase was transferred to a fresh tube and 0.5 ml isopropanol was 
added to precipitate RNA. Samples were kept on ice for 15 minutes and centrifuged for  
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10 minutes at 12,000 x g (4°C). Supernatant was removed carefully and the RNA pellet was 
washed twice with 75% ethanol (prepared with DEPC-treated water) by vortexing and 
subsequent centrifugation for 10 minutes at 12,000 x g (4°C). RNA pellet was air-dried to 
remove the excess isopropanol and resuspended in RNase-free water. Concentration was 
measured with NanoDrop spectrophotometer. RNA was stored at -80°C or immediately used 
for cDNA synthesis. 
 
2.2.8.2    Complementary DNA (cDNA) synthesis 
For reverse transcription of the whole RNA we used the QuantiTect® Reverse Transcription 
Kit (Qiagen) according to the manufacturer's instruction. Genomic DNA elimination reaction 
was prepared on ice, mixed, incubated for 2 minutes at 42°C and then placed immediately on 
ice. Reverse transcription master mix was prepared, mixed and kept on ice. The appropriate 
volume of master mix was distributed into individual tubes. The template RNA (from gDNA 
elimination reaction) was added, mixed and incubated for 15 minutes at 42°C. To inactivate 
Reverse Transcriptase, the samples were incubated at 95°C for 3 minutes, immediately placed 
on ice and stored at -20°C. 
 
2.2.8.3    Quantitative reverse transcriptase PCR (qRT-PCR) 
To analyse mRNA related gene expression, a master mix was prepared as following: 
 
 
 
 
 
 
 
 
The mixture-containing tubes were closed and put in the 72-well-carousel of a Rotor-Gene Q 
real-time PCR machine. The following program was used: 
 
 
 
 
 
Glycerinaldehyd-3-phosphate-dehydrogenase (GAPDH) served as housekeeping gene and 
was used to normalize gene expression data. 
Reagent Volume/reaction 
FastStart Universal SYBR Green Master (Rox) 6.250 µl 
Forward Primer 0.375 µl 
Reverse Primer 0.375 µl 
H2O 5.000 µl 
cDNA 0.500 µl 
Total reaction volume 12.50 µl 
Cycle(s) Temperature Hold Time 
1 95°C 10 min 
40 95°C 60°C 
15 seconds 
60 seconds 
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2.2.9    Fibroblasts isolation and treatment 
2.2.9.1    Primary culture of mouse embryonic fibroblasts (MEFs) 
Mouse embryonic fibroblasts isolation was carried out according to the protocols of culture of 
animal cells (Freshney, 2005). Mouse embryos were isolated at day 13th of gestation period 
under sterile conditions. The embryos were transferred into PBS in 10 cm petri dish, rinsed, 
dissected from unwanted tissue, such as fat and placenta, and transferred to a third dish. In the 
following they were chopped with scalpels and scissor, washed with PBS and centrifuged.  
All the pieces were transferred to 500 ml flask filled with 180 ml of PBS plus  
20 ml of 2.5% trypsin. The flask was capped, and stirred in a hybridization oven at 100 rpm 
for 30 minutes at 37°C. In the following the disaggregated cells were collected into a 
centrifuge tube and placed on ice. Then fresh trypsin was added to the pieces that remained in 
the flask, and the same steps were repeated for 3 times. Thereafter the collected cell 
suspensions were centrifuged, resuspended in growth medium (DMEM supplemented with 
10% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 units/ml penicillin, 100 μg/ml 
streptomycin and 0.1 mM β-mercaptoethanol) and filtered with sterile polypropylene cell 
strainer. Thereafter the cell suspensions were centrifuged, resuspended with growth medium 
and cultured in tissue culture flasks at 37°C with 5% CO2.  
 
2.2.9.2    Mouse embryonic fibroblasts (MEFs) treatment 
Wild-type and GABARAP-deficient MEFs at third passage were seeded in 10 cm petri  
dishes and incubated overnight or until they reached 60 - 70% confluence. To obtain 
starvation conditions, cells were washed three times with PBS and incubated in EBSS 
medium in the presence or absence of 10 µM CQ (to inhibit lysosomal degradation) at 37°C 
for 2 h. For DMBA and camptothecin (CPT) treatment, MEFs were treated with 100 nM 
DMBA for 24 and 48 h, 5 mM CPT for 4 and 20 h, and medium containing vehicle (0.1% 
DMSO) as control and subsequently incubated at 37°C and harvested at indicated time point. 
 
2.2.10    Analysis of proteins 
2.2.10.1    Protein extraction and measurement 
MEFs were harvested after they were washed one time with PBS, trypsinized for 2-5 minutes 
at 37°C and resuspended in medium. The cell suspension was transferred to a 15 ml Falcon 
tube and centrifuged for 10 minutes at 300 x g at 4°C. Supernatant was discarded; the pellet 
washed with 1 ml PBS and centrifuged again at 300 x g at 4°C for 10 minutes. Directly after 
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aspiration of the supernatant the cell pellets were placed on ice. For cell lysis, a reasonable 
volume of radioimmunoprecipitation assay (RIPA) buffer (supplemented with protease 
inhibitors) was added to resuspend the cells, and then incubated for 15 - 20 minutes on ice. 
The amount of RIPA buffer was determined according to the size of cell pellet. Thereafter the 
cell debris was removed by centrifugation for 10 minutes at 13,000 x g at 4°C and supernatant 
was transferred to a fresh 1.5 ml tube. The protein concentration was determined by using the 
bicinchoninic acid (BCA) protein assay kit according to the manufacturer’s instructions. The 
two solutions of the kit were mixed and distributed to 0.5 ml tubes (20 µl/ tube), and then 2.5 
µl of the samples were added and incubated at 37°C for 30 minutes. NanoDrop was used to 
determine the protein concentration by photometric measurement. A standard curve was set 
with bovine serum albumin (BSA) and created by preparing 0.5, 0.75, 1, 2, 4, 8, and 10-µg 
duplicate dilutions of 200 mg/ml stock solution of BSA. Cell lysates were stored in the freezer 
at -20°C. 
 
2.2.10.2    Western blot analysis 
Protein samples were separated by sodium dodecyl sulfate-polyacrylamid gel electrophoresis 
(SDS-PAGE) using the standard Laemmli method. Prior to loading, the samples were 
prepared for electrophoresis by addition of 4 fold loading buffer and denatured at 95°C for  
5 minutes. Equal amounts of proteins were loaded onto 12% gel. Electrophoresis was run in 1 
x electrophoresis buffer for 1-2 hours at 100 V (constant voltage) using Mini PROTEAN 
Tetra System (BIO-RAD). Protein separation was controlled by running a prestained protein 
ladder (PageRulerTM Plus, Thermo Scientific). 
 
Following electrophoresis, the stacking gel was discarded, and the separating gel was 
submerged in transfer buffer for several minutes (10-20 minutes). Then the protein samples in 
separating gel were transferred to a nitrocellulose membrane (0.45 µm pore size) using a 
semidry-transfer method. On a semidry transfer unit (PerfectBlue™ 'Semi-Dry'-Electro 
Blotter, peQlab) 3 sheets of Whatman paper pre-wetted in transfer buffer, the PVDF 
Separating gel: 10 ml of 12% gel Stacking gel: 5 ml of 5% gel 
4.3  ml H2O 3.7   ml H2O 
3     ml 40% Acrylamide 0.63 ml 40% Acrylamide 
2.5  ml 1.5 M Tris-HCL, pH 8.8 0.63 ml 1 M Tris-HCL, pH 6.8 
100 µl 10% SDS 50    µl 10% SDS 
100 µl 10% APS 50    µl 10% APS 
10   µl TEMED 5      µl TEMED 
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membrane, the gel, and 3 sheets of pre-wetted Whatman paper were assembled. The transfer 
was performed at 12 V (constant voltage) for 2.5 h. When the blotting was finished, the 
membrane was submerged in blocking buffer (5% non-fat dry milk powder in TBST or 5% 
bovine serum albumin in TBST) for 1 - 1.5 h to block the non-specific binding sites. Then the 
membrane was transferred into 50 ml tubes containing 5 ml primary antibody solution and 
incubated on a shaker overnight at 4°C. The next day, the membrane was washed with TBST 
(3 x 5 minutes), and incubated with the corresponding horseradish peroxidase (HRP) 
conjugated secondary antibody (diluted in blocking buffer) for 1 hour at room temperature. 
Then the membrane was washed again 3 times in TBST (5 minutes each). For visualization  
of immuno-reactive bands, the chemiluminescent detecting luminol reagent was used 
according to manufacturer’s instructions (Santa Cruz Biotechnology). Detection solution  
was applied to the membrane covering it evenly and after a short incubation time excess 
solution was drained from the membrane. Pictures of the chemiluminescent bands were  
taken by putting a light sensitive x-ray film on the top of the membrane in a darkroom.  
The film was developed after different exposure times and fixed according to the  
standard procedure. 
 
2.2.11    B16 melanoma cell inoculation 
B16 melanoma cell line was kindly provided from the Institute of Pathology, Charité in 
Berlin. Thawing of cells was performed quickly in a 37°C water bath for ~2 minutes.  
Then, the cells were transferred immediately into a culture flask containing pre-warmed 
RPMI culture medium supplemented with 10% FCS and incubated at 37°C with 5% CO2. The 
next day, the medium was replaced with fresh medium to remove traces of DMSO. The cells 
were grown to 60 - 70% confluence and harvested by trypsinization (as explain above for 
MEFs harvesting). The cells were collected in 15 ml centrifuge tubes, pipetted vigorously to 
obtain single cell suspension and washed with cold PBS. Then, the cells were adjusted to  
2.5 x 106 cells/ml in ice-cold PBS and transferred to animal facility while maintaining the 
cells on ice. The inoculation region was wetted with 70% ethanol before inoculation. The 
cells were resuspended by inverting the tube several times and a 1 ml syringe attached with 
27½-G needle was filled with cell suspension. Female wild-type and GABARAP KO mice 
were inoculated subcutaneously with 100 µl of cell suspension (2.5 x 105 cells) in the left 
flank region. After one week of B16 cells injection, we monitored the tumor growth daily and 
started tumor measurement when it became palpable. Tumor volume was measured using a 
caliper every other day. 
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2.2.12    Mutation analysis 
Mutation analysis was performed to screen for H-ras mutation in DMBA-induced tumors of 
wild-type and GABARAP KO mice. 
 
2.2.12.1    DNA extraction 
DNA was extracted by using Maxwell® 16 FFPE Plus LEV DNA Purification Kit (Promega) 
according to the manufacturer's instruction. FFPE blocks were sectioned to 10 µm thickness 
with a rotation microtome. The tumor region within the section was identified by Prof. Dr. 
Iver Petersen and Dr. Masoud Mireskandari (Institute of Pathology, Jena). Thereafter, the 
identified tumor region, corresponding to H & E stained section, was scraped from FFPE 
tissue sections by scalpel. The number of sections for each tumor was determined depending 
on tumor size (~10 - 20 sections). Then the scraped sections were collected in microtube and 
briefly centrifuged at full speed to collect the sample at the bottom of the tube. The pellet was 
resuspended in 180 µl of incubation buffer and 20 µl proteinase K solution. The tumor sample 
was incubated at 70°C overnight. In the next day, 400 µl of lysis buffer was added to the 
sample and mixed by vortexing. Then the sample was prepared for Maxwell® 16 automated 
DNA purification instrument (Promega) as illustrated in Figure 11. The cartridge was placed 
in the rack; the LEV plunger was placed in the last well of cartridge, and elution tube was 
placed in the front of the Maxwell® 16 LEV Cartridge Rack (Fig. 11). Nuclease-free water 
(35 µl) was added the elution tube. Subsequently, the sample was transferred to well #1 of the 
cartridge (Fig. 11). Then the rack was transferred to the instrument and we selected the 
program of DNA extraction of FFPE sample. When the automated purification run was 
completed, NanoDrop was used to measure the DNA concentration and the purity (260 / 280 
nm ratio) of the samples. If not used immediately for PCR the samples were stored at -20°C. 
 
 
 
 
 
 
 
 
Figure 11. Sample preparation for Maxwell® 16 LEV Cartridges of FFPE-DNA purification kit (Promega). 
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2.2.12.2    Polymerase chain reaction (PCR) 
For polymerase chain reaction (PCR) we used the primers shown above in paragraph 2.1.11. 
180 ng DNA were used per run and the master mix was prepared as follows: 
 
 
 
 
 
 
 
 
DNA was added to each tube containing master mix as the final step. Tubes were placed in 
the peQSTAR 96 Universal Gradient cycler (peQlab) and the program was started. The 
annealing temperature of H-ras primers was 68°C for the first eight cycles, then 60°C for the 
next 32 cycles of exon 1 primers and 62°C for the next 32 cycles of exon 2 primers. 
 
 
 
 
 
 
 
After the program was completed the PCR products were stored at 4°C. 
 
2.2.12.3    Agarose gel electrophoresis 
Electrophoresis was performed as described above in paragraph 2.2.2.3. 
 
2.2.12.4    Purification of PCR products for sequencing 
The DNA Clean & Concentrator™-5 Kit (Zymo Research) was used for the purification of 
PCR products for sequencing according to manufacturer’s instructions. Two volumes of  
DNA binding buffer were added to the PCR product and the mixture was transferred to  
Reagent Volume/reaction 
10 x buffer S 5 µl 
2.0 mM dNTP mix 5 µl 
Forward Primer (10 pmol/µl) 2 µl 
Reverse Primer (10 pmol/µl) 2 µl 
Taq-polymerase (HotStarTaq) 0.25 µl 
DNA, 180 ng Variable 
H2O Variable 
Total reaction volume 50 µl 
Step Temperature Duration Cycle 
Initial denaturation 95°C 15 minutes 1 
Denaturation 94°C 1 minute  
 
8 Annealing 68°C 45 seconds 
Extension 72°C 45 seconds 
Denaturation 94°C 1 minute  
 
 32 Annealing 60°C exon1, 62°C exon 2 45 seconds 
Extension 72°C 45 seconds 
Final elongation 72°C 7 minutes 1 
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a Zymo-Spin™ column in a collection tube. Then, centrifugation was carried out for 1 minute 
at 12,000 x g and the flow-through was discarded. Thereafter, 200 µl of DNA wash buffer per 
column were added and centrifugation carried out at 12,000 x g for 1 minute. The washing 
step was repeated once. Ten µl of water were added directly to column matrix and incubated 
for 1 minute at room temperature. Column was transferred to a fresh 1.5 ml tube and 
centrifuged for 1 minute at 12,000 x g to elute the DNA. The concentration of purified DNA 
was measured with NanoDrop. 
 
2.2.12.5    Sequencing and result analysis 
Purified PCR products (100 ng) were applied for direct sequencing by capillary 
electrophoresis (LGC Genomics GmbH, Berlin, Germany), and the sequencing-profiling was 
analyzed by the Finch TV 1.4.0 software program (Geospiza, PerkinElmer, MA, USA). 
 
2.2.13    Statistical analysis 
Data are expressed as mean ± SEM (standard error of the mean). Differences between  
groups were calculated using the two-tailed Student’s t-test for unpaired values. Normal 
distribution of the values was checked using the Kolmogorov-Smirnov test (K–S test). 
Survival analysis was calculated by the Kaplan-Meier method. Statistical significance was 
calculated by the SPSS software package (v.16.0, Chicago, USA), p-values below 0.05 were 
considered as being significant (* p < 0.05, ** p < 0.01, *** p = 0). Statistical analysis for 
gene expression profiling was explained above in paragraph 2.2.7.6. 
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3.       Results 
3.1     GABARAP knockout mice exhibited low tumor formation 
In order to investigate the potential roles of GABARAP in the incidence of tumors, we 
attempted to induce tumors in our transgenic animals by treatment with a reliable potent 
carcinogen 7,12-dimethylbenz(a)anthracene (DMBA). Female GABARAP knockout (KO) 
and C57BL/6 wild-type (Wt) mice were given 1 mg doses of DMBA for 6 consecutive weeks 
by oral gavage beginning at 6 - 8 weeks of age. Mice were checked weekly for the presence of 
palpable tumor masses. Tumors arose in 14 of 29 (48.3%) of wild-type mice within  
35 weeks after the last DMBA dose (Table 2). Surprisingly, the numbers of GABARAP KO 
mice exhibiting tumors were significantly less than their wild-type counterparts  
(4 of 33; 12.1%; p < 0.002) (Table 2). A variety of tumors developed in each group of mice, 
for instance mammary, skin, lymphoma and liver tumors. Figure 12 showed gross 
morphologic and histologic features of tumors induced by DMBA. If only mammary tumors 
are considered, this represents a reduction from 3 of 14 (21.4%) in wild-type mice to 0 of 4  
(0%) in GABARAP KO mice (Table 2). 
 
Table 2. Tumor types and incidence in C57BL/6 wild-type (Wt) and GABARAP KO (KO) mice 
 
Tumor type C57BL/6 (Wt) GABARAP -/- (KO)  
DMBA treatment n = 29 n = 33 
Mammary 3 - 
Skin 7 2 
Lymphoma 2 - 
Liver - 1 
Undifferentiated tumors 2 1 
Total 14 (48.3%) 4 (12.1%)** 
   
Spontaneous tumor n = 30 n = 35 
Mammary 2 - 
Lymphoma - 2 
Liver 1 - 
Undifferentiated tumors 1 - 
Total 4 2 
 
** Significant difference between two groups (p-value < 0.01) calculated by Fisher’s exact test. 
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Figure 12. Gross morphologic and histologic features of mice tumors induced by DMBA. A) Upper panel: 
skin tumor in wild-type mouse, bottom panel: H&E staining of skin squamous cell carcinoma. B) Upper 
panel: skin tumor in GABARAP KO mouse, lower panel: H&E staining of skin sebaceous epithelioma. C) 
Upper panel: undifferentiated tumor mass in abdomen of wild-type mouse, bottom panel: H&E staining of 
histologic section of undifferentiated tumor. D) Upper panel: mammary tumor in wild-type mouse, bottom 
panel: H&E staining of mammary squamous cell carcinoma. E) Upper panel: lymphoma in the neck of wild-
type mouse, bottom panel: H&E staining of histologic section of lymphoma. F) Upper panel: two masses of 
liver tumor in GABARAP KO mouse, bottom panel: H&E staining of liver cell carcinoma. The 
magnifications of all histologic sections were 20X.  
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Regarding the spontaneous tumor incidence in female GABARAP KO and wild-type control 
mice over the period of 2 years, 4 spontaneous tumors out of 30 (13.3%) developed in  
wild-type mice compared with 2 out of 35 (5.7%) in GABARAP KO mice (Table 2). 
Furthermore, no spontaneous mammary tumors developed in GABARAP KO mice in 
comparison with wild-type control mice group which developed 2 mammary tumors  
out of 4 spontaneous tumors (Table 2). 
The low percentage of tumor incidence in C57BL/6 (Wt) mice is approximately consistent 
with the data reported by other authors following DMBA treatment and/or spontaneous 
tumors development, and this is due to the fact that the C57BL/6 mouse strain is less sensitive 
to DMBA-induced tumorigenesis than other rodent strains (DiGiovanni et al., 1993; Hennings 
et al., 1993; Woodworth et al., 2004; Medina, 2007). 
The median onset time and latency period of tumors induced by DMBA were not available 
for all tumor types due to a number of mice that had interior tumors; for example liver tumors 
were difficult to detect by palpation. Figure 13 (A and B) showed the latency periods and 
sizes of tumors induced by DMBA in mice groups. The tumor occurrence started earlier in 
wild-type mice compared to GABARAP knockout animals, at the 9th week after the last 
DMBA dose (Fig. 13 A). The tumor sizes in wild-type mice were obviously larger in most of 
induced tumors compared to the tumors formed in GABARAP KO mice which were smallest 
in general (Fig. 13 B). The age in Figure 13 (B) represented the age of mice when they are 
sacrificed. 
 
 
Figure 13. A) Latency period of palpable tumors (skin, lymphoma and mammary tumors) in  
wild-type (Wt) and GABARAP KO (KO) mice after 6 weekly oral doses of 1 mg DMBA. The latency period 
represented the date after the last dose of DMBA, which was indicated as (0) in figure. B) Size of all the 
tumors induced by DMBA in wild-type (Wt) and GABARAP KO (KO) mice. In figure B, the age of mice 
represented the date when the mice are sacrificed. 
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3.2     GABARAP knockout mice reduced the survival after different carcinogen 
treatments 
Female GABARAP KO and wild-type mice treated with different carcinogen regimens at  
6 – 8 weeks of age in order to increase and improve the tumor incidence. In addition, we 
wanted to investigate the lethal susceptibility of GABARAP KO mice, since the GABARAP-
deficient mice showed a significant survival reduction (p = 0.006) after DMBA treatment 
(Fig. 14 A). In addition to polycyclic aromatic hydrocarbon DMBA, N-ethyl-N-nitrosourea 
(ENU) and N-methyl-N-nitrosourea (MNU), alkylating agents and potent mutagens, were 
used in our investigation. Treatment of mice with a single intraperitoneal (i.p.) injection of 
150 mg ENU/kg of body weight showed substantial reduction (p = 0.022) in survival of 
GABARAP KO mice compared with wild-type mice through the period of 53 weeks  
(Fig. 14 B). There was no tumor formation within the period of ENU treatment in  
GABARAP KO mice, while wild-type mice developed tumors in about 21% of ENU-treated 
mice (n = 14 mice per group). 
Furthermore, it was reported that using of medroxyprogesterone acetate (MPA), a steroidal 
progestin, enhanced the mammary tumorigenesis in BALB/c mice following MNU treatment 
(Pazos et al., 1998). We attempted to increase the mammary tumors incidence in our mice 
groups by using the similar treatment regimen; however, we observed that the survival  
of GABARAP KO mice was significantly decreased (p = 0.002) compared with wild-type 
mice (Fig. 14 C). No tumor formation was observed in both treated groups during the period 
of 27 weeks of MPA plus MNU treatment. Indeed, non-occurrence of tumor within a short 
time period after carcinogen treatment consider normal, since those carcinogens  
(DMBA, ENU and MNU) require more time to initiate and promote tumor development in 
mouse models. 
Moreover, the synergistic effect of MNU and DMBA in mammary carcinogenesis of female 
rats has been reported in the literature (Shirai et al., 1997). The combined treatment of MNU 
and DMBA increased the carcinogenic effect and significantly increased the mean number of 
mammary tumors per rat (Shirai et al., 1997). To further examine tumor susceptibility and 
lethality of GABARAP KO mice by carcinogen treatment, female mice were treated with 
MNU and DMBA, which are already promoted with MPA. This combination treatment 
increased lethality in both mice groups with a faster survival reduction in GABARAP KO 
mice (p = 0.002) than wild-type mice (Fig. 14 D). No tumor formation was observed in both 
animal groups after this combination of treatment. 
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In all carcinogen treatment models, deaths were scored when mice were euthanized because 
of tumors or illness, or were found dead. In our models of carcinogen treatments, almost all 
GABARAP KO mice were dead without any tumor formation. Finally, GABARAP KO mice 
have demonstrated higher sensitivity to reduce the survival and tumors incidence than  
wild-type mice groups after exposure to different carcinogens and treatment regimens.  
 
Figure 14. Kaplan-Meier survival plots of GABARAP knockout (KO) and wild-type (Wt) mice after treatment 
with different carcinogen regimens. (A) DMBA – 6 consecutive weeks of 1 mg/mouse by oral gavage, n = 20 
mice per group. (B) ENU – single i.p. injection of 150 mg/kg of body weight, n = 14 mice per group. 
 (C) MPA 40 mg i.m. + MNU 1 mg i.p. + MPA 20 mg i.m., n = 10 mice per group. (D) MPA 20 mg i.m. + 
MNU 1 mg i.p. + MPA 20 mg i.m. + DMBA 1 mg orally, n = 20 mice per group. Deaths were scored when 
mice were euthanized because of tumors or illness, or were found dead. Almost all GABARAP KO mice were 
dead without any tumor incidence in all models of carcinogen treatments. P values indicated in each figure. 
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3.3     High sensitivity of GABARAP KO mice to immunotoxicity of DMBA 
During the time of experiments, we noticed that the control GABARAP KO mice groups 
were phenotypically indistinguishable from wild-type mice and showed no detectable changes 
in gross anatomy, as reported by O’Sullivan (O’Sullivan et al., 2005). DMBA induced tumors 
in our mice models with significant tumor and survival reduction in GABARAP KO mice. 
For this reasons, we wanted to investigate the impact of GABARAP deficiency on the organs 
cellularity and functions after DMBA treatment. Body weights were monitored at different 
intervals time starting from the day before DMBA treatment. We noticed that the mean  
body weights of GABARAP KO mice after 6 weekly oral doses of 1 mg DMBA/mouse  
were noticeably less than wild-type counterpart group (Fig. 15 A). The body weights 
progressively increased in wild-type mice after DMBA treatment, in contrast there were only 
small and tardy increments of body weights in the GABARAP KO mice treated with DMBA 
(Fig. 15 A). 
An immunotoxic effect of DMBA treatment, mainly on the spleen, has been reported (Dean  
et al., 1985; Miyata et al., 2001; Gao et al., 2005, 2007). In order to explore the immunotoxic 
effect of DMBA in our mice groups, spleen parameters were observed by different means. 
Interestingly, the GABARAP KO mice showed a highly decrease of spleen volume compared 
with wild-type mice after treatment with 6 weekly doses of DMBA (Fig. 15 B). Spleen 
weights of DMBA-treated wild-type mice were decreased to about 40.5% (± 0.7%) of control 
(vehicle-treated) wild-type mice (Fig. 15 B and C). However, substantial decrease was 
observed in spleen weights of GABARAP KO mice group treated with DMBA, 13.6%  
(± 1.8%) of control (vehicle-treated) GABARAP KO mice (Fig. 15 B and C). 
To inspect the changes in the cellularity of spleen components of GABARAP KO and  
wild-type mice after DMBA treatment, splenocytes were harvested, counted and 
differentiated. The alterations in total number of spleen cells were concordant with the spleen 
weights, and this gives indication that the cell death of splenocytes occurs in both groups of 
GABARAP KO and wild-type mice treated with DMBA. However, a significant decrease was 
seen in the total number of GABARAP KO splenocytes after treatment with DMBA; 11.6% 
(± 2.4%) of control splenocytes in GABARAP KO mice compared with 44.7%  
(± 2.8%) of control splenocytes in wild-type mice (Fig. 16). These alterations in total number 
of splenocytes were in agreement with morphological changes in spleen volumes and weights 
(Fig. 15 B and C), with a more profound decrease of GABARAP KO cells compared to  
wild-type cells. 
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Figure 15. A) Body weights of mice at different intervals time before and after treatment with 6 weekly oral 
doses of 1 mg DMBA/mouse. Age at 6 weeks represents the day before starting the DMBA treatment. The 
groups consist of 6 mice per each control (vehicle-treated) group and 16-20 mice for DMBA-treated groups. 
B) Changes in spleen volume of GABARAP KO (KO) and wild-type (Wt) mice at the same age and treatment 
condition. C) Spleen weights for mice untreated (control) or treated with DMBA. Data are representative of 7 
mice per group. Spleen volumes and weights were measured at 13 weeks of age, i.e. after one week of 6 
DMBA doses. All data were shown with means ± SD. 
 
 
 
 
 
 
 
 
Figure 16. Total number of splenocytes in control (vehicle-treated) and DMBA-treated mice groups. Data are 
representative of three mice of each group and shown with means ± SEM. P values shown above each two 
groups, (*) p ˂ 0.05, (**) p ˂ 0.01. 
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Furthermore, the cell surface marker analyses was carried out by using BD™ LSR II flow 
cytometer to detect the alterations in cellular population of splenocytes after DMBA treatment 
of GABARAP KO and wild-type mice in comparison with their vehicle control groups. We 
have detected regulatory T cells (Tregs), B cells, T helper cells (CD4), cytotoxic T cells 
(CD8), macrophages and neutrophils. The results were compatible with the decrease of total 
number of splenocytes in both GABARAP KO and wild-type mice (Fig. 17); i.e. GABARAP 
KO mice showed substantial reduction in populations of splenocytes compared to wild-type 
mice after DMBA treatment. That means there was no discrimination for the effect of DMBA 
on particular cell types in both GABARAP KO and wild-type mice. 
 
 
Figure 17. Cell surface markers expression of splenocytes in control (vehicle-treated) and DMBA-treated 
mice. DMBA treatment was 6 weekly oral doses of 1 mg/mouse. Data are representative of three mice of each 
group and were shown with means ± SEM. 
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These results indicate that the reduced growth of GABARAP KO mice after DMBA treatment 
was not only due to the effect of DMBA immunotoxicity in the spleen, since wild-type mice 
showed also reduced spleen weights but the their body weights slightly altered after DMBA 
treatment. This suggests that DMBA treatment in GABARAP-deficient mice may has impact 
on other organs in addition to spleen. 
 
3.4     DMBA treatment enhanced cell death in splenocytes of GABARAP KO 
mice 
Our results demonstrated considerable alterations in volumes, weights and total cell numbers 
in spleens of GABARAP KO mice after DMBA treatment compared with a parallel group of  
wild-type spleens. In general, it is long believed that autophagy blockade may increase 
apoptosis in cells when expose to stress. For these reasons, we have investigated the 
proliferation and cell death of splenocytes of DMBA-treated and untreated mice. 
Immunohistochemistry staining was used to detect the expression of Ki-67, a cellular 
proliferation marker. Female mice have been treated with 6 weekly oral doses of 1 mg 
DMBA/mouse, and vehicle control groups were given sesame oil orally at the same  
time points as the DMBA treatment. Splenocytes of both DMBA-treated GABARAP KO  
and wild-type mice exhibited less Ki-67 expression than their vehicle-treated  
(sesame oil) groups (Fig. 18 A). Ki-67 expression was obviously decreased at a high level in 
DMBA-treated GABARAP KO splenocytes compared with DMBA-treated wild-type 
counterpart (Fig. 18 A). 
Moreover, the TUNEL assay was carried out on the spleen sections to detect the apoptotic 
cells within the spleens. Microscopic examination of TUNEL-stained sections showed an 
increased number of TUNEL-positive spleen cells after in vivo DMBA treatment of both 
GABARAP KO and wild-type mice (Fig. 18 B). However, the TUNEL-stained sections 
indicated a substantial increase of TUNEL-positive cells in the spleen tissues of DMBA-
treated GABARAP KO mice compared with the DMBA-treated wild-type counterparts  
(Fig. 18 B). 
Our results give an indication that the knockout of GABARAP gene in mice enhanced  
the incidence of cell death and reduce the proliferation of splenocytes in the DMBA-treated 
group. Such findings may explain the high reduction of volume, weight and total splenocytes 
number in GABARAP KO mice after treatment with DMBA by oral gavage. 
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Figure 18. Immunohistochemistry and Immunofluorescence staining for spleen sections of vehicle-treated 
(control) and DMBA-treated wild-type (Wt) and GABARAP KO (KO) mice. A) Immunohistochemistry 
staining for Ki-67. Magnifications 20X. B) Immunofluorescence staining/TUNEL assay. Scale bars =100 µm. 
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3.5     GABARAP-deficient immune cells showed high cytokine secretion 
Cytokines secretion can trigger cell signaling toward anti-tumor effects and/or cell death 
mediated by tissue injury and lethal shock. This capacity of cell signaling relies on a panel of 
cytokines and the accurate assignment of effector cells. Macrophages and lymphocytes are the 
major components of the immune system, and both are involved in cytokine secretion as well 
as effector cells. Many autophagic genes play a role in immunity, and disruption of such 
genes as LC3B, Atg16l1, Beclin1 and GABARAP increased lethality and IL-1β expression in 
sepsis mouse models. For these reasons, we wanted to determine whether GABARAP 
deficiency upon treatment with DMBA plays role in enhancement of cytokines secretion to a 
level that may lead to suppress the tumor formation and/or mice death. 
Peritoneal macrophages and spleen lymphocytes of GABARAP KO and wild-type mice either 
treated with sesame oil as vehicle vector (control group) or treated with DMBA were isolated, 
cultured and stimulated. Lipopolysaccharide (LPS), a component of the outer membrane of 
Gram-negative bacteria, were used to elicit an immune response by interacting with the 
macrophage membrane receptor CD14 to induce the generation of cytokines such as IL-1β, 
IL-6 and TNFα (Akira et al., 1993; Tracey and Cerami, 1994; Kielian and Blecha, 1995; 
Meng and Lowell, 1997). Moreover, LPS-primed macrophages treated with adenosine 
triphosphate (ATP) are an established model for NLRP3 inflammasome-mediated IL-1β 
production in vitro by stimulation the cleavage of caspase 1 (Saitoh et al., 2008; Nakahira  
et al., 2011; Zhang et al., 2013). Isolated peritoneal macrophages from vehicle control or 
DMBA-treated GABARAP KO and wild-type mice were stimulated by treatment with LPS 
for 4 h or pretreated with LPS for 4 h followed by stimulation with ATP for 1 h. The levels of 
IL-1β, IL-6 and TNFα in the medium of cultured macrophages were measured by ELISA.  
In vehicle control groups, IL-1β was highly produced after LPS and ATP stimulation in both 
GABARAP-deficient and wild-type macrophages compared to the macrophages stimulated 
with LPS alone (Fig. 19 A). GABARAP-deficient macrophages; from mice treated  
in vivo with 6 weekly doses of 1 mg DMBA and stimulated in vitro with LPS, generated a 
significant higher IL-1β levels than wild-type macrophages (Fig. 19 A). In addition, the level 
of IL-1β production was increased in macrophages of both DMBA-treated GABARAP KO 
and wild-type mice after stimulations with LPS and ATP compared to stimulation with LPS 
alone (Fig. 19 A). However, the production of IL-1β was significantly higher in macrophages 
of DMBA-treated GABARAP KO mice after stimulation with LPS and ATP compared to 
wild-type counterpart macrophages (Fig. 19 A). Similar results were obtained with IL-6; 
except that IL-6 secretion was increased in the similar pattern after both stimulations; LPS 
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alone or LPS and ATP, for macrophages of DMBA-treated groups (Fig. 19 B). Likewise, the 
production of TNFα in macrophages of vehicle-treated and DMBA-treated GABARAP KO 
mice was slightly higher in both stimulations compared with wild-type macrophages  
(Fig. 19 C). 
 
 
Figure 19. Cytokine secretion from peritoneal macrophages of GABARAP KO (KO) and wild-type (Wt) mice 
treated with 6 weekly oral doses of sesame oil (vehicle) or 1 mg DMBA/mouse. Macrophages of each group 
were stimulated with LPS for 4 h or priming 4 h with LPS followed by stimulation with ATP for 1 h 
(LPS+ATP). A) IL-1β, B) IL-6 and C) TNFα were measured in the supernatants by ELISA. Data are 
representative of triplicate experiments and were shown with means ± SEM. (**) p ˂ 0.01; (***) p = 0.  
n.d., not detected. 
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These results could give an indication for sensitivity of GABARAP KO mice after DMBA 
treatment and could explain the increased lethality in these mice after carcinogen treatment. In 
addition, IL-1β has contradictory roles in tumor growth; some studies have shown stimulatory 
effect on the growth of tumor cells, whereas others have shown that it exerts inhibitory 
activity. These contradictory effects are controlled by the level of IL-1β. High concentrations 
of IL-1β induced cellular apoptosis, whereas moderate or low levels of IL-1β in the same cells 
kept the cell normal or stimulated the cell growth (Roy et al., 2006). 
Moreover, isolated lymphocytes from the spleen of vehicle control or DMBA-treated mice 
were investigated for cytokines secretion. DMBA-treated mice had been reported to be 
persistently immunosuppressed after treatment, mainly through IL-2 suppression (House  
et al., 1987; Thurmond et al., 1987, 1988; Burchiel et al., 1990; Saas et al., 1996; Gao et al., 
2008). Therefore, lymphocytes were cultured in 6 well plates coated with CD3 to generate an 
activation signal to T-lymphocytes through association of CD3 with the T-cell receptor 
(TCR). The stimulation period with CD3 lasted for 48 h, and then the cytokine secretion was 
measured in the medium of cultured lymphocytes by ELISA. Vehicle control groups showed 
slightly increased levels of IL-2 in GABARAP-deficient lymphocytes after CD3 stimulation 
compared with wild-type counterparts (Fig. 20 A). As expected, IL-2 was suppressed in 
lymphocytes of DMBA-treated wild-type mice after CD3 stimulation compared with CD3-
stimulated lymphocytes of vehicle-treated wild-type mice (Fig. 20 A). Surprisingly, 
GABARAP-deficient lymphocytes of DMBA-treated mice produced more IL-2 after CD3 
stimulation than lymphocytes of vehicle-treated GABARAP KO mice (Fig. 20 A). This result 
indicates that DMBA does not induce suppression of IL-2 production in GABARAP-deficient 
lymphocytes, in contrast to the normal consequence of DMBA-treated mice which manifested 
by disruption of T-helper cell function specifically by inhibition of IL-2 production. Likewise, 
IFN-γ showed similar predisposition of IL-2 after CD3 stimulation of lymphocytes from 
vehicle-treated and DMBA-treated mice (Fig. 20 B). Stimulated lymphocytes of DMBA-
treated GABARAP KO mice showed an increased production of IFN-γ compared either with 
stimulated lymphocytes of vehicle-treated GABARAP KO or wild-type counterparts. 
Moreover, the opposite tendency of IFN-γ production was evident between the lymphocytes 
groups; i.e. less IFN-γ production by stimulated lymphocytes of DMBA-treated wild-type 
mice than their vehicle-treated wild-type counterparts, and a contrary trend in case of 
GABARAP-deficient lymphocytes (Fig. 20 B).  
It is well known that IFN-γ serves to limit the IL-17-producing T cell population. We 
measured the IL-17 production from lymphocytes, and we found an antagonist effect between 
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IL-17 and IFN-γ after stimulation of lymphocytes from DMBA-treated groups; i.e. increased 
level of IFN-γ led to diminished levels of IL-17 generated by lymphocytes and vice versa 
(Fig. 20 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Cytokines secretion from Lymphocytes of GABARAP KO (KO) and wild-type (Wt) mice treated 
with sesame oil (vehicle) or DMBA. Lymphocytes of each group were stimulated with CD3 for 48 h. A) IL-2, 
B) IFN-γ and C) IL-17 were measured in the supernatants by ELISA. Data are representative of triplicate 
experiments and were shown with means ± SEM. (**) p ˂ 0.01. n.d., not detected. 
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Altogether, these results elucidated that the knockout of GABARAP gene has considerable 
impact on the immunity of mice through enhancing the secretion of regulatory cytokines,  
for instance IL-1β and IL-2. Some of these cytokines, especially IL-2 and IFN-γ, have reliable 
anti-tumor effects and may explain why GABARAP KO mice developed less tumor 
formation than wild-type mice after DMBA treatment. 
 
3.6     GABARAP deficiency reduced the growth of mammary glands after 
DMBA treatment 
Our in vivo results proved that female GABARAP KO mice did not develop any mammary 
tumors during the time of experiments whether treated with DMBA or not. DMBA is highly 
carcinogenic when administered to adult female mice by oral gavage and especially relevant 
to the study mouse mammary gland tumorigenesis (Ethier and Ullrich, 1982; Medina, 1996; 
Currier et al., 2005; Klos et al., 2012). For this reason, we explored the mammary epithelial 
cell growth and ductal trees morphogenesis in our experimental mice groups to evaluate the 
gland architecture, proliferation and cell death by means of mammary gland whole mount 
morphology analysis and immunostaining. Female mice were treated with 1 mg doses of 
DMBA or 200 µl sesame oil (as vehicle control) for 6 consecutive weeks by oral gavage 
beginning at 6 - 8 weeks of age. 
The abdominal mammary glands of female GABARAP KO and wild-type mice at 14 weeks 
of age showed normal mammogenesis and there are no obvious phenotypic consequences of 
GABARAP deficiency on mammary epithelial cell growth at this age (Fig. 21 A). 
Furthermore, the mammary glands of female wild-type mice treated with 6 weekly doses of  
1 mg DMBA/mouse showed a phenotypically normal mammary epithelial trees compared 
with their age-matched (14 weeks old) control wild-type group (Fig. 21 A). Interestingly, 
GABARAP deficiency had a significant impact on the mammary epithelial cell growth and 
ductal branching of female mice after treatment with 6 weekly doses of 1 mg DMBA/mouse. 
The mammary glands of DMBA-treated female GABARAP KO mice showed a significant 
reduction of epithelial cell outgrowth and ductal branching compared either with their age 
matched control GABARAP KO mice or DMBA-treated wild-type mice (Fig. 21 A). 
Moreover, analysis of mammary gland whole mount morphology was performed by 
measuring the distance of epithelial growth from the lymph node to the end of epithelial tree 
by using a ruler, according to de Assis et al. (2010). The distances of mammary epithelial 
growth in DMBA-treated female GABARAP KO mice were significant shorter than their age-
matched control GABARAP KO mice or DMBA-treated wild-type mice (Fig. 21 B).  
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Figure 21. A) Whole mount analysis of mammary glands from wild-type (Wt) and GABARAP KO (KO) 
female mice, vehicle-treated (Control) or DMBA-treated. The female mice were either treated with 6 weekly 
oral doses of 1 mg DMBA/mouse or given sesame oil (vehicle) at the same time of DMBA treatment.  
L.N = lymph node, N = nipple; scale bars = 5 mm. B) Mammary epithelial growth of female mice treated as 
described in A. The epithelial growth was determined by measuring the distance from the lymph node to the 
end of epithelial tree (in millimetres = mm), using a ruler. Values are representative of 6 - 9 mice and were 
shown with means ± SEM. (**) p ˂ 0.01; (***) p = 0. 
 
Furthermore, immunostaining for mammary gland sections were done by using Ki-67 and 
TUNEL assay. Similarly to the spleen, mammary glands of DMBA-treated GABARAP KO 
female mice revealed higher reduction in proliferation by decreased Ki-67 expression 
compared to mammary glands of vehicle-treated (control) GABARAP KO or DMBA-treated 
wild-type groups (Fig. 22 A). DMBA-treated wild-type mice showed a slight inhibition of Ki-
67 expression in mammary glands compared with their control wild-type counterparts. 
Moreover, TUNEL staining of mammary gland sections from DMBA-treated GABARAP KO 
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mice showed an increasing number of TUNEL-positive cells compared with other groups 
(Fig. 22 B). Altogether, our results showed that cellular deaths were highly elevated in 
GABARAP KO mice when exposed to genotoxic carcinogen (DMBA) and this may explain 
the inhibition of tumor formation and the increased lethality of mice after DMBA treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Immunohistochemistry and Immunofluorescence staining for mammary gland sections of vehicle-
treated (control) and DMBA-treated wild-type (Wt) and GABARAP KO (KO) mice. A) Immunohistochemistry 
staining for Ki-67. Magnifications 20X. B) Immunofluorescence staining/TUNEL assay. Scale bars = 50 µm. 
Arrows indicate the epithelial cells. 
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3.7     Gene expression profiling indicated differential expression of tumor     
suppressor gene Xaf1 in mammary glands of GABARAP KO mice 
To further investigate the molecular mechanism by which GABARAP deficiency reduced 
tumor formation, spontaneously or after genotoxic carcinogen (DMBA) treatment, the 
workflow of Agilent Whole Mouse Genome expression analysis by microarray gene 
expression detection was employed. GABARAP KO and wild-type mice were either treated 
with sesame oil as vehicle (control group) or with 6 weekly oral doses of 1 mg DMBA/mouse 
beginning at 6 -8 weeks of age. The RNAs from abdominal mammary glands of each group 
were isolated and hybridized with one-color oligo microarrays 8x60K chips. The data was 
computed to identify genes that had a significant modification in the expression level in both 
control and DMBA-treated groups of GABARAP KO and wild-type mammary glands. Four 
comparisons were generated between control wild-type (CWT), control GABARAP KO 
(CKO), DMBA-treated wild-type (DWT) and DMBA-treated GABARAP KO (DKO) groups. 
Next, a subset of genes that had GABARAP-dependent altered expression compared to CWT 
and DWT was derived from this data, and a selected list of the most differentially expressed 
genes is represented in a heat map (Fig. 23). In Figure 23, the heat map showed GABARAP 
gene expression as well as 50 other genes which are exclusively modulated upon GABARAP 
knockdown. GABARAP expression was shown also in a boxplot (Fig. 24 A). The biological 
functions for some genes listed in Figure 23 are so far unknown. For instance, five Mup 
(major urinary protein) family proteins were differentially downregulated in mammary glands 
of GABARAP KO mice. Mups belong to a larger family of proteins known as lipocalins. The 
precise role of these genes is not yet clarified, but some authors propose that Mups have 
beneficial effects on energy metabolism by enhancing mitochondrial function, and also may 
act as a regulator for glucose and lipid metabolism in mice (Hui et al., 2009; Zhou et al., 
2009). Moreover, Rab4a (Ras-related protein), has shown to be upregulated in GABARAP 
KO mammary glands compared to wild-type counterparts. Rab proteins constitute the largest 
subfamily of the Ras family of small GTPases and are involved in the regulation of vesicular 
transport. The encoded protein of this gene is associated with early endosomes and plays a 
role in regulating the recycling of receptors from endosomes to the plasma membrane 
(Olkkonen and Stenmark, 1997; Yudowski et al., 2009). Interestingly, tripartite motif-
containing protein 16 (Trim16) has been significantly downregulated in GABARAP KO 
groups (control and DMBA-treated) compared to their wild-type counterparts (Fig. 23 and 24 
B). Trim16 is a ubiquitously expressed protein and was identified as an estrogen and anti-
estrogen regulated gene in epithelial cells stably expressing estrogen receptor. TRIM proteins 
 
 72    
3. Results 
 
have been reported to have important roles in cell growth, differentiation, ubiquitination, 
retroviral immunity and cancer (Cao et al., 1998; Beer et al., 2002; Meroni and Diez-Roux, 
2005; Marshall et al., 2010; Liu et al., 2014). 
 
 
Figure 23. Heatmap of differentially expressed genes in mammary glands of GABARAP KO and wild-type 
mice. The comparison of control wild-type (CWT) and DMBA-treated wild-type (DWT) with their untreated 
(CKO) and treated (DKO) GABARAP KO counterparts identified 50 most distinct genes. The control groups 
included 3 replicates, whereas DMBA-treated groups included 6 replicates. 
 
In our attempt to identify candidate genes related to GABARAP deficiency and interpret our 
phenotypic results, we found that the knockout of GABARAP resulted in highly and 
differentially expression of Xiap-associated factor 1 (Xaf1) gene (Fig. 23). Published 
evidence indicated that Xaf1 functions as a tumor suppressor, and the epigenetic silencing of 
Xaf1 by aberrant promoter methylation was associated with cancer development and 
progression (Fong et al., 2000; Byun et al., 2003; Lee et al., 2006; Tu et al., 2009; Huang  
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et al., 2010; Tu et al., 2010; Sun et al., 2011). GABARAP-deficient mammary glands of 
control and DMBA-treated mice showed significantly high expression levels of Xaf1 
compared with wild-type counterparts (Fig. 23, 24 C and Table 3). Xaf1 was originally 
identified as a novel negative regulator of X chromosome-linked inhibitor of apoptosis protein 
(Xiap) (Liston et al., 2001). Xiap is the most potent member of the family of mammalian 
inhibitor of apoptotic proteins (IAP), and functions through binding to tumor necrosis factor 
(TNF) receptor-associated factors and caspase family and thereby inhibits apoptosis. 
Interestingly, Xiap showed a significant upregulation in mammary glands of wild-type mice 
upon DMBA treatment, whereas mammary glands of DMBA-treated GABARAP KO mice 
exhibited only modest changes in Xiap expression levels compared to their vehicle control 
group (Table 3). These finding indicated that Xaf1 upregulation in mammary glands of 
GABARAP KO mice may contribute to the inhibition of tumor formation and may enhance 
apoptosis induction upon DMBA treatment. 
 
 
 
Figure 24. Boxplots of differentially expressed genes in mammary glands of GABARAP KO and wild-type 
mice. A) GABARAP. B) Trim16. C) Xaf1. Gene expression represents logarithmic fold change in each group. 
CKO = control (vehicle-treated) GABARAP KO, CWT = control (vehicle-treated) wild-type, DKO = DMBA-
treated GABARAP KO, DWT = DMBA-treated wild-type.  
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Moreover, there are dramatic changes in the genes expression levels when DMBA-treated 
groups were compared to control (vehicle-treated) groups. The genes listed in Table 3 have 
been selected according to the phenotypic changes that have been observed in mammary 
glands (Fig. 21). Most of these genes are involved in apoptosis, cell death, cell cycle control, 
DNA replication and autophagy, as indicated in the Table 3. Interestingly, GABARAP 
deficiency boosted the incidence of cell death and cell cycle arrest in mammary glands. The 
global gene expression profiling of mammary glands of control groups in comparison with 
DMBA-treated groups, resulted in the identification of a significantly higher expression of 
pro-apoptotic proteins (Bid, Apaf1 and Bax), tumor necrosis factor receptor superfamily 
(Tnfrsf10b) and receptor (TNFRSF)-interacting serine-threonine kinase 1 (Ripk1) in 
mammary glands of DMBA-treated GABARAP KO mice (Table 3). Furthermore, 
GABARAP-deficient mammary glands of DMBA-treated mice showed a high expression 
level of cyclin-dependent kinase inhibitor p21 (Cdkn1a) and p18 (Cdkn2c) compared to their 
control groups (Table 3). In addition, the mammary glands of DMBA-treated wild-type mice 
exhibited also high expression level of Bax and p21 (Table 3), and this may be due to the 
genotoxic effect of DMBA; however, there was no massive impact on the epithelial growth of 
wild-type mammary glands compared with GABARAP KO counterparts (Fig. 21). In 
contrast, we have found that Cdc7 and Cdk1, essential proteins for G1/S and G2/M phase 
transitions of eukaryotic cell cycle, were significantly higher expressed in mammary glands of 
DMBA-treated wild-type mice compared to their control counterparts. Likewise, Siva1, an 
apoptotic inducer protein (Prasad et al., 1997; Xue et al., 2002; Chu et al., 2005; Du et al., 
2009; Resch et al., 2009), was significantly upregulated in mammary glands of DMBA-
treated GABARAP KO and wild-type mice. Overexpression of Siva1 had been detected to 
inhibit stathmin (Stmn), an important regulatory protein of microtubule dynamics, leading to 
suppression of epithelial-mesenchymal transition (EMT) and metastasis (Li et al., 2011). 
Interestingly, mammary glands of treated GABARAP KO mice showed downregulated 
expression levels of Stmn4, in parallel with high expression of Siva1 (Table 3). 
There are other genes listed in Table 3 that showed differential expression levels, for instance 
genes involved in DNA replication or transcriptional factors as well as autophagic genes. For 
example, NF-κB1 and E2F were significantly upregulated in the mammary glands of DMBA-
treated wild-type mice (Table 3). NF-κB1 had been reported to play a role in mammary 
tumorigenesis. The E2F family of transcription factors plays a crucial role in the control of the 
cell cycle and the action of tumor suppressor genes like pRB (retinoblastoma protein). 
 
 
 75    
3. Results 
 
 Table 3. List of differentially expressed genes in mammary gland of GABARAP KO and wild-type mice  
with known functions 
 
* Significant expression difference between two groups (p-value ≤ 0.05) calculated by moderate t-test. 
- The values in table represent the logarithmic fold change for each gene. 
- CWT = control (vehicle-treated) wild-type, CKO = control (vehicle-treated) GABARAP KO, DWT = DMBA-
treated wild-type, DKO = DMBA-treated GABARAP KO. 
Gene Full name 
CWT  
vs  
CKO 
CWT  
vs  
DWT 
CKO  
vs  
DKO 
DWT 
 vs  
DKO 
Function 
GABARAP gamma-aminobutyric acid receptor  associated protein -4.05* 0.2 0.09 -4.16* autophagy 
Xaf1 XIAP associated factor 1 3.25* 0.22 0.36 3.39* apoptosis 
Xiap X-linked inhibitor of apoptosis 0.51 0.86* 0.05 -0.31 apoptosis 
Bid BH3 interacting domain death agonist 0.16 0.53 0.76* 0.39 apoptosis 
Apaf1 apoptotic peptidase activating factor 1 -0.33 0.08 0.59* 0.18 apoptosis 
Bax BCL2-associated X protein 0.03 1.79* 2.03* 0.27 apoptosis 
Tnfrsf10b tumor necrosis factor receptor superfamily,  member 10b -0.02 0.62 0.89* 0.25 cell death 
Ripk1 receptor (TNFRSF)-interacting serine-threonine kinase1 0.24 0.29 0.53* 0.48 cell death 
Siva1 apoptosis-inducing factor 0.08 1.3* 1.79* 0.57 apoptosis 
Stmn4 stathmin-like 4 -0.01 -0.51 -1.14* -0.65 microtubule destabilizer 
Il1r1 interleukin 1 receptor, type I -0.41 0.08 0.95* 0.45 cytokine receptor 
Cdkn1a cyclin-dependent kinase inhibitor 1A (P21) -0.1 3.08* 3.73* 0.55 cell cycle control 
Cdkn2c cyclin-dependent kinase inhibitor 2C (p18) -0.16 0.58 0.86* 0.12 cell cycle control 
Rbx1 ring-box 1 0.17 0.49* 0.3 -0.02 cell cycle control 
Cdc7 cell division cycle 7 0.29 0.5* 0.23 0.02 cell cycle control 
Cdk1 cyclin-dependent kinase 1 0.77 1.06* 0.35 0.07 cell cycle control 
Tgfb3 transforming growth factor, beta 3 -0.19 -0.51 -0.86* -0.55 DNA replication 
NF-κB1 nuclear factor of kappa light polypeptide gene  enhancer in B-cell 1 0.34 0.71* 0.6 0.23 transcription factor 
Smad2 SMAD family member 2 0.42 0.67* 0.38 0.13 transcription factor 
E2f1 E2F transcription factor 1 -0.22 -0.9* -0.62* 0.07 transcription factor 
E2f4 E2F transcription factor 4 0.71 1.24* 0.76 0.23 transcription factor 
Tfdp2 transcription factor Dp 2 0.17 0.68* 0.47 -0.04 transcription factor 
GABARAPL2 GABARAP-like 2 0.09 0.65* 0.62* 0.06 autophagy 
Atg12 autophagy related 12 -0.02 0.53* 0.62* 0.07 autophagy 
Prkaa1 protein kinase, AMP-activated, alpha 1  catalytic subunit 0.2 0.79* 0.7* 0.11 autophagy 
Atg3 autophagy related 3 0.1 0.79* 1.08* 0.4 autophagy 
Atg4b autophagy related 4B, cysteine peptidase -0.57 -0.65* -0.15 -0.07 autophagy 
Atg5 autophagy related 5 0.33 0.5* 0.28 0.11 autophagy 
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We next performed qRT–PCR analyses to verify the results for a subset of genes using the 
same set of mRNAs that have been used in oligo microarray chips. We found that the relative 
mRNA expression of Xaf1 was upregulated more than twofold in mammary glands of control 
and DMBA-treated GABARAP KO mice in comparison with mammary glands of wild-type 
counterparts (Fig. 25). Consistent with microarray data, we found that the expression levels of 
Bid, Bax and p21 were upregulated in both DMBA-treated groups. The relative mRNA 
expression level of Bid in mammary glands of DMBA-treated GABARAP KO group was 
upregulated more than twofold in relation to control counterparts, as well as in comparison 
with their DMBA-treated wild-type counterparts (Fig. 25). The mRNA expression level of 
Bax was upregulated in mammary glands of both DMBA-treated groups; the level of Bax 
expression was twofold higher in DMBA-treated GABARAP KO group when compared to 
wild-type counterpart (Fig. 25). Interestingly, the expression level of p21 in the mammary 
glands of DMBA-treated GABARAP KO mice was upregulated to 27-fold in relation to the 
GABARAP KO control group, whereas p21 was upregulataed 10-fold in the mammary glands 
of DMBA-treated wild-type mice relative to their control group (Fig. 25). In comparison of 
the DMBA-treated groups, we found that p21 was upregulated threefold in the mammary 
glands of GABARAP KO mice in relation to their wild-type counterparts (Fig. 25).   
Considering that upregulated Xaf1 and apoptosis signaling play an important role in antitumor 
activities (Byun et al., 2003; Brown and Attardi, 2005; Adams and Cory, 2007; Hanahan and 
Weinberg, 2011; Sun et al., 2011; Wong, 2011), these results suggested that GABARAP 
deletion might trigger enhanced antitumor activity through augmentation of cell death and  
cell cycle inhibition, and thus contribute to the suppression of mammary tumorigenesis in 
these mice. 
 
3.8     Xaf1 highly expressed in organs of GABARAP KO mice 
Our results of gene expression microarray analysis showed that the tumor suppressor Xaf1 
was differentially expressed in mammary glands of 14 weeks old GABARAP KO mice 
(control and DMBA-treated). We wanted to check the expression of Xaf1 in different organs 
and ages of wild-type and GABARAP KO mice. RNA was isolated from mammary gland, 
liver, lung, spleen and kidney of 6 weeks old mice. qRT–PCR was employed to screen the 
expression of Xaf1. GABARAP KO organs showed relatively higher mRNA expression  
of Xaf1 compared with their wild-type counterparts (Fig. 26). It is not doubt that the knockout 
of GABARAP gene resulted in differential Xaf1 expression in our transgenic mouse model. 
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Figure 25. Relative mRNA expression of Xaf1, Bid, Bax and p21 in mammary glands of vehicle-treated 
control (C) and DMBA-treated (D) mice measured by quantitative reverse transcriptase PCR (qRT-PCR). The 
groups are divided as: control wild-type (CWT), DMBA-treated wild-type (DWT), control GABARAP KO 
(CKO) and DMBA-treated GABARAP KO (DKO) and each figure is representative of four comparisons as 
indicated. Values are mean ± SEM of 4-6 samples of each group. The relative expression values of each gene 
to GAPDH in each sample were calculated and compared. (*) p ˂ 0.05; (**) p ˂ 0.01; (***) p = 0. 
 
 
 
 
 
 
 
 
 
Figure 26. Relative mRNA expression of Xaf1 in mammary gland, spleen, liver, lung and kidney at 6 weeks 
old of wild-type (Wt) and GABARAP KO (KO) mice measured by quantitative reverse transcriptase PCR 
(qRT-PCR). The relative expression value of Xaf1 to GAPDH in each sample was calculated and compared. 
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3.9     DNA damage repair impaired in GABARAP-deficient fibroblasts 
Fibroblasts are the most ubiquitous cell type within the body and have long been considered 
to be important investigator tool to identify the functional mechanism of gene in different 
signaling pathways. Mouse embryonic fibroblasts (MEFs) were isolated from the embryos of 
GABARAP KO and wild-type mice and cultured for further investigations. Firstly, we were 
tested whether the GABARAP gene has a crucial role in autophagy machinery. GABARAP-
deficient and wild-type MEFs were incubated in starvation medium (EBSS) in the  
presence or absence of the autophagy inhibitor, chloroquine (CQ), and the autophagic  
flux was tested by monitoring the autophagic markers LC3 and p62. As depicted in Figure 27 
A, both LC3A/B-II and p62 accumulated in GABARAP-deficient MEFs and were not 
affected by the CQ treatment indicating an inhibition in autophagic flux. Thus, our data 
suggest that the GABARAP gene has an essential role in the autophagic process in our  
cell model system. 
Furthermore, accumulative evidence indicated that autophagy is involved in DNA damage 
repair. DMBA has been shown to induce DNA damage in several tissues (Muqbil et al., 2006; 
Henkler et al., 2012; Ganesan et al., 2013). In addition, camptothecin (CPT) is considered as 
a DNA damage inducer and showed remarkable anticancer activity in preliminary clinical 
trials. CPT inhibits replication and transcription by trapping DNA topoisomerase I (Top1) 
covalently to DNA in a “cleavable complex” (Hsiang et al., 1985; Hsiang and Liu, 1988; Lin 
et al., 2008; Veloso et al., 2013). To investigate a potential role of GABARAP in the DNA 
damage response, GABARAP-deficient and wild-type MEFs were treated with DMBA and 
CPT to induce DNA damage. At various times after treatment with 100 nM DMBA and  
5 mM CPT, lysates were prepared from control and treated MEFs and analyzed by western 
blotting using antibodies against autophagy markers (LC3, p62 and GABARAP), DNA 
damage repair biomarker (γH2AX) and Cyclin D1, as a cell cycle progression indicator. As 
shown in Figure 27 B, induction of autophagy was detected in MEFs after treatment with 
DMBA and CPT. The conversion of soluble LC3A/B-I to lipid bound LC3A/B-II was shown 
as an indicator of autophagy induction as well as upregulation of GABARAP in wild-type 
MEFs and accumulation of p62 protein in GABARAP-deficient MEFs (Fig. 27 B). 
Moreover, DNA damage repair was detected by upregulating of phosphorylated γH2AX  
(p-γH2AX) in both GABARAP-deficient and wild-type MEFs after treatment for  
24 h (DMBA) or 4 h (CPT) (Fig. 27 B). In wild-type MEFs, p-γH2AX level thereafter 
gradually decreased by 48 h (DMBA) or 20 h (CPT) treatment, indicating repair or at least no 
more accumulation of the DNA damage (Fig. 27 B). In contrast, the protein level of p-γH2AX 
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Figure 27. Analysis of autophagy, DNA damage repair and proliferation of wild-type (Wt) and GABARAP 
KO (KO) MEFs after treatment with DMBA and CPT. A) Wild-type and GABARAP KO MEFs cultured in six 
well plates, then the cells incubated for 2 h in EBSS medium in the absence or presence of 10 µM 
chloroquine (CQ) and subjected to western blot analysis after lysis with RIPA extraction buffer. B) Wild-type 
and GABARAP KO MEFs cultured and treated with 100 nM DMBA for 24 and 48 h or 5 mM CPT for 4 and 
20 h. The cells were then lyzed and analyzed by western blotting using antibodies as indicated in figure. C) 
The cells treated as indicated in B, then the cells photographed after 24 h of DMBA treatment or 20 h of CPT 
treatment. 
C 
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remained high and accumulated more at 48 h (DMBA) or 20 h (CPT) after treatment  
in GABARAP-deficient MEFs, suggesting a defect in the repair of DNA damage induced by 
DMBA and CPT in these cells. Furthermore, Cyclin D1 was used to detect the progression of 
cell cycle. Accumulation of p-γH2AX in GABARAP-deficient MEFs after treatment with 
DMBA and CPT was accompanied with high reduction in Cyclin D1 protein level compared 
with their wild-type counterparts (Fig. 27 B). As depicted in Figure 27 C, GABARAP-
deficient MEFs showed a decreased proliferation rate after DMBA and CPT treatment 
compared with their wild-type counterparts. 
Together, these results indicated that deletion of GABARAP resulted in defective DNA 
damage repair and inhibition of cell cycle progression in our cell model system after DMBA 
and CPT treatments. 
 
3.10    GABARAP KO mice inhibited proliferation of inoculated B16 melanoma 
cells 
To further investigate the potential role of GABARAP gene in tumor progression, 
GABARAP KO and wild-type mice were subcutaneously inoculated with mouse  
B16 melanoma cells. After one week of B16 cells injection, we monitored the tumor  
growth daily and measured the tumor volume every other day beginning from the  
day when the tumor became palpable. All the wild-type mice presented palpable tumors  
at 9th day of cell injection compared with 66.7% of GABARAP KO mice showed  
palpable tumors at this day. The tumor growth increased constantly in wild-type mice.  
In contrast, tumor growth was clearly reduced in GABARAP KO mice (Fig. 28 A and B). 
This result suggests that intact GABARAP function in the host animal was advantageous  
for the growth of the inoculated syngeneic melanoma cells. 
 
3.11    GABARAP-deficient tumors did not exhibit Ras mutation 
Many studies indicated that carcinogens, in general, induce molecular changes in target 
organs (Hoenerhoff et al., 2009). DMBA has been reported to induce point mutations in the 
H-ras gene resulting in an A > T transversion at the middle adenosine nucleotide of codon 61 
(Dandekar et al., 1986; Cardiff et al., 1988; Qing et al., 1997). Recently, the protumorigenic 
function of autophagy has been demonstrated through its ability to increase the glucose 
metabolism and thereby facilitating Ras-mediated cell transformation and promoting Ras-
driven tumor growth. For this reason, we performed H-ras mutation analysis in DMBA-
induced tumors from GABARAP KO and wild-type mice. Our analysis of the hotspot codons 
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12 and 13 in exon 1 and codon 61 in exon 2 revealed no mutations in the 4 tumors of the 
GABARAP KO mice compared to 5 mutations in 14 tumors of the wild-type mice (Table 4). 
The mutations included transversion of CAA > CTA or CAA > CAT (Fig. 29). This result 
could explain the importance of GABARAP gene, through its involvement in autophagy, in 
Ras-mediated cellular transformation to induce tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Inhibition of B16 melanoma cells growth in GABARAP KO mice. A) Morphologic picture of wild-
type (Wt) and GABARAP KO (KO) mice at the 17th day of 2.5 x 105 B16 melanoma cell inoculations. 
B) Growth curve of B16 melanoma cells in Wt and KO mice after inoculation with 2.5 x 105 B16 cells. Values 
are representative of 12 mice and were shown with means ± SEM. (**) p ˂ 0.01, (***) p = 0. 
 
Table 4. Tumor types and H-ras mutation in C57BL/6 wild-type (Wt) and GABARAP KO mice 
Tumor type C57BL/6 (Wt) GABARAP KO 
DMBA treatment 
n = 29 H-ras mutation n =33 H-ras mutation 
Tumors number 12 13 61 Tumors number 12 13 61 
Mammary 3 - - 2 - - - - 
Skin 7 - - 3 2 - - - 
Lymphoma 2 - - - - - - - 
Liver - - - - 1 - - - 
Undifferentiated tumors 2 - - - 1 - - - 
Total 14 - - 5 4 - - - 
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Figure 29. H-ras mutation analysis of GABARAP KO and wild-type tumors. A) Exon 2 (codon 61) of H-ras in 
GABARAP tumor showed wild type sequences of forward and reverse primers. B) Wild-type tumor showed 
mutation at forward (CAA > CTA) and reverse (TTG > TAG) sequences of exon 2 (codon 61). C) Wild-type 
tumor showed mutation at forward (CAA > CAT) and reverse (TTG > ATG) sequences of exon 2 (codon 61). 
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4.       Discussion 
The main biological role of GABARAP has been previously involved in clustering the 
neurotransmitter receptors GABAA by mediating interaction with the cytoskeleton (Wang  
et al., 1999; Chen et al., 2000). Later on, authors have shown that GABARAP has an essential 
role in the elongation and maturation of autophagosome, a key structure in the process of 
autophagy (Nakatogawa et al., 2007; Xie et al., 2008; Weidberg et al., 2010). GABARAP is 
ubiquitously expressed in all tested normal tissues, and has been explored in primary tumor 
samples and cancer cell lines and showed a diversity of expression levels. We previously 
reported that GABARAP may function as a tumor suppressor in breast cancer (Klebig et al., 
2005). However, the precise role and mechanism that GABARAP played in tumorigenesis 
were not elucidated. Our study considered the first attempt to clarify the role of GABARAP in 
tumorigenesis by using the transgenic mouse model. We used DMBA, a reliable and potent 
carcinogen, as well as other carcinogens to investigate the potential role of GABARAP in 
tumorigenesis. In addition, the spontaneous tumor formation was investigated in this mouse 
model over the period of 2 years. The major findings present in the current study can be 
summarized as follows: 1) GABARAP KO mice exhibited less tumor formation 
spontaneously and after carcinogen treatment. 2) High sensitivity of GABARAP KO mice to 
the toxicity of carcinogens. 3) GABARAP-deficient immune cells enhanced the cytokine 
production. 4) GABARAP-deficient mammary glands showed a significant decrease in 
epithelial growth upon DMBA treatment. 5) The tumor suppressor gene and apoptosis inducer 
Xaf1 differentially expressed in mammary glands of GABARAP KO mice as well as in other 
organs. 6) DNA damage repair impaired in GABARAP-deficient MEFs. 7) B16 melanoma 
cell inoculation and Ras mutation in tumor samples showed the potency of GABARAP gene 
in tumor initiation and progression. 
 
4.1     Less tumor formation in GABARAP KO mice 
The role of autophagy in tumorigenesis is complex and likely tissue and genetic context-
dependent. Contradictory roles of autophagy in tumor initiation and progression have been 
mentioned in several reports. In some instances autophagy may serve as protumorigenic 
mechanism, whereas in others, it contributes to tumour suppression (Levine, 2007; Mathew  
et al., 2007; Wilkinson and Ryan, 2010; Rosenfeldt and Ryan, 2011). Beclin-1 represented the 
first genetic link between autophagy and tumorigenesis (Qu et al., 2003; Yue et al., 2003). 
Heterozygous loss of Beclin-1 promoted spontaneous malignancies in mice. Later on, studies 
showed that the increased rate of tumor formations in mice with heterozygous loss of 
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Beclin-1 is not due to autophagy, since that Beclin-1 has been shown to interact and 
associated with apoptotic protein (Bcl-2) and tumor suppressor p53 (Pattingre et al., 2005; 
Liu et al., 2011; Lorina et al., 2013). Moreover, Atg4C-deficient mice showed increased 
susceptibility to fibrosarcoma induced by the intradermal injection of chemical carcinogen 
MCA in a tissue-specific mode (Marino et al., 2007). In contrast, knockout of FIP200, an 
important regulator of autophagy, suppressed mammary tumor initiation and progression in a 
mouse model of breast cancer driven by the PyMT oncogene (Wei et al., 2011). In our 
investigation, we used the chemical carcinogen (DMBA) in order to enhance the tumor 
induction and to explore the potential role of GABARAP in tumorigenesis. DMBA is a 
widely used carcinogen and can induce various types of cancer in animal models (de Oliveira 
et al., 2013). Most studies have used DMBA to induce mammary tumors following 
administration by oral gavage in mouse models (Medina, 1974, Currier et al., 2005). We 
found that GABARAP KO mice significantly reduced the tumor formation after DMBA 
treatment compared with wild-type mice. In addition, no mammary tumors developed in 
DMBA-treated GABARAP KO mice. Regarding spontaneous tumor formation, GABARAP 
KO mice exhibited less tumors compared with wild-type mice, and also without mammary 
tumorigenesis in GABARAP KO mice. For this reason we concluded that the GABARAP 
gene may play an influential role in the process of tumor development. Based on our 
knowledge, this is the first report providing evidence for the role of GABARAP in 
tumorigenesis in a mouse model. 
 
4.2     High sensitivity of GABARAP KO mice upon carcinogens treatment 
Autophagy occurs at low basal levels in most normal cells to maintain cellular homeostatic 
functions or occurs when the cells need to ‘self-cannibalize’ or to proceed the cell survival 
under stress in order to maintain cellular integrity (Mizushima et al.; 2008). Mice with 
homozygous mutation of Beclin-1 die in early embryonic development (Yue et al., 2003). In 
contrast, mice with homozygous deletion of others autophagy gene showed a normal 
embryonic phenotype (Marino et al., 2007; Wei et al., 2011). During our experiments, we 
noticed that GABARAP KO mice are viable and fertile and do not display any obvious 
abnormalities, as reported by O’Sullivan (O’Sullivan et al., 2005). This indicates that 
GABARAP KO mice are able to develop the autophagic response in demand during the 
embryogenesis and early neonatal period. 
Moreover, administration of genotoxic carcinogens to the mice triggers several processes in 
order to bypass the stress and the damage induced by such chemicals. Autophagy is one of 
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these processes which stimulated under such circumstances to overcome stressful conditions 
(Rodriguez-Rocha et al., 2011; Murrow and Debnath, 2013). In our experiment, we used 
different carcinogens and different treatment regimens in order to enhance tumor formation. 
Unlike our expectation, carcinogen-treated GABARAP KO mice manifested higher 
sensitivity and reduced survival in comparison with treated wild-type mice. Moreover, almost 
all GABARAP KO mice were died without any tumor formation after carcinogens treatment, 
except in DMBA treatment. On the other hand, wild-type mice showed tumor formation 
within the period of some carcinogen treatments, for instance after DMBA and ENU 
exposure. Normally, carcinogen treatment required several months to initiate and promote 
tumor development in mouse models. The non-occurrence of tumors in some carcinogen 
treatment in wild-type mice was due to the shortage of exposure period of carcinogens, 
because we finished the experiment when all GABARAP KO mice were died. Based on these 
results, we propose that GABARAP is not essential for autophagy development under normal 
conditions but may be required for a proper autophagic response under stressful conditions 
such as genotoxic carcinogen treatment. 
DMBA-treated mice have been reported to decrease the spleen weight and cellularity; this 
decrease was associated with cell death of splenocytes (Dean et al., 1985; Miyata et al., 2001; 
Gao et al., 2005, 2007). However, the body weight of mice was not substantially affected by 
DMBA treatment (Miyata et al., 2001; Gao et al., 2005). We found that upon DMBA 
treatment GABARAP KO mice significantly reduced the spleen cellularity as well as 
decreased the spleen volume and weight in comparison to DMBA-treated wild-type mice. The 
body weights of GABARAP KO mice were tardily increased compared to treated wild-type 
mice. The immunohistochemistry staining revealed a considerable decrease in the 
proliferation of splenocytes in DMBA-treated GABARAP KO mice, which occurred together 
with increased cellular death. It seems that GABARAP or “autophagy” deficiency heightened 
the incidence of cell death and reduced the cellular proliferation rate in spleen under 
carcinogenic effect which led to a significant reduction in spleen cellularity. The slower 
growing of GABARAP KO mice upon DMBA treatment may provide insight into the impact 
of GABARAP deficiency on other organs apart from the spleen. Moreover, the cell surface 
marker analysis of splenocytes showed a substantial reduction in all cell populations: 
regulatory T cells (Tregs), B cells, T helper cells (CD4), cytotoxic T cells (CD8), 
macrophages and neutrophils, which were more profoundly affected by DMBA treatment in 
GABARAP KO mice than wild-type mice. The pattern of reduction for the populations of 
splenocytes was consistent with the reduction of the total number of splenocytes, which 
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means that there was no discrimination for the effect of DMBA on particular cell types of the 
spleen in both GABARAP KO and wild-type mice groups. 
 
4.3     Enhancement of cytokine secretion in GABARAP-deficient immune cells  
The interaction between autophagy and innate immune response has been proven through the 
capability of TLRs to induce autophagy as well as the negative regulator role of autophagy for 
inflammasome activation (Shi and Kehrl, 2010; Levine et al., 2011; Nakahira et al., 2011; Shi 
et al., 2012; Araya et al., 2013). The disruption of autophagy genes in macrophages have been 
shown to increase ROS production and translocation of mtDNA into the cytosol upon 
treatment with LPS and ATP, leading to enhance the secretion of proinflammatory cytokines, 
which can mediate tissue injury and lethal shock in the context of a sepsis model (Hotchkiss 
and Karl, 2003; Tal et al., 2009; Nakahira et al., 2011; Zhang et al., 2013). In our results, we 
found that macrophages of DMBA-treated GABARAP KO mice significantly boosted the 
secretion of IL-1β and IL-6 upon stimulation with LPS alone or in the combination of LPS 
and ATP. The high production of proinflammatory cytokines may be responsible for the 
increase the lethality of GABARAP KO mice upon DMBA treatment. The in vivo activation 
of immune cells may happen during the mice handling or by natural pathogens of laboratory 
mice as well as the environmental pathogens in the animal houses (Baker, 1998; Connole et 
al., 2000). Regarding TNFα, the tendencies of secretion from macrophages of DMBA-treated 
GABARAP KO mice; upon stimulation with LPS alone or LPS and ATP, were higher than 
macrophages of treated wild-type mice. There was no significant association between TNFα 
secretion of GABARAP KO and wild-type macrophages upon stimulation possibly due to a 
relatively few number of macrophages that can be obtained from mice after DMBA treatment. 
It was reported that autophagy is required for mitochondrial maintenance and preservation of 
mitochondrial function, as well as the removal of damaged mitochondria by the process called 
mitophagy (Guo et al., 2011; Aung-Htut et al., 2013; Yang and Yang, 2013). DMBA 
treatment causes oxidative stress and mitochondrial dysfunction (Frenkel et al., 1995; 
Arulkumaran et al., 2007; Priyadarsini and Nagini, 2012). It has been shown that 
accumulation of damaged mitochondria could activate the inflammasome and thereby 
increased the proinflammatory cytokine secretion (Tal et al., 2009; Nakahira et al., 2011; 
Zhang et al., 2013). According to these findings we propose that autophagy deficiency, in our 
case by GABARAP deficiency, under a genotoxic stress of DMBA may activate the 
inflammasome in macrophages by increasing the damaged mitochondria and ROS production. 
Thus activation of the inflammasome may be responsible for the increased production of 
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proinflammatory cytokines (IL-1β and IL-6) from macrophages of DMBA-treated 
GABARAP KO mice. 
Furthermore, it is known that DMBA treatment resulted in suppression of immune response in 
mice, both cell-mediated and humoral immunity, for prolonged periods of time (Prehn, 1963; 
Ward et al., 1986; Burchiel et al., 1990; Gao et al., 2007, 2008). DMBA exerts this effect 
through inhibition of lymphocyte activation, mainly by suppressing the production of IL-2 
from splenocytes and depressing the ability to generate CTL and NK cells (Ward et al., 1986; 
House et al., 1987; Burchiel et al., 1990; Saas et al., 1996; Gao et al., 2007, 2008). Thereby, 
this effect of DMBA acts as an important mechanism; in association with its genotoxicity, 
contributing to tumor outgrowth (Ward et al., 1986). On the other hand, tumor-host cell 
interaction and tumor microenvironment play an essential role in tumor initiation and 
progression of breast and other tumor types in vivo (Wiseman and Werb 2002; Luo et al. 
2009; Hanahan and Weinberg 2011). Moreover, the host immune defense mechanisms play a 
crucial role in tumor immune surveillance and removal of cancerous cells (Koebel et al. 2007; 
Finn 2008). For example, De Palma et al. (2008) and Wei et al. (2011) showed effective 
inhibition of PyMT-driven tumor growth and metastasis through upregulation of interferon 
target genes. In our results, lymphocytes of DMBA-treated GABARAP KO mice produced 
higher levels of IL-2 and IFN-γ after in vitro stimulation with CD3 than lymphocytes of their 
untreated control group. In contrast, it was clear that lymphocytes of DMBA-treated wild-type 
mice suppress IL-2 and IFN-γ production after CD3 stimulation. That means our results 
demonstrated immune enhancement, rather than immunosuppression, in GABARAP KO mice 
upon DMBA treatment. The levels of IL-2 and IFN-γ secretion did not reach statistical 
significance possibly due to a relatively few number of lymphocytes that can be obtained 
from GABARAP KO mice after DMBA treatment. 
The high production of some cytokines has a critical mechanism in the inhibition of tumor 
outgrowth and metastasis. For instance, IL-1β was shown to be engaged in different cellular 
signaling pathways. The engagement of IL-1β in specific signaling pathways relies on its 
concentration or level. At high levels, cells received genotoxic insults and triggered cellular 
apoptosis, whereas moderate or low levels in the same cells may keep the cells normal or 
stimulate cell growth (Roy et al., 2006). Moreover, the outcome of antigen-specific T cell 
responses is mainly regulated by cytokines. When a T cell responds to an antigen, its cytokine 
profile engages certain T-helper cell pathway stimulated by the antigen-presenting cell. 
Moreover, the existence of IL-2 and IFN-γ can modulate effector cell differentiation, for 
instance Th1 cells, via regulation of cytokine receptor expression (Liao et al., 2011). Many 
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investigations indicated the importance of IL-2 and IFN-γ in immunological reactions to 
tumor cell growth and promoting innate and adaptive immune responses (Yang et al., 2003). 
IL-2 displayed significant anti-tumor activity for a different type of tumors, for instance 
advanced renal cancer and melanoma (Clement and McDermott, 2009; Halama et al., 2010) 
since it supports the proliferation and clonal expansion of T cells (CD4+T cells and CD8+T 
cells) that specifically attack certain tumor types (Stern and Smith, 1986; Liao et al., 2011). 
However, high doses of IL-2 were found to be accompanied by severe toxicity. To overcome 
the toxicity of IL-2, they found that inhibition of autophagy by using chloroquine during IL-2 
immunotherapy in a mouse model led to significantly regression of tumor growth and 
prolonged survival (Liang et al., 2012). This finding may support our results of tumor 
inhibition in GABARAP KO mice, since autophagy already attenuated in this mouse model 
by GABARAP knockout as well as IL-2 was found to be upregulated in lymphocytes of 
DMBA-treated group upon stimulation with CD3. 
Our finding of immunomodulation upon DMBA treatment represents the first report for 
enhancement of immunity and/or “anti-tumor immunity” in our GABARAP KO mouse model 
of autophagy, which requires further investigation to explore the mechanism by which 
GABARAP executes this modulation. 
 
4.4     Inhibition of epithelial growth in mammary glands of GABARAP KO 
mice after DMBA treatment 
Mouse models have provided information for understanding the biological, cellular and 
molecular alterations involved in mammary tumorigenesis (Medina, 2007). The mammary 
gland is one of dominant target organs for the carcinogenicity of DMBA when administered 
by oral gavage (Medina, 1974, Currier et al., 2005). Terminal end buds (TEB) are specialized 
structures in the mammary gland responsible for duct elongation during the immediate post 
pubertal period of development. TEBs of mammary glands are thought to be the target sites 
for the origin of tumors. Since the presence of TEBs in the time period of 4 - 8 weeks of age, 
the susceptibility of the mammary gland to DMBA carcinogenesis is highly age-dependent 
(Williams and Daniel, 1983 Medina, 2007). For this reason we used the female mice of 6 - 8 
week age in all our investigations. Our results for tumor induction by DMBA revealed no 
mammary tumors in GABARAP KO mice compared to 21.4% mammary tumors in wild-type 
mice. We investigated the mammary epithelial cell growth and ductal tree morphogenesis 
after 6 weekly doses of 1 mg DMBA/mouse in both GABARAP KO and wild-type mice to 
evaluate the gland architecture and proliferation by means of mammary gland whole mount 
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morphology analysis. The impact of DMBA on the epithelial cell growth and ductal 
branching was obvious in mammary gland of GABARAP KO mice. Although the mammary 
glands of DMBA-treated female wild-type mice appeared to have a significant alteration in 
epithelial growth compared to aged-matched control wild-type counterparts, this change could 
be a normal consequence of treatment with genotoxic carcinogen like DMBA. The ability of 
DMBA to induce apoptosis has been indicated in lymphoid organs and bone marrow (Miyata 
et al., 2001; Page et al., 2003). Recently, Stolpmann et al. (2012) showed that activation of 
AhR (aryl hydrocarbon receptor) sensitised the cells to induce apoptosis. We propose that 
DMBA can induce apoptosis in mammary glands, since AhR has been showed to be 
upregulated upon DMBA treatment in mammary glands (Swanson et al., 1995; Trombino  
et al., 2000; Denison and Nagy, 2003; Currier et al., 2005).  
Furthermore, immunohistochemistry staining for Ki-67 revealed inhibition of epithelial cell 
growth in mammary glands of DMBA-treated GABARAP KO mice as well as increased 
incidence of cell death compared to mammary glands of DMBA-treated wild-type mice. In 
general, knockout of GABARAP seems to sensitise the cell to inhibit the proliferation and 
increases cell death induction which was obvious in spleen and mammary gland. 
 
4.5     Gene expression profiling indicated differential expression of tumor 
suppressor and apoptosis inducer genes in GABARAP KO mice 
Microarray analysis is a widely used technology for studying gene expression on a global 
scale that can be used to investigate the molecular mechanisms that contribute to disease. 
Several studies have shown that microarray gene expression profiling results in improved 
diagnosis and risk stratification in cancer (van 't Veer et al., 2002; Jackson et al., 2013). To 
explore the molecular mechanisms by which deficiency of GABARAP led to reduced tumor 
formations, we employed Agilent Whole Mouse Genome expression microarrays to analyse 
mammary glands of vehicle-treated (control) and DMBA-treated GABARAP KO and wild-
type mice. We found a subset of genes that had GABARAP-dependent alterations in both 
control and DMBA-treated groups. Xaf1 is the most important gene that was differentially 
expressed in mammary gland of both control and DMBA-treated GABARAP KO mice. This 
gene has been widely studied in the last decade and characterized as an apoptosis inducer and 
tumor suppressor gene. Xaf1 is expressed ubiquitously in all normal cells (Fong et al., 2000). 
In contrast, extremely low or undetectable Xaf1 expression is a frequent event in several 
cancer cell lines (Fong et al., 2000), as well as in many types of human cancer tissues (Byun 
et al., 2003; Ma et al., 2005; Lee et al., 2006; Tu et al., 2009; Huang et al., 2010). Moreover, 
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Kempkensteffen et al. (2007) found that loss of Xaf1 expression correlated strongly with 
tumor staging, implicating loss of Xaf1 function in tumor progression. The epigenetic 
silencing of Xaf1 by aberrant promoter methylation (hypermethylation) has been associated 
with cancer development and progression (Byun et al., 2003; Lee et al., 2006; Zou et al., 
2006; Huang et al., 2010). The restoration of Xaf1 expression induced cancer cell apoptosis 
and inhibited tumor growth in various types of cancers including gastric, colon, liver, 
pancreatic and prostate cancers, as well as increased cell sensitivity to drug-induced apoptosis 
(Byun et al., 2003; Lee et al., 2006; Arora et al., 2007; Tu et al., 2009, 2010; Huang et al., 
2010). Recently, Zhang et al. (2011) showed that Xaf1 inhibited cell invasion, it interacts with 
and attenuates the trans-activity of Four and a Half LIM protein 2. Moreover, Straszewski-
Chavez et al. (2007) showed that Xaf1 re-localized to mitochondria in response to TRAIL and 
promoted translocation of Bax into mitochondria and cytochrome C release from 
mitochondria, and thereby induced apoptosis. Interestingly, our results demonstrated 
enhancement of pro-apoptotic gene (Bid, Apaf1 and Bax) expression in mammary glands of 
DMBA-treated GABARAP KO mice. Bax expression was elevated also in DMBA-treated 
wild-type mammary glands and this may be due to the genotoxic effect of DMBA. 
Furthermore, Xaf1 has been shown to induce cell cycle arrest in G2/M phase and mitotic 
catastrophe (Tu et al., 2009; Wang et al., 2009a; Zhang et al., 2011). In our results, mammary 
glands of DMBA-treated GABARAP KO mice exhibited differential expression of cyclin-
dependent kinase inhibitors p21 (Cdkn1a) and p18 (Cdkn2c) that could explain the inhibition 
of epithelial cell growth. The results of relative mRNA expression of Bax and p21 by using 
qRT-PCR revealed differences in the expression of these genes when we compared the 
DMBA-treated groups. In addition, Zou et al. (2012) showed recently that Xaf1 is a novel 
target of p53 and that it enhances p53-mediated apoptosis via post-translational modification. 
We proposed that despite the high expression of Xaf1 in mammary gland of GABARAP KO 
mice, its extreme effect as an apoptosis inducer may not detect entirely at the mRNA level. 
Nevertheless, high Xaf1 expression in mammary glands of GABARAP KO mice fits well 
with the observed phenotype, i.e. high Xaf1 expression predisposes mammary gland 
epithelium to undergo apoptosis after genotoxic insult thereby preventing tumor formation 
and favoring inhibition of branching/growth of the glandular tissue. 
Xaf1 was originally identified as a binding partner and a novel negative regulator of apoptosis 
inhibitor protein Xiap thereby acting itself as an apoptosis inducer. Xaf1 directly interacts 
with endogenous Xiap and results in Xiap sequestration to nuclear inclusions, thereby 
antagonizing the anti-caspase activity of Xiap and reverses the protective effect of Xiap 
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overexpression in cell lines (Liston et al., 2001). High relative expression of Xiap compared 
to Xaf1 expression in cancer cells has provided a survival preference through increasing the 
Xiap anti-apoptotic function (Fong et al., 2000). We found that Xiap was significantly 
upregulated in the mammary glands of DMBA-treated wild-type mice. This may be an 
indication that the gene provides a protective mechanism for wild-type mammary glands 
against cellular death signaling. Moreover, Xiap overexpression may confer a possibility  
for mammary tumor formation in wild-type mice. In contrast, the mammary glands of 
DMBA-treated GABARAP KO mice demonstrated insignificant alterations in the expression 
level of Xiap. 
However, Xaf1 have been reported to induce cell death also by Xiap-independent pathways 
(Xia et al., 2006; Yu et al., 2007; Tu et al., 2010). Xia et al. (2006) showed that Xaf1 
activates the mitochondrial apoptotic pathway that was dramatically enhanced by TNFα; they 
found no evidence for an interaction between Xaf1 and Xiap. Thus, Xaf1 induces apoptosis 
through multiple mechanisms. Interestingly, we found that Tnfrsf10b and Ripk1, both are 
TNF receptors, significantly upregulated in mammary glands of DMBA-treated GABARAP 
KO mice. Tnfrsf10b is a member of the tumor necrosis factor (TNF) receptor superfamily and 
contains an intracellular death domain that can induce apoptosis in many physiological 
events, such as autoimmunity and activation-induced cell death (Chaudhary et al., 1997;  
Zhao et al., 2014). 
We screened the expression level of Xaf1 in several organs and found that Xaf1 was highly 
expressed in the investigated organs of GABARAP KO mice compared to the wild-type mice. 
This indicates that Xaf1 is a general event of GABARAP deficiency, and may explain the 
reduction of tumor formation in general and the cytotoxic effect of DMBA in the spleen of 
GABARAP KO mice. 
Expression profiles displayed several differentially expressed genes upon GABARAP 
deficiency. We reviewed most of these genes to identify the biological functions that may 
provide an interpretation for the phenotypic changes in the mammary glands as well as the 
reduction in tumor formation of GABARAP KO mice. Many of these genes are with 
unknown functions so far, but some of them have been reported to play a role in 
tumorigenesis and/or cell death or may function as a transcription factor. For instance, we 
found Trim16 significantly downregulated in mammary glands of both control and DMBA-
treated GABARAP KO mice. Trim16 is a ubiquitously expressed protein and was identified 
as an estrogen and anti-estrogen regulated gene in epithelial cells stably expressing estrogen 
receptor. The family of this protein play essential roles in cell growth, differentiation, 
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ubiquitination, retroviral immunity and cancer (Cao et al., 1998; Beer et al., 2002; Meroni 
and Diez-Roux, 2005; Marshall et al., 2010; Liu et al., 2014). The expression of Trim16 is 
induced by estrogen in breast cancer cells and keratinocyte growth factor in keratinocytes, 
when the cells are forced to proceed into a differentiation pathway (Beer et al., 2002; 
Marshall et al., 2010). There is evidence that Trim16 reduced the cell viability in retinoid-
sensitive neuroblastoma cells and retinoid-resistant breast and lung cancer cells, however the 
viability of non-cancer cells was unaffected by Trim16 overexpression (Cheung et al., 2006; 
Raif et al., 2009; Marshall et al., 2010). Recently, Liu et al., (2014) showed that inhibition of 
one protein of the Trim family, Trim24, promoted apoptosis in hepatocellular carcinoma by 
increasing the protein levels of p53, Bax, and caspase-8, and decreasing the expression of 
Bcl-2, Survivin, Cyclin D1, and CDK4. They also proved the involvement of Trim24 in EMT. 
These findings provide an indication for the essential role of the Trim family in tumor 
initiation and progression. However, the exact role of Trim16 in our studies is not clear and 
requires further investigations to clarify it. 
Moreover, Siva1 has been proven as an apoptotic inducer protein (Prasad et al., 1997; Xue  
et al., 2002; Chu et al., 2005; Du et al., 2009; Resch et al., 2009). Li et al., (2011) showed 
that overexpression of Siva1 inhibited stathmin (Stmn), an important regulatory protein of 
microtubule dynamics, leading to suppression of EMT and metastasis. In our results, Siva1 
was upregulated in DMBA-treated groups; GABARAP KO and wild-type mice, but the 
expression level of Stmn4 was significantly downregulated in DMBA-treated GABARAP KO 
mice. This finding may explain the inhibition of mammary gland proliferation and 
tumorigenesis of GABARAP KO mice upon DMBA treatment, since EMT is an essential 
process for epithelial cells to develop, migrate, invade and initiate metastasis and tumor 
progression (Yang and Weinberg, 2008; Kalluri and Weinberg, 2009; Thiery et al., 2009). 
Furthermore, several transcription factors have been shown to be upregulated in mammary 
glands of wild-type mice upon DMBA treatment, for instance NF-κB1, Smad2, E2f4 and 
Tfdp2. NF-κB is an important regulator of mammary gland development, where it controls 
proliferation and branching (Brantley et al., 2001; Cao et al., 2001), and also protects the 
epithelial cells during apoptotic alveolar involution (Clarkson et al., 2000). These findings 
support our results of the occurrence of mammary tumorigenesis in wild-type mice upon 
DMBA treatment in contrast to GABARAP KO mice. Mammary glands of wild-type mice 
can develop protective mechanisms upon DMBA treatment against cellular death represented 
by a significant upregulation of NF-κB as well as Xiap. In addition, constitutive activation of 
NF-κB factors have been demonstrated in breast cancer; high nuclear NF-κB levels were 
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found in the majority of specimens from DMBA-induced rat mammary tumor and primary 
human breast tumor, carcinogen transformed human mammary epithelial cells and breast 
cancer cell lines (Sovak et al., 1997). Kim et al. (2000) and Currier et al. (2005) showed that 
NF-κB upregulation occurs as an early event and can precede DMBA-induced mammary 
tumor formation in rats and mice. Moreover, overexpression of NF-κB family member c-Rel 
in the mammary gland promotes breast cancer in transgenic mice (Romieu-Mourez et al., 
2003). Thus, the expression profile analysis is consistent with our experimental observation 
that wild-type mice exhibited mammary tumor formation in contrast to GABARAP KO mice. 
Tumor development is a result of aberrant cellular proliferation and failure to undergo 
apoptosis in response to normal signaling cues (Green and Evan, 2002). One “hallmark” of 
cancer is the dysregulation of cell death pathways (Igney and Krammer, 2002), and this 
dysregulation is required for tumor initiation and progression (Hanahan and Weinberg, 2011). 
Autophagy and apoptosis are both well-controlled biological processes and play fundamental 
roles in development, maintenance of tissue homeostasis and diseases. Accumulating 
evidence revealed that autophagy and apoptosis can cooperate, antagonize or assist each 
other, for subsequently determining the fate of cells. Recently, many studies have delineated 
pathways that mediate the complex interplay between autophagy and apoptosis providing 
molecular insight into the signaling network that regulates both processes, as we showed in 
Figure 6. Indeed, there are many crucial factors governing the cross-talk between autophagy 
and apoptosis, several autophagic proteins showed essential roles in apoptosis and vice versa, 
as elucidated in Table 1 (Mukhopadhyay et al., 2014). Autophagy has been well established 
as an important cell survival mechanism, especially in cells under stress conditions (Cecconi 
and Levine, 2008; Kroemer and Levine, 2008). Elliott and Reiners (2008) showed that 
suppression of autophagy enhanced the cytotoxicity of DNA-damaging agents. This let us to 
propose that attenuation of autophagy, or GABARAP deletion, deprives the cells from 
essential survival mechanisms leading to an increase of sensitivity against exposure to stress 
like genotoxic carcinogens.  
Finally, the mechanisms linking autophagy and apoptosis are not fully defined. However, our 
results demonstrated a unique interaction between GABARAP and Xaf1 expression. The high 
expression of Xaf1 was not only detectable in mammary glands but also in different organs of 
GABARAP KO mice. This observation requires further study to clarify how GABARAP 
knockout influences Xaf1 expression. We propose two possibilities of interaction; one could 
be by direct genetic interaction of GABARAP and Xaf1 and the second by indirect 
interaction. Indeed, several regulatory pathways of Xaf1 expression have been reported. 
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Wang et al. (2006a) demonstrated heat shock factor 1 (Hsf1) as a negative regulator of Xaf1. 
Moreover, Xaf1 has been recognized as an interferon-stimulated gene and its expression has 
been promoted by both IFN and TNFα (Leaman et al., 2002). The mechanism by which IFN 
induced Xaf1 expression was either through interaction with the interferon regulatory factor 
1-binding element (Irf-E) or demethylation of CpG sites within the Xaf1 promoter (Wang  
et al., 2006b; Micali et al., 2007; Wang et al., 2009b). Micali et al. (2007) showed that Xaf1 
knockdown in cancer cells led to complete loss of IFN-β-mediated TRAIL-induced cell death. 
It has been reported that IFN-β-induced Xaf1 expression was mediated by Stat1 through the 
interaction with IFN stimulated response element-Xaf1. Stat1 knockdown and blocking its 
phosphorylation decreased IFN-β-induced Xaf1 expression (Sun et al., 2008). Recently,  
Qiu et al. (2014) showed that Irf-1-enhanced Xaf1 gene activation in glomerular mesangial 
cells in a rat nephritis model. Therefore, Xaf1 appears to be a mediator or effector of 
cytokine-induced apoptosis. Interestingly, we found that GABARAP deficiency modulated 
cytokine secretion, for instance IFN-γ (Fig. 20 B). According to our findings we would like to 
promote the idea of cytokines being involved in the enhancement of Xaf1 expression thus 
pointing to an indirect mechanism of Xaf1 regulation by GABARAP knockout. 
 
4.6     Impairment of DNA damage repair in GABARAP-deficient MEFs 
There are many factors that can cause DNA damage and DNA damage response (DDR). 
These factors are either exogenous environmental agents, like genotoxic chemicals and 
chemotherapeutic drugs, or endogenous byproducts of regular cellular metabolism 
(Rodriguez-Rocha et al., 2011). Recently, autophagy has been showed to be induced in 
response to DNA damage; however the precise role of autophagy in DDR is still unclear 
(Klionsky and Emr, 2000; Polager et al., 2008; Kang et al., 2009). We observed that 
autophagy was induced after treatment of GABARAP-deficient and wild-type MEFs with 
DMBA and CPT, both are DNA-damaging agents. Autophagy induction after treatment with 
DNA-damaging agents may represent a pro-survival function to maintain cellular integrity. 
However, GABARAP-deficient MEFs have been shown to accumulate p62 as an indicator of 
autophagy impairment; p62 is associated with the autophagosome membrane and in case of 
intact autophagy p62 undergoes degradation by the action of the lysosome. 
One important event in DDR activation is phosphorylation of histone H2AX (termed γH2AX) 
which leads to recruitment of DNA repair molecules to the site of damage. Therefore it is 
considered as a marker for DNA double-strand break (DSB) formation (Kinner et al., 2008; 
Svetlova et al., 2010). After DSB re-joining γH2AX foci are eliminated from the nucleus and 
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this elimination can serve as a useful marker of DSB repair in normal cells and tissues 
(Svetlova et al., 2010). We found that γH2AX was accumulated in the GABARAP-deficient 
MEFs in a time-dependent manner after treatment with DMBA and CPT; in contrast wild-
type MEFs showed no change or decrease in amount of γH2AX protein at 48 h (DMBA) or 
20 h (CPT) treatment. These findings denoted that GABARAP deficiency resulted in the 
impairment of the DNA damage repair mechanism induced by the genotoxic chemical DMBA 
and the chemotherapeutic agent CPT. Moreover, lack of DNA damage repair in GABARAP-
deficient MEFs was accompanied with decrease in cell survival and reduction in Cyclin D1 
protein expression. 
The mechanisms underlying GABARAP deficiency leading to defective DNA damage repair 
are not well understood at present. However, Bae and Guan (2011) showed that p62 
accumulation may be responsible for defective DDR and reduced cellular survival in FIP200-
deletion MEFs upon CPT treatment. In addition, inhibition of autophagy by heterozygous loss 
of Beclin-1 or homozygous deletion of Atg5 in apoptosis-defective tumor cells induced p62 
accumulation which led to increased DNA damage (Karantza-Wadsworth et al., 2007; 
Mathew et al., 2009). Interestingly, we also observed accumulated p62 in GABARAP-
deficient MEFs upon DMBA and CPT treatment. Furthermore, Bae and Guan (2011) 
indicated that direct inhibition of p62 expression by using RNA interference suppressed 
accumulation of γH2AX in FIP200-deficient MEFs and rescued the increased sensitivity of 
CPT-induced cell death. We suggest that upregulation of p62 in GABARAP-deficient MEFs 
may mediate the reduction of DNA damage repair and the inhibition of cell proliferation. 
Indeed, it is known that p62 is localized primarily in the cytoplasm as a cargo protein of 
ubiquitinated proteins for autophagic degradation (Moscat and Diaz-Meco, 2009). However, 
Pankiv et al. (2010) showed that p62 contains two nuclear localization signals and a nuclear 
export signal. It is required for polyubiquitinated protein interaction with promyelocytic 
leukemia (PML) nuclear bodies. PML nuclear bodies are implicated in DNA damage repair, 
they contain several DDR proteins such as TopBP1 (Lallemand-Breitenbach and de Thé, 
2010). Despite this, Moscat and Diaz-Meco (2009) pointed out that accumulation of p62 in 
the cytoplasm also impact on DNA damage repair through its indirect interaction with 
multiple other proteins. The other possibility of defective DNA damage repair is increased 
production of ROS in autophagy-deficient cells (Mathew et al., 2007; Liu et al., 2010). 
Finally, our results showed that DNA-damaging agents extremely increased inhibition of 
proliferation of GABARAP-deficient cells. This is consistent with the observed increased 
vulnerability of autophagy-defective cell to DNA damage and the rationale for using drugs 
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like camptothecin in chemotherapy together with autophagy inhibitors in cancer therapy. 
However, further investigations are required to explore the exact mechanisms of GABARAP 
in this process.  
 
4.7     In vivo inhibition of B16 melanoma cells growth in GABARAP KO mice 
Using the GABARAP KO mice we also addressed the question whether the genetic 
background may affect the in vivo tumor growth of inoculated tumor cells. To address this 
issue, we used the transplantable murine melanoma B16 cell line. The subcutaneous 
inoculation of melanoma B16 cells is widely used for the evaluation of gene deletion 
consequences and/or therapy (Overwijk and Restifo, 2001). Several studies have shown a 
significant decrease of tumor cells growth, in vivo and in vitro, treated with autophagy 
inhibitor chloroquine (Fan et al., 2006; Zheng et al., 2009; Noman et al., 2011). Our 
investigation of tumor cells inoculation in GABARAP-deficient mice model represents the 
first inspection for the role of the in vivo effect of autophagy-related gene deletion on tumor 
growth. Noman et al. (2011) showed that targeting Beclin-1 in B16 melanoma cells reduced 
tumor growth, which was associated with an increase in apoptotic cells. In the same study, 
they found that autophagy prevented T cell-mediated cytotoxicity in the context of hypoxia in 
lung cancer cells (Noman et al., 2011). Our in vivo results showed that GABARAP knockout 
reduced B16 melanoma cells growth. 
The molecular mechanisms how autophagy-related gene deficiency in the mouse model could 
influence the growth of the inoculated tumor cells is unknown so far. GABARAP-deficient 
immune cells demonstrated modulation in the cytokine secretion upon CD3 stimulation. It 
might be speculated that this effect may influence the growth of B16 melanoma cells by 
increased anti-tumor immunity. However, the precise role of tumor growth reduction in 
GABARAP KO mice needs to be clarified by studying microenvironment factors which 
represent an essential demand for tumor growth in vivo. Tumor microenvironment can 
enhance tumor cell growth by recruitment of angiogenesis-promoting factors, in addition to 
the role of immune system as a key determinant in the regulation of tumor growth or rejection 
(Witz and Levy-Nissenbaum, 2006). 
 
4.8     Absence of Ras mutation in DMBA-induced tumors of GABARAP KO 
mice 
Many chemical carcinogens induce molecular alterations in target organ, and the most 
frequently involved genes are Ras and Tp53 (Hoenerhoff et al., 2009). It is well known  
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that DNA damaging effect of DMBA mostly induced point mutations in genes such as  
c-H-ras (Dandekar et al., 1986; Cardiff et al., 1988; Qing et al., 1997). Ras oncogenes play a 
fundamental role in regulation of cell growth and survival and they are frequently activated in 
cancer (Schubbert et al., 2007). Previous studies showed that active oncogenic Ras induced 
autophagy to promote and facilitate oncogenic transformation by maintaining and improving 
cell metabolism (Guo et al., 2011; Kim et al., 2011; Lock et al., 2011). Indeed, Ras-
transformed cells have been shown to enhance glucose uptake, whereas autophagy-deficient 
counterparts have decreased rates of glycolysis (Lock et al., 2011). Moreover, Wei et al. 
(2011) observed that FIP200-null mammary tumor cells and transformed MEFs had reduced 
glycolysis and suppressed mammary tumor initiation and progression in a mouse model of 
breast cancer driven by the PyMT oncogene. These findings elucidated the essential role of 
autophagy-related genes in tumorigenesis induced by oncogenic signaling. Since DMBA has 
been reported to induce point mutations in H-ras gene leading to A > T transversion in codon 
12, 13 and 61 (Dandekar et al., 1986; Cardiff et al., 1988; Qing et al., 1997), we wanted to 
investigate the H-ras status in the tumors obtained from GABARAP KO and wild-type mice 
after treatment with 6 weekly oral doses of DMBA. Interestingly, we did not find any 
mutations within the hot spots of exon 1 (codon 12, 13) and exon 2 (codon 61) of H-ras in the 
tumors of GABARAP KO mice. In contrast, tumors of wild-type mice were shown to harbour 
H-ras mutation within codon 61 of exon 2 in about 36% of total tumors number. 
We suggested an essential role of GABARAP gene in tumorigenesis, and this role may be 
through its involvement in the autophagy process. Furthermore, the non-occurrence of  
H-ras mutations in the tumors of GABARAP KO mice may indicate the involvement of 
autophagy/GABARAP in Ras-mediated cellular transformation. 
 
4.9     Conclusions 
By using a mouse model, we have identified a novel role of GABARAP in tumor formation 
and progression. GABARAP knockout (KO) mice showed less tumor formation, 
spontaneously and after carcinogen treatment. The tumor inhibition of GABARAP knockout 
mice was characterized by absence of mammary tumors in the both conditions. We found that 
GABARAP plays a role in immunomodulation after carcinogen treatment and that the gene 
knockout induced alterations of the gene expression profile. 
Treatment by chemical carcinogens was accompanied by less tumor formation and increased 
lethality of GABARAP KO mice. Moreover, DMBA showed a massive impact to decrease 
the cellularity of splenocytes of GABARAP KO compared to the wild-type counterparts. This 
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effect was due to decreased proliferation rates and increased cellular death of GABARAP-
deficient splenocytes. The in vitro stimulation of macrophages and lymphocytes from 
GABARAP KO mice resulted in a high increment in cytokine secretion. Proinflammatory 
cytokines, IL-1β and IL-6, were significantly produced by macrophages of DMBA-treated 
GABARAP KO mice compared to wild-type counterparts. Lymphocytes of DMBA-treated 
GABARAP KO mice showed immune enhancement by increasing the production of IL-2  
and IFN-γ. In contrast, lymphocytes of DMBA-treated wild-type mice demonstrated 
immunosuppression represented by repression of IL-2 and IFN-γ production. 
Mammary epithelial cell growth of GABARAP KO mice showed an inhibition in the growth 
and branching of the glandular tissue upon DMBA treatment compared to wild-type 
counterparts. This inhibition was accompanied by a decreased proliferation rate and increased 
cellular death of mammary gland epithelium. Gene expression profiling analysis indicated 
high and differential expression of the tumor suppressor gene Xaf1 in mammary glands of 
GABARAP KO mice. Studies on expression of Xaf1 in several cancer cells identified it as an 
apoptosis inducer and tumor suppressor gene as well as a potential inhibitor of invasion. In 
addition, several cell death/apoptosis genes were found to be upregulated in mammary glands 
of DMBA-treated GABARAP KO mice compared to wild-type counterparts. In our view the 
high Xaf1 expression predisposed the mammary gland epithelium to undergo apoptosis after 
genotoxic insult thereby preventing tumor formation. 
Mouse embryonic fibroblasts (MEFs) revealed impairment of DNA damage repair and 
reduction in proliferation rate after genotoxic agents (DMBA and camptothecin (CPT)) 
treatment in GABARAP-deficient cells. Failure of DNA damage repair has evidenced by 
accumulation of histone H2AX (γH2AX) protein in a time-dependent manner in association 
with downregulation of the Cyclin D1 protein. 
The growth of mouse B16 melanoma cells inoculated subcutaneously in GABARAP KO mice 
was inhibited. Furthermore, the mutation analysis of H-ras in DMBA-induced tumors 
revealed no mutation within the hot spots of exon 1 and 2 in tumors of GABARAP KO mice 
which may indicate that these neoplasms develop in an alternative way compared to the 
classical, DMBA-induced, Ras-mediated activation of tumorigenesis. 
Altogether, our results demonstrated different aspects for the role of GABARAP in 
tumorigenesis. The challenge of future investigations will be to explore the molecular 
mechanisms of GABARAP in the regulation of gene expression, more specifically of Xaf1 
expression, and immunomodulation after genotoxic stress. Figure 30 summarizes our working 
model for the potential mechanisms of tumor inhibition in GABARAP KO mice. 
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Figure 30. Working model summarizing the potential mechanisms of tumor suppression in GABARAP KO 
mice subjected to genotoxic stress (DMBA). GABARAP deletion results in impairment of autophagy in the 
cells. In non-immune cells, knockout of GABARAP gene leads to over- and differential expression of tumor 
suppressor gene Xaf1 that may trigger cell death events under stress leading to the inhibition of tumor 
formation. Under genotoxic stress, GABARAP-deficient immune cells highly produce several cytokines which 
could suppress tumor formation and/or may trigger cell death. Similarly, tumor cell inoculation might induce 
inflammasome activation and cytokine secretion leading to inhibition of tumor growth by the enhancement of 
antitumor immunity. 
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